Molecular mechanisms of immune deficiency in adenosine deaminase (ADA)-deficient SCID patients: implications for stem cell gene therapy by Cassani, Barbara
Open Research Online
The Open University’s repository of research publications
and other research outputs
Molecular mechanisms of immune deficiency in
adenosine deaminase (ADA)-deficient SCID patients:
implications for stem cell gene therapy
Thesis
How to cite:
Cassani, Barbara (2007). Molecular mechanisms of immune deficiency in adenosine deaminase (ADA)-deficient
SCID patients: implications for stem cell gene therapy. PhD thesis The Open University.
For guidance on citations see FAQs.
c© 2007 Barbara Cassani
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
BARBARA CASSANI
MOLECULAR MECHANISMS OF IMMUNE DEFICIENCY IN 
ADENOSINE DEAMINASE (ADA)-DEFICIENT SCID PATIENTS: 
IMPLICATIONS FOR STEM CELL GENE THERAPY
PhD Thesis submitted in partial fulfilment of the requirements of the 
Open University for the degree of Doctor of Philosophy 
in Molecular and Cellular Biology
May 2007
Sponsoring establishment:
San Raffaele Telethon Institute for Gene Therapy
(HSR-TIGET)
Milan, Italy
Director of studies Additional supervisor External supervisor
Dr. A. Aiuti Prof. M.G. Roncarolo Prof. M. Collins
ProQuest Number: 13889957
All rights reserved
INFORMATION TO ALL USERS 
The qua lity  of this reproduction  is d e p e n d e n t upon the qua lity  of the copy subm itted.
In the unlikely e ve n t that the au tho r did not send a co m p le te  m anuscrip t 
and there are missing pages, these will be no ted . Also, if m ateria l had to be rem oved,
a no te  will ind ica te  the de le tion .
uest
ProQuest 13889957
Published by ProQuest LLC(2019). C opyrigh t of the Dissertation is held by the Author.
All rights reserved.
This work is protected aga inst unauthorized copying under Title 17, United States C o de
M icroform  Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 4 81 06 - 1346
ACKNOWLEDGEMENTS
I would like to thank Dr. Alessandro Aiuti, Prof. Maiy Collins and Prof. Maria Grazia 
Roncarolo for the precious supervision during the course of my PhD project and for 
critical reading of this thesis. I am grateful to Anna Mondino and to Daniela Talarico for 
helpful scientific discussions and suggestions. I also want to thank all the past and 
present lab members for their continuous encouragements and discussion, in particular 
Grazia Andolfi, Massimiliano Mirolo and Luca Biasco for the precious help in the 
vector integration studies. A special thank to Federica Cattaneo at the Pediatric Clinical 
Research Unit of TIGET for her constant support and friendship. I thank Fabrizia 
Urbinati and Fulvio Mavilio at the Department of Biomedical Sciences (University of 
Modena and Reggio Emilia) and Eugenio Montini and Luigi Naldini at the Telethon 
Institute for gene therapy (HSR-TIGET) for the precious collaboration. I thank Clelia 
DiSerio and Alessandro Ambrosi for the statistical analysis in the vector integration 
studies.
All the work presented in this thesis has been performed at the San Raffaele Telethon 
Institute for Gene Therapy (HSR-TIGET), in the laboratory directed by Alessandro Aiuti 
and Maria Grazia Roncarolo.
1
ACKNOWLEDGEMENTS 1
INDEX 2
ABBREVIATIONS 11
DECLARATION 12
ABSTRACT 13
CHAPTER 1-Introduction 15
1.1 Severe Combined Immunodeficiency (SCID) 15
1.1.1 Adenosine Deaminase (ADA)-deficient SCID: an overview 17
1.2 ADA: molecular organization of the gene 18
1.3 ADA: the enzyme and its role in purine metabolism 19
1.4 Ecto-ADA: the cell-surface molecule and its anchoring proteins 21
1.4.1 CD26 21
1.4.2 Adenosine Receptors 24
1.5 The enzymatic and extra-enzymatic role of ADA
in the immune system 24
1.6 Biochemical basis of AD A-SCID 26
1.6.1 Mechanisms of toxicity: dAdo 27
1.6.2 Mechanisms of toxicity: Ado 29
1.6.2.1 Thymocytes 31
1.6.2.2 Mature T lymphocytes 32
1.6.2.3 B lymphocytes 33
1.7 TCR signalling: an overview 34
1.7.1 TCR signalling: proximal events 34
1.7.2 Regulation of TCR signaling by cAMP/PKA I pathway 41
1.8 AD A-SCID: pathology 44
1.8.1 Diagnosis 44
1.8.2 Genotype-phenotype correlation 45
1.8.3 Clinical aspect of immunodeficiency 47
1.8.3.1 Infections 47
1.8.3.2 Serum Immunoglobulins 48
1.8.3.3 Autoimmunity 48
1.8.3.4 Additional non-immunological abnormalities 48
1.9 AD A-SCID: Clinical management 49
2
1.9.1 Bone Marrow transplantation 49
1.9.2 Enzyme replacement therapy 50
1.9.3 Gene therapy 52
1.9.3.1 Pilot gene therapy studies 52
1.9.3.2 Gene therapy with peripheral blood T lymphocytes 52
1.9.3.3 Impact of PEG-ADA discontinuation on PBL gene therapy 54
1.9.3.4 Gene therapy with hematopoietic stem cells 54
1.9.3.5 HCS gene therapy combined with non-myeloablative
conditioning 56
1.9.4 Open issues in gene therapy with HSC 58
1.10 Retroviral vectors: Murine leukaemia virus 5 9
1.11 Side effects evaluation of RV-mediated gene transfer 62
1.11.1 Risks related to vector production 62
1.11.2 Risks related to transgene insertion 62
1.11.2.1 Patterns of integration of RV vectors 63
1.11.2.2 Factors influencing integration site selection 64
1.11.2.3 Hot spots for retroviral integration 65
1.11.2.4 Impact of integration on expression of nearby genes 66
1.11.2.5 Silencing 67
1.11.3 Risks related to transgene expression 67
1.11.4 Risks related to conditioning 6 8
1.11.5 Risks related to immune surveillance 69
1.12 Genotoxic effects of RV gene transfer in GT clinical trials: the
paradigm of SCID-X1 and Chronic Granulomatous Disease 70
1.13 Future perspective for safety improvement 73
1.14 SPECIFIC AIMS 75
CHAPTER 2 -  Materials and Methods 77
2.1 Patients and clinical trial 77
2.2 Cells 78
2.2.1 Purification of cell subsets from peripheral blood and BM 78
2.2.2 T-cell lines 78
3
2.2.3 T-cell clones 79
2.3 Reagents 80
2.4 Flow cytometry 80
2.4.1 ADA expression 80
2.4.2 A2A Adenosine receptor expression 80
2.4.3 Apoptosis 81
2.4.4 TCR-Vbeta repertoire 81
2.5 ADA and SAHH enzymatic activity 81
2.6 T-cell proliferation 81
2.7 Analysis of cytokine production 82
2.7.1 ELISA 82
2.7.2 Intracellular cytokine staining 82
2.7.3 Cytokine mRNA expression 82
2.8 T-bet and GATA-3 mRNA expression 83
2.9 Adenosine receptors mRNA expression 83
2.10 Intracellular cAMP detection 84
2.11 Western Blotting 84
2.11.1 ADA expression 84
2.11.2 Analysis of ERK1/2 phosphorylation 85
2.11.3 Analysis of CREB and IkBa phosphorylation 85
2.12 DNA purification and quantitative PCR for vector positive cells 86
2.13 Analysis of retroviral vector integration site 86
2.13.1 Inverse-PCR 86
2.13.2 LM-PCR 87
2.14 PCR products cloning 87
2.15 Integrants-specific Q-PCR 87
2.16 RNA purification and retrotranscription 88
2.17 RT- PCR analysis for LM02 expression 88
2.18 Microarray: Affymetrix HG-U133A Gene Chip Array 89
2.19 Taqman Low Density Array 89
2.20 Functional clustering analysis 90
2.21 Bioinformatics 90
2.22 Statistics 90
4
CHAPTER 3 -Results 92
3.1 Generation of untransformed T-cell lines
from AD A-SCID patients 92
3.2 Restoration of ADA expression after gene therapy corrects the
SAHH defect in ADA-deficient T cells 94
3.3 Characterization of the defective T-cell functions
in ADA‘a T cells 96
3.3.1 ADA T cells show defective proliferation in response to
TCR/CD28-mediated stimulation 96
3.3.2 Defective production of cytokines by ADA'7" CD4+ T cells
upon TCR/CD28 triggering 96
3.3.3 Defective cytokine production reflects impaired cytokine gene
transcription in ADA'7' CD4+ T cells 100
3.4 Reduced T-bet mRNA induction in ADA'7' CD4+ T cells 101
3.5 Biochemical basis for impaired effector function
ofADA'7'T  cells 103
3.5.1 Reduced ERK1/2 phosphorylation in ADA'7' CD4+ T cells 103
3.5.2 Defective CREB phosphorylation in ADA'7' CD4+ T cells 104
3.5.3 Defective IkBa phosphorylation in ADA'7' CD4+ T cells 106
3.6 dAdo completely abrogates T-cell activation and function in
ADA'7'T  cells 107
3.7 dAdo-related inhibitory effects are mdiated by the extracellular
A2A adenosine receptor signaling 110
3.8 dAdo induces higher intracellular cAMP levels
in ADA'7'CD4+ T cells 111
3.9 PKA hyperactivation is the downstream effector of dAdo
suppressive function 114
3.10 Increased susceptibility to apoptosis in ADA'7' cells upon
exposure to ADA substrates 116
3.11 Analysis of retroviral vector integrations in hematopoietic cells
from AD A-SCID patients: In vitro vs Ex vivo integrations 119
3.11.1 Genomic distribution of RV integration sites
in AD A-SCID gene therapy 119
5
3.12 Retroviral integration hot spots in AD A-SCID gene therapy 123
3.13 Long-term monitoring of LM02-carryng clones 127
3.14 LM02 integrations do not lead to over-expression in vivo 129
3.15 Integrations are found preferentially in/near genes expressed
in CD34+cells 130
3.16 ADA selective advantage favors survival of vector clones
integrating in/near genes transcriptionally active in T cells 131
3.17 No evidence of in vivo selection for integrations targeting
“dangerous” genes 133
3.18 Normal profile of gene expression in CD4+ T cells from
GT treated patients 135
3.19 Analysis of vector clonal composition in distinct
hematopoietic lineages 137
3.20 Generation of T-cell clones from AD A-SCID patients 139
3.21 Analysis of RV integration sites in T-cell clones 141
3.22 Gene expression analysis of integration-targeted genes 143
CHARPTER 4 -  Discussion 146
4.1 Characterization of the T-cell defect in AD A-SCID patients 146
4.2 Role of altered purine metabolism in the defect
of ADA-deficient T cells 150
4.3 Efficacy of HSC gene therapy 154
4.4 Clonal analysis and in vivo dynamics of hematopoietic
stem cells and lymphocytes in AD A-SCID patients 156
4.5 Vector integration sites analysis in AD A-SCID GT trial 157
4.6 Comparison with other GT clinical trials 159
4.7 Ongoing studies evaluating the potential risk
of transcriptional perturbation 161
REFERENCES 163
6
ILLUSTRATIONS, TABLES AND FIGURES INDEX
Illustrations
Illustration I: Three dimensional structure of ADA 19
Illustration II: Role of ADA in the purine metabolism 20
Illustration III: A model of CD26/DPPIV action at the T cell surface 23
Illustration IV: Proposed pathogenetic mechanisms in AD A-SCID 26
Illustration V: Postulated mechanism by which a lack of ADA can cause
apoptosis in the thymus 29
Illustration VI: Classification of adenosine receptors and their coupling
to the enzyme adenylyl cyclase 30
Illustration VII: TCR signaling: proximal events 35
Illustration VIII: ERKs activation 36
Illustration IX: Inositol lipid metabolism 38
Illustration X: Activation of JNK and p3 8 MAPKs 39
Illustration XI: AP-1, NFkB and CREB 41
Illustration XII: Intracellular signaling is regulated by PKA
at multiple levels 43
Illustration XIII: Mutations causing ADA deficiency 46
Illustration XIV: Gene transfer protocol into autologous BM-CD34+ cells
of AD A-SCID patients 57
Illustration XV: Delivery of nucleic acids by retroviral particles 61
Illustration XVI: Activation of cellular genes by insertional mutagenesis 64
Illustration XVII: Experimental model 93
7
Tables
Table I: 
Table II:
Table III:
Table 1: 
Table 2: 
Table 3:
Table 4A: 
Table 4B:
Classification of severe combined immunodeficiencies 17
Gene therapy trials for AD A-SCID based on engineered peripheral 
blood lymphocytes 53
Gene therapy trials for AD A-SCID based on engineered 
haematopoietic stem cells 55
Mutations of AD A-SCID patients 93
Cytokines production of activated CD4+ cells from patients 99
Retroviral integration site distribution in hematopoietic cells 
from AD A-SCID patients 121
Hotspots: list of genes hit independently by two integration sites 124
Hotspots: list of genomic sites frequently hit by RV integrations 125
8
Figures
Figure 1:
Figure 2:
Figure 3: 
Figure 4:
Figure 5:
Figure 6:
Figure 7:
Figure 8:
Figure 9:
Figure 10:
Figure 11:
Figure 12:
Figure 13:
Restored ADA and SAHH activity in T cells from AD A-SCID 
patients after gene therapy 95
Characterization of the T-cell effector functions defect in CD4+ 
ADA-deficient T cells 98
Analysis of cytokine mRNA expression in CD4+ T-cell lines 101
Analysis of T-bet and GATA-3 relative mRNA levels in resting 
and activated CD4+ T-cell lines from AD A-SCID patients 102
Analysis of ERK1/2 phosphorylation in CD4+ T-cell lines 
from ADA-SCID patients 104
Analysis of CREB phosphorylation in CD4+ T-cell lines 
from AD A-SCID patients 105
Analysis of IkBa phosphorylation in CD4+ T-cell lines 
from AD A-SCID patients 107
dAdo strongly inhibits ERKs activation and effector functions in 
ADA-deficient T cells 109
The selective A2A receptor agonist mimics dAdo-induced 
inhibitory effect 111
cAMP levels and Ado receptors expression in ADA-deficient 
cells 113
PKA hyperactivation is responsible for dAdo-mediated suppression 
of T cell function in ADA-deficient cells 115
Dose- and time-dependent apoptosis induced in ADA-deficient T 
cells by ADA substrates 117
Genomic distribution of RV integration site in AD A-SCID
patients 122
Figure 14: Schematic representation of the most frequent hotspots found in
ADA-SCID 127
Figure 15: Quantification of the contribution of the LM02 clones to the total
T cell population 128
Figure 16: Expression of LM02 in peripheral blood T cells and granulocytes 129
Figure 17: Correlation between insertion sites and gene expression profile of
CD34+ cells at the time of transduction 131
Figure 18: Correlation between insertion sites and genes expressed in T cells 132
Figure 19: Gene Ontology (GO) functional clustering of targeted genes 134
Figure 20: Gene expression profile in CD4+ T cells from patients 136
Figure 21: Vector clonal composition in distinct hematopoietic lineages after
gene therapy 138
Figure 22: Characterization of T-cell clones generated from two GT treated
ADA-SCID patients 140
Figure 23: RIS distribution in T-cell clones from two ADA-SCID patients 141
Figure 24: Evidences for stem cell origin of T-cell clones 142
Figure 25: Expression analysis of gene targeted by RIS in T-cell clones 144
10
Abbreviations used in this thesis (unless otherwise stated in the text)
ADA Adenosine Deaminase
Ado Adenosine
dAdo 2’ -deoxyadenosine
mAb(s) Monoclonal antibody(ies)
Ag(s) Antigen(s)
Ig Immunoglobulin
IVIg Intravenous Immune Globulin
PB L Peripheral Blood Lymphocytes
N K Natural Killer
HSC Hematopoietic Stem/progenitor Cells
G T Gene Therapy
LV Lentiviral Vector
RV Retroviral Vector
RIS Retroviral Insertion Site
bp Base pair
cpm Counts per millions
FACS Fluorescence Activated Cell Sorter
11
DECLARATION
This thesis has been composed by myself and has not been used in any previous 
application for a degree. The results presented here were generated by myself, with the 
exception of the Affymetrix HG-U133A Gene Chip arrays, which were performed in 
collaboration with Fabrizia Urbinati and Fulvio Mavilio at the Department of 
Biomedical Sciences, University of Modena and Reggio Emilia.
All sources of information are acknowledged by means of reference.
Some of the results presented and discussed here are contained in the following articles:
A. Aiuti, B. Cassani. G. Andolfi, M. Mirolo, L. Biasco, A. Recchia, F. Urbinati, C. 
Valacca, S. Scaramuzza, M. Cazzola, D. Sartori, A. Ambrosi, C. Di Serio, M.G. Roncarolo, 
F. Mavilio, and C. Bordignon. “Multilineage hematopoietic reconstitution without clonal 
selection in ADA-SCID patients treated with stem cell gene therapy”. J. Clin. Invest. In 
press
B. Cassani. M. Mirolo, F. Cattaneo, U. Benninghoff, F. Carlucci, A. Tabucchi, C. 
Bordignon, M. G. Roncarolo and A. Aiuti. “Deoxyadenosine Inhibits T-cell Activation 
in ADA-SCID Patients Through a cAMP/PKA-Dependent Pathway Initiated by A2A 
Adenosine Receptor”. Submitted.
12
ABSTRACT
Mutations in the Adenosine Deaminase (ADA) gene are responsible for a form 
of Severe Combined Immunodeficiency (SCID), explained by the lymphotoxic 
accumulation of ADA substrates, adenosine and 2’-deoxy-adenosine. Haematopoietic 
stem cells (HSCs)-based gene therapy (GT) has been shown to correct both the immune 
and metabolic defect of ADA-SCID children, thus providing a unique model to 
investigate the molecular mechanisms linking the altered purine metabolism to T cell 
dysfunction. We found that severely compromised effector functions in ADA-deficient 
T cells associate with an intrinsically reduced ERK1/2 signaling, a defective activation 
of CREB and possibly to an altered nuclear recruitment of NF-kB, as predicted by the 
decreased phosphorylation of IkBa. Conversely, in T-cell lines generated from patients 
after GT, the biochemical events following TCR-triggering occur properly, leading to 
restored effector functions. Remarkably, in ADA-deficient but not in gene-corrected T 
cells, exposure to 2’-deoxy-adenosine induces a strong inhibition of T cell activation. 
This effect is consistent with an aberrant A2A receptor-mediated signaling and PKA 
hyperactivation.
To assess the long-term safety of GT, retroviral integration sites (RIS) were 
cloned and analyzed from transduced bone marrow-derived CD34+ cells before 
transplantation and from their multilineage progeny in five patients. RIS occur 
preferentially around transcription start sites and in gene-dense regions, favoring genes 
transcriptionally active in CD34+ cells at the time of transduction as well as genes 
expressed in T cells. However, preliminary quantitative transcript analysis, at clonal cell
r
level, showed no significant alteration in expression of genes correlated with the nearby 
vector integration, in agreement with the normal gene expression profile and functional 
behavior of T cell population.
Altogether, these results contribute to extend the present knowledge on the 
pathogenesis of ADA-SCID and demonstrate the efficacy and safety of HSC gene 
therapy as a treatment for this disease.
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CHAPTER 1-Introduction
1.1 Severe Combined Immunodeficiency (SCID)
Severe Combined Immunodeficiency (SCID) consists of a group of heterogenic 
genetic disorders characterized by a block in T lymphocyte differentiation that is 
variably associated with abnormal development of other lymphoid lineages, i.e. B or 
NK lymphocytes or more rarely of the myeloid lineage (Fischer et al., 1997). The 
overall incidence is estimated to be on the order of 1:75,000 live births (Buckley et al., 
1997). Patterns of inheritance, immunological characteristics, and more recently 
genotyping have led to the detection of 10 SCID conditions (Table I). Four main 
pathogenetic mechanisms have been identified:
1. Defective cytokine-dependent survival signaling in T and sometimes Natural 
Killer (NK) cell precursors. This mechanism causes the most frequent type 
of SCID (45-60% cases). Deficiency in expression or function of the yc 
cytokine receptor subunit shared by the receptors of interleukin (IL)-2, IL-4, 
IL-7, IL-9, IL-15, and IL-21 causes X-linked form of SCID (SCID-X1), 
characterized by absence of both T and NK lymphocytes (Notarangelo et al., 
2000). Deficiency in Janus kinase 3 (JAK-3), which is normally associated 
with the cytoplasmic region of yc, results in identical phenotype. Deficiency 
in the IL-7Ra subunit only impairs T cell development (Candotti et al., 
2002).
2. Defective V(D)J rearrangement of T cell receptor (TCR) and B cell receptor 
(immunoglobulin genes). This group accounts for 25-30% of SCID. It results 
in a T- B- NK+ phenotype. Deficiency in RAG-1 or RAG-2, the lymphoid-
specific recombination initiating elements, or in Artemis, a factor involved 
in the non-homologous end-joining repair pathway, lead to defective V(D)J 
rearrangements and thereby death of thymocytes and pre-B cells (de 
Villartay et al., 2003).
3. Defective purine metabolism. Deficiency of Adenosine Deaminase (ADA) 
affects all lymphocyte lineages (T- B- NK-). Because ADA is ubiquitously 
expressed, it is thought that the additional metabolic toxicity can contribute 
to the poor prognosis of ADA deficiency compared to the other forms of 
SCID.
4. Defective pre-TCR and TCR signaling. Rare cases of pure T cell deficiency 
(l%-2%) are caused by defects in either a CD3 subunit, such as CD36 or 
CD3s, or the CD45 tyrosine phosphatase (de Saint Basile et al., 2004; Kung 
et al., 2000).
For some cases of SCID, the molecular basis remains unknown. These include a few 
pure T cell deficiencies as well as the so-called reticular dysgenesis condition. It 
consists of a profound deficiency in T and NK cells and a milder B cell deficiency. 
Reticular dysgenesis has an autosomal recessive inheritance. Putative key factors in 
hematopoiesis are probably involved.
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Disease Affected cells Gene Product
Reticular dysgenesis AR T, B, NK, myeloid cells, 
platelets
Unknown
Alymphocytosis AR T. B RAG-1
RAG-2
AR T, B Artemis
Absence of T lymphocytes 
and NK
X-L T, NK yc chain
AR T, NK JAK-3
Absence of T lymphocytes AR T IL-7Ra chain
AR T CD45
AR T CD35
ADA deficiency AR T, B, NK ADA
Table I. Classification of severe combined immunodeficiencies. AR, autosomal recessive; X- 
L, X-linked recessive.
1.1.1 Adenosine Deaminase (ADA)-deficient SCID: an overview
In 1972, ADA-deficiency was the first of the human immunodeficiency diseases
for which the underlying genetic and biochemical defects were identified (Giblett et al.,
1972), revealing the crucial importance of this purine catabolic enzyme for the immune
development. ADA-deficiency represents the cause of approximately 15-20% of all
cases of SCID (Buckley et al., 1997; Kalman et al., 2004), with an overall prevalence
ranging from 1:375.000 to 1:660.000 live birth (Buckley et al., 1997). The clinical
spectrum of ADA-SCID is quite broad, including severe and milder phenotypes
according with the severity of genetic mutations, the residual ADA activity and the
extent of the metabolic poisoning, due to the accumulating ADA natural substrates,
Adenosine (Ado) and Deoxy-adenosine (dAdo) (Arredondo-Vega et al., 1998). The
most relevant clinical manifestations include panlymphocytopenia and impaired
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humoral and cellular-mediated immune responses, which are the cause of recurrent 
opportunistic, often life-threatening, infections. Although the metabolic basis for 
immune deficiency has largely been established, the causal link between altered purine 
metabolism and the immunological defect has not been clarified. This is the reason why 
ADA-SCID has been, and continues to be, the object of several studies aimed to unravel 
the disease pathogenesis and the role of purine metabolism in the immune system.
1.2 ADA: molecular organization of the gene
The human gene for adenosine deaminase (ADA, adenosine aminohydrolase) 
was found to be located in the long arm of chromosome 20 at 20ql2-ql3.1 (Tischfield 
et al., 1974) and it was subsequently isolated by positional cloning (Wiginton et al., 
1986). The ADA gene is constituted by 12 exons and 11 introns. The promoter region 
lacks the “TATA” and “CAAT” sequences and is extremely G/C rich, with a binding 
site for the transcription factor Spl. Two regulatory sequences driving the tissue 
specific expression have been identified in the large (15Kb) first intron and at the end of 
exon 1 (Aronow et al., 1989). The enhancer in the first intron, responsible for the high 
expression in T cells, displays consensus sequences for binding sites of ADA NF-1 and 
ADA NF-2 factors, API, TC Fla, pE and proteins belonging to the Ets transcription 
factor family. The regulatory region at the end of exon 1 might function as a 
transcriptional arrest 10 bp long beyond the translational initiation codon in many 
tissues, such as liver expressing low levels of ADA (Chen et al., 1990). The gene is 
highly enriched in repetitive sequences of Alu type (23 copies for 18% of total 
sequence), all but one located in the first 3 introns or in the 5’ flanking region, 
implicated in causing deletions in ADA gene. The mRNA is only 1497 nucleotides long 
and limited information is available on its post-transcriptional regulation. In cell 
differentiation studies, it has been demonstrated that ADA mRNA and protein levels
18
changed while transcription remained constant. The mechanism o f this regulation is still 
not known (Berkvens et al., 1987).
1.3 ADA: the enzyme and its role in purine metabolism
The cDNA length containing a coding region o f 1.089 nucleotides predicts a 
polypeptide o f 363 amino acids. However, the amino-terminal methionine is likely to be 
removed by post-translational processing to give rise a mature ADA peptide o f 362 
residues (Daddona et al., 1984). The crystal structure o f the closely related mouse ADA 
shows a parallel a / (3 barrel architecture with 8  central (3 strand and 8  peripheral a  
helixes. A zinc ion essential for activity is situated in the active site pocket coordinated 
with three histidine and one aspartate residues (Illustration I) (Wilson et al., 1991).
Illustration I. Three dimensional structure of ADA. The image in the right panel presents the 
active site at the center, and polar and non-polar side chains are depicted in pink and yellow, 
respectively (From Franco R. et al., Immun.Review, 161, 1998)
In mammals, ADA exists in various molecular forms with different m olecular weight.
In cell extracts, ADA can be found in its monomeric 40kDa form and in m olecular form
of 200kDa or higher. This high molecular mass form results from the association o f
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ADA with an ADA-binding (or -com plexing) protein (see next section for details) 
present on the cell surface. The small form represents the cytosolic enzyme o f the 
purine salvage pathway, w hich catalyzes the irreversible deam ination o f Ado and 
dAdo into inosine and d-inosine, respectively (Illustration II). M ost o f Ado derived 
endogenously, from the normal intracellular breakdown o f ATP and degradation of 
RNA, or taken up intracellularly, via an ubiquitously expressed nucleoside transporter, 
is normally phosphorylated rather than deaminated because the Km for adenosine kinase 
is an order o f magnitude lower than that for ADA (Simmonds et al., 1978). Unlike Ado, 
dAdo formed by DNA degradation is predom inantly catabolized by ADA. Further 
mobilization o f inosine nucleoside leads to hypoxanthine, which can be either enter a 
nonreversible pathway to uric acid or salvaged back into other mononucleosides.
Illustration II. Role of ADA in the purine metabolism.
HPRT, hypoxanthine phosphoribosyl transferase; NT, nucleoside transporter; PNP, purine 
nucleoside phosphorylase; SAH, S-adenosyl homocysteine; SAM, S-adenosyl methionine, AK, 
adenosine kinase
hyi
CD73
A denosine
Adenosine 
Receptor complexHom ocysteine HPRT
-  PLC <- 
activation% A denosine ► inosine —ADA PNP Hypoxanthine
t^^^D eoxyadenosine —► dlnosine ^  PKC f
xrH 3 I Uric acid activation ATP
Methyl i ° K cAMP
Transferase dAMP * *
X | ▼ pka  activation
<  Multiple ^dADP p, , . . . . . . .Protein phosphorilations
Inosine
d-lnosine
Adenosine
d-Adenosine^(NTrasp(
dATP
CD73 AMP 
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In the absence of ADA, the presence of these alternative “bypass” pathways results in 
normal concentrations of the catabolic products of the enzyme reaction in patients with 
ADA-SCID. Conversely, the levels of ADA substrates, Ado and dAdo, not only are 
found in increased amounts in extracellular body fluids, but they also “spill over” into 
additional pathways normally only minimally utilized (Simmonds et al., 1978) (Mills et 
al., 1976) (Hirschhom et al., 1982) thus contributing to the pathogenetic mechanisms of 
the disease (a detailed description is reported in section 1.6).
1.4 Ecto-ADA: the cell-surface molecule and its anchoring proteins
Although ADA is more than 90% intracellular, it can be found as ecto-enzyme 
associated to ADA-binding proteins at the membrane level in human but not murine 
cells (Dinjens et al., 1989). No differences in terms of catalytic activity and protein 
structure has been observed between the two isoforms, thus indicating the common 
function in deaminating Ado and dAdo. Two types of ADA-binding protein has been so 
far identified: CD26 and Adenosine Receptors.
1.4.1 CD26
The first ADA-complexing protein identified was CD26 (Kameoka et al., 1993). 
CD26 is a type II membrane sialoglycoprotein, consisting of two identical subunit of 
about 100 kDa, with a postproline dipeptidyl aminopeptidase activity (DPP IV) in the 
dimeric form. It has been demonstrated that CD26 does not participate in the transport 
of ADA toward the cell surface but anchors ADA after the protein has been released 
from homologous or heterologous cells (Dong and Morimoto, 1996). The CD26- 
binding site of human ADA has been localized to the peripheral alpha 2-helics (amino 
acids 126-143) and involved both charge and hydrophobic interaction (Jones and 
Thornton, 1996) highly conserved inter-species during the evolution. The significance 
of the selective advantage of this interaction is likely related to the additional control
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provided over the extracellular concentrations of inhibitory purines. The enzymatic 
activities of ADA and CD26 are unaffected by their binding, indicating that this binding 
is independent from the catalytic functions of both the enzymes (De Meester et al., 
1994). CD26 has a broad tissue distribution and among lymphoid cells, CD26 is 
expressed in medullar thymocytes (Dang et al., 1991) and at detectable level in 
peripheral lymphocytes, being its expression strongly upregulated following in vivo and 
in vitro activation (Fox et al., 1984), primarily in T cells. The significance of CD26 in 
T-cell function resides in its ability to modulate the activity of several chemokines 
(Oravecz et al., 1997) and to provide a costimulatory signal required for optimal T cell 
activation (Bristol et al., 1992) (Tanaka et al., 1993), which to a final extent results in 
upregulation of activation markers, increase cytokine secretion and proliferation, 
augment of T cell responses to foreign antigens, induction of differentiation into 
effector cells and enhanced helper function to B cells and cytotoxic T lymphocytes 
(Morimoto and Schlossman, 1998). The signal transduction machinery initiated by 
CD26 is not fully characterized. Cross-linking CD26 with a monoclonal antibody 
induces an increased tyrosine phosphorylation of a variety of protein similarly triggered 
by TCR-mediated stimulation (Illustration III), thus indicating a functional relationship 
between CD26 and TCR/CD3 complex (Hegen et al., 1997) (Mittrucker et al., 1995), 
but not their physical interaction.
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Illustration III. A model of CD26/DPP IV action at the T cell surface. The ADA binding 
activity of CD26 contributes to the control of adenosine levels at the T-cell surface. The 
peptidase activity of CD26 requires dimerization but the dimerization-site is unknown. The 
CD26-triggered signal transduction pathway is CD3zeta chain dependent and includes 
phosphorylation of the PTKs p56 (Lck), p59 (Fyn) and zeta associated PTK of 70 000 kDa 
(ZAP-70), and of MAP kinase, Cbl, and phospholipase Cg, suggesting that such signals are 
transmitted to the nucleus via the TCR/CD3 pathway.
CD26 has been shown to coprecipitate w ith an isoform  o f CD45, expressed 
preferentially on CD45RO+ m em ory T-cell subset (Torim oto et al., 1991). This 
interaction could account for the activation o f protein tyrosine kinases and calcium  
mobilization upon anti-CD26 stimulation.
Several lines o f evidence suggest that the binding o f ecto-ADA to CD26 is a 
prerequisite for the exerted stimulatory properties on immune function, thus envisaging 
a possible important role o f ecto-ADA as a co-stimulatory molecule in T cells.
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1.4.2 Adenosine Receptors
One of the substrates of ADA, Ado, is an autacoid that exerts multiple 
physiological actions in various systems (Tucker and Linden, 1993) (Fredholm and 
Dunwiddie, 1988) (Churchill and Bidani, 1982) (Merrill et al., 1997). Ado acts through 
specific receptors present on the surface of target cells, four of which have been cloned 
(Ai, A2A, A2B and A3; section 1.6.2). Adenosine receptor type 1 (AiR) (Ciruela et al., 
1996) and 2B (A2bR) (Herrera et al., 2001) have been identified as the other ADA- 
binding proteins. It has been demonstrated that ADA and Ado receptors interact and 
that the proteins are functionally coupled. Indeed, ecto-ADA can regulate receptor 
engagement either by degrading extracellular Ado to inosine or modulating their 
binding affinity to other agonists (Herrera et al., 2001).
1.5 The enzymatic and extra-enzymatic role of ADA in the immune system
ADA is present in all tissues but its levels vary widely and are controlled in a cell- 
specific as well as developmentally programmed manner, suggesting that ADA plays a 
more important role in some tissues or species than others. In humans, ADA activity is 
highest in the thymus followed by the peripheral lymphoid tissues, gastro-intestinal tract 
and possibly a portion of the cerebral cortex (Chinsky et al., 1990) (Witte et al., 1991). 
All of these tissues contain predominantly the small intracellular form of ADA but also 
detectable amounts of the ecto-ADA complex. In peripheral blood mononuclear cells, 
ADA is found as ecto-enzyme in the majority of monocytes and B cells and in some 
(10-20%) T cells (Aran et al., 1991). Other tissues including liver, lung and kidney have 
similar and lower activities of ADA, but greater than that found in erythrocytes. All of 
these tissues exhibit predominantly the large form of ADA. The enzyme activity is 
subjected to changes depending upon the state of cellular activation or differentiation. In 
the human thymus, ADA activity is highly elevated in cortical thymocytes and it is
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down regulated at the medullar stage (Chechik et al., 1981). In the mature lymphoid 
cells ADA activity is highest in T lymphocytes compared to B cells (Barton et al., 
1979). In contrast with the total enzyme activity, the number of ADA molecules on the 
plasma membrane is much higher in B cells than in T cells (Aran et al., 1991). Until 
very recently, the role of ADA, irrespectively of its cellular localization, was thought to 
be the maintenance of non-toxic levels of purine metabolites. However, several 
experimental evidences have then suggested an extra-enzymatic role for the complexed 
form of ADA as co-stimulatory molecule, by virtue of its ability to physiologically 
interact with CD26. Firstly, exogenous ADA could enhance proliferation of CD4+ cells 
induced by anti-CD3 even in presence of ADA inhibitors, indicating an enzyme- 
independent mechanism of ADA action (Martin et al., 1995). Secondly, incubation of T 
cells with exogenous ADA enhanced the increase in intracellular calcium induced by 
anti-CD3 mAbs, indicating that ADA initiated signaling events (Franco et al., 1998). 
Thirdly, anti-CD26 mAbs, that blocked ADA binding, costimulated anti-CD3- 
dependent T cell proliferation (De Meester et al., 1995) (Plana et al., 1991), suggesting 
that ligation of the ADA binding site on CD26 may be sufficient to trigger a signaling. 
The role of ecto-ADA in T-cell activation complements with its expression in resting or 
activated lymphocytes. Indeed, relatively low level of ecto-ADA can be detected in 
resting T cells whereas its expression, as for CD26, markedly increases upon activation 
(Franco et al., 1998). Based on the existence of signaling pathways in lymphocytes via 
the ADA/CD26 interaction and of other binding proteins, ecto-ADA has been 
demonstrated to mediate specific contacts between lymphocytes and dendritic cells at 
the level of immunological synapse, which finally resulted in potentiated T cell effector 
functions (Pacheco et al., 2005). This potential role of ecto-ADA in facilitate 
information exchange from cell to cell would be of relevance in the functionality and 
development of lymphoid tissues.
1.6 Biochemical basis of ADA-SCID
It is well established that the m etabolic basis for A DA -deficient SCID are 
related to the physiological im pact o f the ADA substrates, Ado and dAdo. In the 
absence o f ADA, these nucleosides are m etabolized differently and have distinct 
biochemical action. dAdo behaves as a cytotoxic metabolite and is believed to provide 
the direct cause o f the lym phocytes’ depletion by intracellular poisoning. On the other 
hand, Ado may function as an extracellular signal transducer that mediates a variety o f 
physiological effects by binding to G-protein coupled adenosine receptors present on 
the surface o f target cells. The major toxic effects o f Ado, dAdo and their nucleotides 
derives that have been considered as potential causes o f the immune deficiency in 
ADA-SCID are summarized in Illustration IV.
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Illustration IV. Proposed pathogenetic mechanisms in ADA-SCID.
AXP, adenosine nucleotide derives; 5’-NT, ecto-5’-nucleotidase; AC, adenylyl cyclase; 
ADOHCY, S-adenosyl homocysteine.
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However, the exact molecular mechanisms of lymphotoxicity are still elusive, and the 
relative contribution of intracellular toxicity vs signaling properties of extracellular 
adenosine remains incompletely understood. An important part of my PhD project has 
focused on the clarification of this aspect. This introduction presents the knowledge in 
the fields at the beginning of this project and the advancement, made in these years, 
which, together with our contribution, helped to elucidate the cellular and molecular 
basis of ADA-SCID pathology.
1.6.1 Mechanisms of toxicity: dAdo.
Although a limited knowledge exists regarding its own biological properties, the 
biochemical hallmarks of ADA deficiency are consistent with the general belief 
indicating dAdo as the primary cause of lymphotoxicity in ADA-SCID. Although dAdo 
is a weak substrate for Ado kinase and deoxycytidine kinase, in the absence of ADA 
these enzymes can phosphorylate dAdo. In turn, the resulting dATP pool expansion 
may interfere with a number of critical metabolic pathways. dATP is known to be a 
feedback inhibitor of ribonucleotide reductase, an enzyme required for normal DNA 
synthesis (Mann and Fox, 1986). In particular, it has been speculated that dNTP 
accumulation may preferentially exert its inhibitory effect in cells at the Gl/S boundary, 
possibly preventing the association of the reductase with other complexing proteins 
required for initiation of replicative DNA synthesis (Waddell and Ullman, 1983). A 
reciprocal correlation has been established between the levels of ATP and dATP in red 
blood cells (RBC) of ADA-SCID patients (Simmonds et al., 1982), which manifested 
episodes of haemolytic anemia. The mechanism of dAdo-induced ATP catabolism was 
more readily explained by the ability of dATP to selectively activate the enzymes 
responsible for the adenine ribonucleotide catabolism (Bagnara and Hershfield, 1982). 
An additional mechanism was based upon in vitro findings demonstrating the inhibition 
of methyl-transfer reactions by suicide inactivation of SAH hydrolase consequent to
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accumulating ADA substrates (Hershfield, 1979). Inhibition of SAH hydrolase has been 
also demonstrated in vivo in RBC of patients, but inhibition of specific methylation 
reactions has not been documented. In addition, SAH has been shown to act as a 
physiological modulator of APO-l/Fas-mediated cell death, suggesting another possible 
mechanism contributing to lymphocyte depletion in ADA-SCID (Ratter et al., 1996). 
The cause of lymphocytes depletion has been examined using foetal thymic organ 
cultures (FTOC) generated from gestational day -15 thymi (Thompson et al., 2000) 
(Van De Wiele et al., 2002). In the ADA'7' FTOC, thymocyte differentiation was 
blocked within the double negative (DN) stage. Introducing a Bcl-2 transgene or using 
FTOC from apaf7' mice prevented the thymocyte loss induced by ADA inhibitor in 
ADA+/+ FTOC, consistent with mitochondria-dependent apoptosis due to dATP 
accumulation. Indeed, the excess of dATP has been shown to promote the release of 
cytochrome c from mitochondria and facilitate its association with apaf-1 and 
procaspase 9 in the formation of apoptosome complex (Illustration V) (Purring-Koch 
and McLendon, 2000) (Yang and Cortopassi, 1998). dAdo was also reported to affect 
mature lymphocyte. Studies performed in human lymphocytes, in which deaminase has 
been chemically-inhibited, indicated that dAdo is able to interfere with early process of 
T cell activation, namely the hydrolysis of PIP2 and the consequent IP3 mediated 
mobilization of cytoplasmic free Ca2+, initiated by the interaction of PHA with its 
receptor (Scharenberg et al., 1989). The observed reduction in intracellular free Ca2+, 
which is vital to many signal transduction events, may account for the sensitivity of 
mitogen-stimulated lymphocytes to growth and IL-2 production inhibition by this toxic 
metabolite (Ruers et al., 1987).
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Illustration V. Postulated mechanism by which a lack of ADA can cause apoptosis in the 
thymus. Pathway A: accumulated dATP causes release of cytochrome c from mitochondria, 
leading to formation of the apoptosome and initiation of the apoptotic cascade. Pathway B: 
abnormal levels of purine metabolites cause the induction of pro-apoptotic Bcl-2 family 
members, leading to cytochrome c release from mitochondria. Pathway C: abnormal levels of 
purine metabolites cause induction of death receptor signaling, leading to caspase 8 activation 
and cleavage of Bid. Truncated Bid then binds to pro-apoptotic Bcl-2 family members leading 
to release of cytochrome c from mitochondria.
1.6.2 Mechanisms of toxicity: Ado.
The ability o f Ado to cause depletion o f cellular pyrimidine nucleotides has been 
one o f the first mechanism proposed as the cause o f lym phopenia in ADA deficiency 
(Green and Chan, 1973). Pyrimidine depletion in vitro requires the phosphorylation o f 
Ado, and appears to be dependent by inhibition o f phosphoribosylpyrophosphatase 
(PRPP) synthetase. However, neither exogenously added uridine nor inhibited  
adenosine kinase were able to prevent the A do-m ediated block o f  pro liferative 
responses o f hum an peripheral blood lym phocytes (Carson and Seegm iller, 1976) 
(Hershfield et al., 1977). Moreover, normal levels o f UTP and CTP were found in the
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body fluids o f one ADA-deficient patient (Mills et al., 1979), thus the occurrence o f 
pyrimidine starvation in vivo in ADA-SCID is still to be demonstrated.
Alternatively, Ado may initiate an aberrant extracellular signaling by binding to G- 
protein coupled adenosine receptors present on the surface o f target cells (Sitkovsky et 
al., 2004). Physiologically, Ado-mediated triggering o f these receptors can promote a 
fine-tuning o f the inflam m atory responses, but in the context o f defective ADA- 
m etabolizing enzyme, where the extracellular levels o f adenosine w ould be likely 
dramatically increased, this regulation may be overstated, leading to immune defect.
To date, four subtypes have been identified: Ai, A2A, A2B and A3 (Fredholm  et al., 
2001).
Inhibition Stimulation
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Low affinity A3 Low affinityA.
NH,
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Illustration VI. Classification of adenosine receptors and their coupling to the enzyme 
adenylyl cyclase. Adenosine receptors belong to the family of heptahelical transmembrane G- 
protein-coupled receptors. Extracellularly orientated adenosine receptors bind adenosine with 
high and low affinity and can either stimulate or inhibit the enzyme adenylyl cyclase. The 
adenylyl cyclase consist of two regulatory and two catalytic units and generate from ATP the 
potent second messenger, cAMP.
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Their cloning helped to prove that high-affinity A2A and low-affinity A2B receptors 
activate adenylyl cyclase, whereas high-affinity Ai and low-affinity A3 inhibit it 
(Illustration VI). Accordingly, when immune cells acquire the expression of all types of 
these receptors, they will be recruited in a stepwise manner with Gi-coupled Ai 
receptors activated first at very low Ado levels, followed by the stimulation of Gs- 
coupled A2A and A2B receptors, and finally by Gi-coupled A3 receptors (Fredholm et al., 
2001). When activated pharmacologically, cAMP-elevating A2A and A2B receptors 
inhibit inflammatory immune responses (Sitkovsky, 2003) (Linden, 2001). Activation 
of A3 receptors exerts anti-inflammatory effects by still unknown mechanisms 
(Salvatore et al., 2000). Very low concentrations of Ado can bind to and activate Ai 
receptors that can inhibit the adenylyl cyclase-activating A2A and A2B receptors. 
Because higher levels of Ado can overcome the inhibition mediated by Ai receptors, Ai 
receptors are thought to exert a tonic inhibitory effect on A2 receptor functions.
The effects of Ado-mediated signaling on immune cell function will be 
discussed hereinafter, in the view of their possible involvement in the main cellular 
defects observed in ADA-SCID.
1.6.2.1 Thymocytes
The thymic environment is normally conducive to Ado-mediated signaling, as 
significant amount of Ado is generated through physiological mechanisms of 
lymphocyte selection. Accumulated Ado can induce apoptosis in mouse or human 
thymocytes (McConkey et al., 1994) (Szondy, 1994), mostly via adenosine A2A 
receptors. The signaling pathway involves adenylyl cyclase and the pro-apoptotic 
protein Bim, and is negatively regulated by Nur77 transcription factor (Kiss et al., 
2006). The ADA-SCID knock-out mouse model, retaining many of the features 
associated with ADA-deficiency in humans, was generated by two-stage genetic
engineering (Blackburn et al., 1998). An abundance of apoptosis was observed in thymi 
of ADA"7" mice compared to control animals (Apasov et al., 2001), localized 
predominantly to the cortical-medullary boundary, where CD4+CD8+ double-positive 
thymocytes should accumulate (Apasov et al., 2001). A direct apoptotic effect on this 
specific thymocyte subset by extracellular Ado was demonstrated using A2A receptors 
knock-out mouse (Apasov et al., 2000), thus suggesting that thymocytes depletion in 
ADA-SCID is likely due to aberrant engagement of A2A receptor-mediated signaling. 
Moreover, reduced phosphorylation of CD3 £ chain and inhibition of Ca2+ mobilization 
has been described in vivo and in vitro in ADA'7* thymocytes (Apasov et al., 2001) and 
attributed to Ado. Therefore, two alternative or simultaneously operating mechanisms 
could account for T cell depletion in ADA-SCID: a) a direct apoptotic effect and b) 
inhibition of TCR signaling and, hence, inhibition/block of TCR-driven process of T- 
cell selection.
1.6.2.2 Mature T lymphocytes
Mature CD4- and CD8-positive T cells from ADA'7' mice have decreased TCR- 
triggered activation (low CD25 and CD69 marker expression) in vivo and in vitro 
(Apasov et al., 2001). This inhibitory effect is more readily explained by Ado-mediated 
signaling through A2A receptor, the major adenosine receptor subtype expressed in 
murine as well as human lymphocytes (Koshiba et al., 1999) (Thiel et al., 2003). 
Indeed, although the biochemical mechanisms potentially involved have been 
incompletely demonstrated in ADA-SCID, studies carried out with artificial system, 
using ADA-inhibitory drugs or selective A2A receptors agonists/antagonists, showed 
that the pharmacologic increase of intracellular cAMP levels interferes with the 
proximal biochemical events following T-cell receptor-triggering, leading to inhibition 
of interleukin-2 receptor a  chain (CD25) upregulation (Huang et al., 1997). This event 
associated with decreased tyrosine phosphorylation of STAT-5 proteins, due to
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activation of SHP-2 tyrosine phosphatase (Zhang et al., 2004), and TCR-triggered 
proliferation. In activated CD4+ T cells Ado had a broad inhibitory effect on secretion 
of IL-2, INF-y, TNF-a and IL-4 cytokines (Lappas et al., 2005) (Erdmann et al., 2005), 
whereas in resting lymphocytes it induced upregulation of CD 152, CTLA-4, normally 
involved in the termination of immune response (Vendetti et al., 2002). In addition to 
defective cytokine production and Ag-driven proliferation (Erdmann et al., 2005), CD8+ 
T cells displayed reduced granule exocytosis and FasL mRNA upregulation upon A2A 
receptors ligation (Koshiba et al., 1997), which may account for the inability to clear 
viral infection in vivo. The A2B and A3 receptor types are upregulated, as the A2A, in 
activated lymphocytes (Mirabet et al., 1999) (Gessi et al., 2004). However, while A2B 
increases its expression predominantly in CD8+ cells, A3 is upregulated mainly 
exclusively in CD4+ cell subset, thus leading to selective regulation of both cytotoxic 
CD8 and helper CD4 T cell activities. Overall, these evidences strongly suggest that the 
extracellular-related mechanisms of toxicity might be relevant as the intracellular 
poisoning in the pathophysiology of the disorder. In this view, the engagement of an 
aberrant adenosine receptor signaling may offer a better comprehension for the 
autoimmune manifestations observed in ADA-SCID patients (Kohn DB, 1996) 
(Ozsahin et al., 1997), because of their cell-specific expression and regulation.
1.6.2.3 B lymphocytes
With respect to T lymphocytes, limited knowledge is available about the effects 
exerted by Ado on B-cell function. However, recent studies have defined downstream 
consequences of adenosine receptors ligation on the response of B cells to antigen- 
receptor engagement. Minguet et al. reported that exogenous Ado inhibits NF-kB 
activation in primary murine B cells stimulated via the BCR or by LPS via TLR4 
(Minguet et al., 2005). The effect of Ado on NF-kB activation in B cells was associated 
to inhibition of BCR-induced IkB phosphorylation. Therefore, Ado may drive BCR-
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stimulated B cells towards an anergic rather than an immunogenic response. Such a 
mechanism might contribute to B-cell dysfunction in ADA deficiency, and may better 
explain the defective B-cell activation and proliferation observed in ADA'7' mice.
1.7 TCR signaling: an overview
The detection of antigens by T cells is achieved through recognition by the TCR 
of antigenic peptides presented in association to MHC molecules. The final outcome of 
this recognition can be either full activation and acquisition of effector functions or 
establishment of anergy. The current model of T cell activation proposes that at least 
two signals must be provided to a naive T cell to be fully activated and to avoid anergy 
(Linsley and Ledbetter, 1993; Schwartz, 2003). The first signal is necessarily delivered 
through the TCR, while the second signal, generally referred to as costimulation, is 
provided by receptors expressed by APCs or by soluble factors. The main molecule 
involved in the delivering of “signal two” is CD28, whose natural ligand (B7.1/2) is 
highly expressed by activated/mature APC (Acuto and Michel, 2003). Engagement of 
the TCR elicits a cascade of signaling events, which leads to transcriptional activation 
of multiple genes involved in T cell proliferation and differentiation, and to cytoskeletal 
rearrangements (van Leeuwen and Samelson, 1999). The main molecular events 
downstream of TCR and CD28 triggering will be presented here.
1.7.1 TCR signaling: proximal events
The first event upon TCR triggering is the phosphorylation of different tyrosine 
residues in the immunoreceptor tyrosine-based activation motifs (ITAMs) of the CD3-y, 
6, s and t, invariant chains of the TCR. This phosphorylation is exerted by Src kinases 
(mainly Lck) and regulated by the phosphatase CD45 (Zamoyska et al., 2003) (Palacios 
and Weiss, 2004). Phosphorylated ITAMs mediate the recruitment and activation of the 
Syk kinase ZAP-70 (Neumeister et al., 1995). Full phosphorylation of the CD3-^ is
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essential for productive T cell activation (Sloan-Lancaster et al., 1994) and is achieved 
with the help o f CD4/CD8 co-receptors, which are constitutively associated to Lck. 
ZAP-70 is a central kinase as it phosphorylates a number o f molecules including the 
adaptor m olecules LAT (linker o f activated T cells), which is constitutively rafts- 
associated (Zhang et al., 1998) and SLP-76. LAT-SLP-76 complex is a fundamental 
organizer o f TCR signaling (Illustration VII) (Myung et al., 2000).
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Illustration VII.
a. ERKs activation
One crucial function o f LAT is coupling the TCR to the Ras pathway. Indeed,
phosphorylated LAT recruits the adaptor protein Grb2, which associates w ith the Ras
guanine nucleotide exchange (GEF) protein, Sos. Sos/Grb2 can activate the small G
protein Ras, although an alternative pathway o f Ras activation has also been described,
involving the guanyl nucleotide releasing protein GRP, which can be recruited by DAG
(see after) (Cantrell, 2003b). Activation o f Ras is a crucial event, as it initiates the
activation o f the R af-l/M EK  signaling pathway, which in turn leads to activation o f
RSK2 and ERKs. ERK1/2 (also called p44/42 M APKs) controls T cell cycle
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progression and the transcription o f the Fos gene (Illustration VIII) (Hunter and Karin, 
1992). Fos gene transcription is essential for the activation o f  the AP-1 complex, which 
is required for IL-2 gene transcription (see section g).
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c. Inositol lipid metabolism (I): from PLCy to activation of NFAT
In addition, LAT, together w ith SLP-76 and the adaptor Gads, m ediates the 
recruitment o f PLCy, a key molecule o f the inositol lipid metabolism. PLCy activation 
requires the activity o f Lck, Zap-70 and o f the Tec kinases (see section e). The products 
o f PLCy enzymatic activity are inositol 1,4,5-triphosphate (IP3) and diacylglycerol 
(DAG). IP3 is responsible for release o f Ca2+ from the endoplasmic reticulum  (ER), 
which then mediates the opening o f Ca2+ channels (Ca2r release activated channels: 
CRAC) on the plasma membrane (Lewis, 2001). Ca2+ increase induces the activation o f  
several calm odulin-dependent enzym es, including  calcineurin  and C A M K II. 
Calcineurin has a crucial role as it dephosphorylates multiple phosphoserine residues on
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the transcription factors NFAT. Phosphorylated NFAT is retained in the cytoplasm in 
resting cells, and upon dephosphorylation it translocates to the nucleus, where it 
mediates the activation of many cytokine genes, including IL-2, IL-4, IFN-y, IL-3, GM- 
CSF, IL-10 (Hogan et al., 2003). Five NFAT family members have been identified, 
which are named NFAT-1-2-3-4 (also called NFATc2-l-4-3) and NFAT-5 (also called 
TonEBP), which is regulated in a different way.
d. Inositol lipid metabolism (II): from PLCy to activation of PKC
Production of DAG is critical for the activation of the serine/threonine kinases 
of the PKC family and also to link lipid metabolism to the Ras pathway (Ebinu et al., 
2000). PKCs can be divided into two groups according to their dependence on Ca2+ 
(Mellor and Parker, 1998). In T cells the more relevant form of PKC is the Ca2+- 
independent PKC0. The importance of PKC0 in T cell activation has been highlighted 
in the last years. This kinase is specifically expressed in T cells (and in skeletal muscle). 
Upon TCR triggering, PKC0 translocates to the immune synapse at the levels of lipid 
rafts (Bi et al., 2001) and it positively regulates IL-2 gene transcription, likely by 
modulating the activity of the transcription factors AP-1 and NFkB (Bi et al., 2001; Lin 
et al., 2000; Werlen et al., 1998).
e. Inositol lipid metabolism (III): PI3K signaling
A second pathway of inositol lipid metabolism activated by TCR and CD28 
involves the activation of PI3K (Cantrell, 2001). PI3K can be divided into three classes. 
Class I PI3Ks are generally coupled to extracellular stimuli. In T cells, PI3K, which can 
be also activated through CD28, independently on TCR triggering (Ward et al., 1993), 
generates PI(3,4,5)P3, starting from PI(4,5)P2. PI(3,4,5)P3 is then metabolized to 
produce PI(3,4)P2. Generation of PIP3 and PI(3,4)P2 is crucial as these lipids mediates 
the recruitment of several proteins containing pleckstrin homology (PH) domains, 
including the Tec kinases (Finkelstein and Schwartzberg, 2004), the phosphoinositide
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dependent protein kinase (PDK) 1, the protein kinase B (PKB/AKT) (Cantrell, 2001) 
and, possibly, Vav-1, which is the guanine nucleotide exchange proteins (GEFs) for 
Rho, Rac and Cdc42 . PDK1 targets different kinases, including p70SK l, GSK3 and 
PKB itself, thus regulating a variety o f processes including T cell size, growth, survival, 
glucose metabolism and NFAT localization (Cantrell, 2003a) (Patra et al., 2004). Tec 
kinases belong to a large family o f non-receptor tyrosine kinases. T cells mainly express 
Itk and Rtk Tec kinases (Schwartzberg et al., 2005). Besides being required for full 
PLCy activation, Tec kinases exert an important role in coupling TCR/CD28 triggering 
to actin cytoskeleton rearrangement, by association and functional interaction with Vav- 
1 and WASP. A schematic representation o f inositol lipid m etabolism  is depicted in 
Illustration IX.
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f. Activation of JNK and p38 MAPKs
Activation o f Rho GTPases links TCR/CD28 triggering to the activation o f the 
MAPKs JNK1/2 and p38 (Illustration X) (Davis, 2000; Dong et al., 2002). Both p38 
and JNK are involved in the transcriptional activation o f IL-2 gene, the first by 
phosphorylation o f ATF2 transcription factor, the second by phosphorylation o f the c- 
Jun transcription factor, which, together with Fos, forms the AP-1 complex (Illustration 
XII) (M acian et al., 2001). In addition, JNK has been shown to stabilize IL-2 mRNA 
(Chen et al., 2000).
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Illustration X.
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g. AP-1, NFkB and CREB
AP-1 complex is formed by Fos family members (c-Fos, FosB, Fra-1 and Fra-2) 
and by Jun family members (c-Jun, JunB and JunD). AP-1 dimer binds DNA either 
alone, or together with NFAT (Karin et al., 1997). During T cell activation, AP-1 binds 
and positively regulates the IL-2 promoter. NFkB comprises a family of factors which 
acts as dimers. NFkB is retained in the cytoplasm of resting T cells through the binding 
to the inhibitors of kB (IkBs). Phosphorylation of IkBs by IkB kinases (IKKs) 
determines their degradation through the ubiquitin-proteasome pathway. PKC0 is 
involved in NFkB activation, possibly by direct phosphorylation of IKK(3 (Lin et al., 
2000). Importantly, NFkB activity is also regulated by direct phosphorylation of its 
transactivating subunits p65, c-Rel and relB (Weil and Israel, 2004). NFkB dimers bind 
to IL-2 promoter, contributing to IL-2 gene transcription. The transcriptional activity of 
CREB is regulated by a RSK2-mediated single phosphorylation on Ser-133 that leads to 
complex formation with the coactivator, CBP and binding to CRE elements (Brindle et 
al., 1993). In T cells, CRE elements can be found in TCR and CD3 genes as well as in 
other genes involved in lymphocytes activation, including cytokine genes (Barton et al., 
1996). A schematic representation of IL-2 gene transcription is depicted in Illustration 
XI.
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1.7.2 Regulation of TCR signaling by cAMP/PKA I pathway
Control and fine-tuning o f the proxim al TCR signaling are required both for 
effective activation and to avoid inappropriate or exaggerated immune activation and 
autoim m unity. In this regard, inhibitory signaling m echanism s interact w ith the 
activated pathways as means o f modulating the immune responses. The role o f cAMP 
and cAM P-dependent protein kinases (protein kinase A, PKA) in such m odulation o f 
immune function is discussed here.
Stimulation o f the TCR alone leads to a transient rise in cAMP (Ledbetter, JI 1986) 
levels, generated by recruitments o f Gs and dissociation o f Gi proteins in lipid rafts. 
Increased cAMP serves to down-m odulate TCR-triggered signal transduction and 
prevent full T cell responses, as a consequence TCR-mediated cAMP production m ust
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be regulated for T cell activation to occur. Recently, it has been shown that stimulation 
of the coreceptor CD28 markedly potentiates the recruitment of a p-arrestin/PDE4 
complex into rafts upon TCR activation (Abrahamsen et al., 2004). Delivery of active 
PDE4 enhanced cAMP degradation, thereby amplifying T cell activation. With few 
exceptions, the effects of cAMP are mediated by cAMP-dependent protein kinase A 
type I (PKAI) (Torgersen et al., 2002). This isoenzyme is thought to play a major role in 
cAMP-mediated effects in T lymphocytes, because it redistributes and colocalizes with 
the capped TCR (Vang et al., 2001). PKA regulates immune function at multiple levels 
(Illustration XII). PKA consensus phosphorylation sites have been identified in NFAT, 
NF-kB and CREB transcription factors, indicating that they can be regulated by PKA 
activity. Phosphorylation of NFAT by PKA occurs at conserved sites adjiacent to a 
nuclear localization sequence that regulates the association between NFAT and 14-3-3 
protein (Chow and Davis, 2000). Dephosphorylation by Calcineurin results in release of 
NFAT from 14-3-3 and its nuclear translocation. A proportion of PKA catalytic subunit 
(PKA-C) binds to IkB and associates with NF-kB-IkB complex (Zhong et al., 1997). 
PKA-C is kept in inactive state until IkB is degraded and the active PKA-C is released.
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Illustration XII. Intracellular signaling is regulated by PKA at multiple levels. Several 
targets for PKA phosphorylation have been localized that can modulate the immune response. 
At the transcriptional level, this includes CREB, NFAT and NF-kB (p56Rel). Further upstream 
targets like HePTP, Ras, Raf, MEK and MAPK provide means for PKA to regulate MAPK 
pathway differentially, while PKA phosphorylation of PLCy can modulate signaling through 
phospatidylinositols. Finally, PKA substrates like Csk and RhoA make PKA able to regulate 
proximal T-cell signaling and cyytoskeletal processes important in immune activation.
Active PKA-C will then phosphorylate the p65 Rel subunit o f  N F-kB leading to
increased transactivating activity o f N F-kB, possibly by increasing binding o f the
coactivator com plex CBP/p300 to p65. A lthough activation o f CREB after TCR
stimulation seems to be independent o f PKA and rather involves RSK2 pathway, the
ability o f PKA to phosphorylate Ser-133 clearly opens for similar effects o f  stimuli
activating PKA (Gonzalez and Montminy, 1989). PKA-mediated modulation o f protein
in the MAP kinase pathway has also been identified. The R as-Raf interaction may be
attenuated by PKA phosphorylation o f Ser-43in the Ras-interacting domain o f Raf-1
(Wu et al., 1993). Further downstream, PKA phosphorylation o f Ser-23 in the small
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haematopoietic phosphatase HePTP leads to dissociation of MAPKs from HePTP and 
allows activation by Mek (Saxena et al., 1999). Treatment of T cells with cAMP- 
elevating agents resulted in PKA phosphorylation of PLC-yand suppression of Ca2+ 
mobilization and phosphatidylinositol hydrolysis upon T cell activation (Alava et al., 
1992). Interestingly, cAMP causes morphological changes in different cell types 
including lymphocytes, which appears to involve PKA-mediated phosphorylation and 
regulation of RhoA (Lang et al., 1996) (Laudanna et al., 1997). Since Rho proteins 
family are key players in the reorganization of actin cytoskeleton during immune 
activation, it appears clear the significance of PKA activity in the formation of the 
immunological synapse. Finally, PKA-mediated inhibitory pathways can be assembled 
even at the site of T cell activation to provide precise temporal and spatial modulation 
of proximal TCR signaling. Indeed, PKA phosphorylates/activates Csk, which 
subsequently inhibits Lck, thereby attenuating T cell activation.
1.8 ADA-SCID: pathology
1.8.1 Diagnosis
In the absence of ADA, the purine metabolites Ado, dAdo and adenine 
deoxyribonucleotides (dAXP) accumulate at high levels in plasma, red blood cells, and 
tissues. These metabolic hallmarks of ADA deficiency provide the biochemical 
diagnosis of ADA SCID, which is essentially based on ADA activity and dAXP 
concentrations in erythrocytes, measured by a capillary electrophoretic separation 
tecniques. A dramatic reduction of ADA activity (56.9 + 48.3 nmol/s per liter of packed 
cells vs 5619 + 2584 nmol/s/L in healthy individuals) and high dAXP concentrations in 
erythrocytes (300-450 [imol/L vs undetectable level in healthy individuals) represent a 
universal finding for homozygous ADA deficiency (Carlucci et al., 2003). 
Heterozigosity for the defect can be difficult to detect, since many heterozygote carriers
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have ADA levels at the lower limit of the normal range (Morgan et al., 1987). Later 
onset patients may retain 2-5% of normal activity, with the highest residual activity 
reported in case the adult onset of the disease. An additional group of individuals have 
been described who lack ADA in erythrocytes but express 5-80% of normal activity in 
lymphoid cells. It has been referred to these individuals as “partially” ADA deficients. 
Pregnatal diagnosis is possible using chorionic villus sampling (Perignon et al., 1987), 
fetal blood (Morgan et al., 1987) and cultured amniotic fluid cells. Since ADA activity 
could be considered a useful prognostic indicator even in these cell type, its 
determination may help in the clinical management of the newborn patients and in the 
evaluation of the best therapeutic option.
1.8.2 Genotype-phenotype correlation
More than 50 unique ADA gene mutations were identified from 59 unrelated 
families and collected in an ADA database (http://www.uta.fi/imt/bioinfo/ADAbase/). 
These mutations are scattered throughout the entire length of the ADA gene, although 
some hotspots have been identified (Arredondo-Vega et al., 1998) (Hirschhom et al., 
1990), landed in critical region of the molecule important for the substrate binding or the 
catalytic activity (exon 4 and 7; Illustration XIII). Mutations in ADA gene are consistent 
with alterations in ADA activity, enzyme stability and survival (Hirschhom, 1999).
Over two-third of the patients are genetic compounds, carrying two different allelic 
mutations, with the remainder homozygous for the same mutation. Many patients with 
homozygous mutations are from populations with high frequency of inbreeding.
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Illustration XIII. Mutations causing ADA deficiency. Three large 5' genomic deletions are not 
shown (two of 3.25 kb that include the promoter and Exon 1, and a >30 kb deletion that includes 
exons 1-5). For exonic mutations, the number in parentheses after the mutation name denotes the 
effect on ADA activity, as defined in Arredondo-Vega et al., 1998: deletion and nonsense 
mutations are designated "0", and missense mutations "I", "II", "III", or "IV" based on increasing 
ADA activity derived from constitutively expressing an ADA cDNA carrying the mutation in an 
ADA deletion strain of E. coli. Patients with genotypes composed only of alleles from groups "0" 
or "I" were very likely to have SCID, whereas those with at least one allele from groups "II" or 
"III" were very likely to have a milder "delayed onset" or "late/adult onset" phenotype; 
individuals who possessed one group "IV" allele were healthy and had "partial ADA deficiency" 
(Arredondo-Vega et al., 1998). Mutations designated IV were also associated with "partial" 
deficiency and found to provide substantial residual activity by semiquantitative methods 
(Hirschhom et a l, 1990).
Studies performed on large cohorts o f patients allowed to highlight a good correlation 
between genotype and both clinical and m etabolic phenotype. Thus, mutations that 
express residual ADA activity have been associated with milder form o f disease. Indeed, 
certain missense and some splicing mutations found in healthy individual with “partial” 
deficiency or in immunodeficient patients with delayed/late onset phenotypes, have not 
been retrieved in patients w ith SCID, the m ost com m on early-onset phenotype 
(Hirschhom, 1995).
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1.8.3 Clinical aspect of immunodeficiency
The majority of ADA-SCID patients are diagnosed in the first year of life (early 
onset) and rarely survive beyond 1 to 2 years unless a therapeutic intervention leading 
to restored immune function is provided (Parkman et al., 1975). Thymic hypoplasia, 
broad lymphopenia, absence of humoral- and cellular-mediated immunity, recurrent 
infections and failure to thrive are consistent with the early onset forms of ADA- 
deficiency (Giblett et al., 1972) (Buckley et al., 1997). About 20% of ADA-SCID cases 
occur later in childhood (delayed) or beyond (late/adult onset). These forms show 
progressive immunological and clinical deterioration, often associated with autoimmune 
manifestations (Parkman et al., 1975) (Aiuti et al., 2003).
1.8.3.1 Infections
The vast majority of early onset ADA-SCID patients have a history of recurrent 
infections, which can be life-threatening. Initially, infections involve areas with the 
greatest exposure to organism, such as skin, gastrointestinal and respiratory systems. 
Infectious agents include bacteria, fungi, viruses and protozoa (Meuwissen et al., 1975). 
Pneumocystis carinii pneumonia and giant-cell pneumonia occur frequently. 
Candidiasis is almost invariably present, causing both “rash” and more extensive 
infections involving skin, oral and esophageal mucosa. Diarrhea, which is generally 
secondary to abnormal intestinal flora, is a common feature and may seriously 
compromise nutrition. Later-onset forms are characterized by recurrent sinopolmunary 
bacterial, mainly due to Streptococcus Pneumoniae, and herpes zoster infections. An 
increased propensity to develop lymphomas has been reported among later ADA-SCID 
presenters, usually related to infection with Epstein-Barr virus (EBV) or 
Cytomegalovirus (CMV) (Shovlin et al., 1993) (Kurlandsky et al., 1994).
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1.8.3.2 Serum Immunoglobulins
Total immunoglobulin levels may be only slightly depressed at birth due to the 
maternal contribution of IgG, whereas both IgM and IgA, which ordinarily do not cross 
the placental barrier, are often absent. However, once IgG levels decline as maternal 
antibodies are cleared (1 or 2 months of age), a pronounced hypogammaglobulinemia 
signals the absence of humoral immunity. Serum immunoglobulin levels are altered in 
later presenters, with IgG2 levels being generally highly reduced or absent. IgE levels 
are elevated and often associated to eczema and asthma. An inability to produce Abs 
against polysaccharide and pneumococcal Ags was frequently found in ADA-SCID 
patients with milder forms of the disease (Morgan et al., 1987) (Levy et al., 1988).
1.8.3.3 Autoimmunity
A severe complication associated to milder forms of the disease is 
autoimmunity. Autoimmune manifestations include haemolytic anemia, type I diabetes, 
hypothyroidism and autoimmune thrombocytopenia (Notarangelo et al., 1992) (Ozsahin 
et al., 1997). Similar manifestation of haemolytic anemia has been reported in patients 
experienced long-term treatment with enzyme replacement therapy (Ratech et al., 
1989), indicating that PEG-ADA is not sufficient to correct the immune dysregulation. 
Mechanisms of ADA-SCID-associated autoimmunity are not clear, although alterations 
of either central or peripheral tolerance could be responsible for these complications. 
Indeed, escaping or poor immune surveillance may be related to a different sensitivity 
of regulatory T cells to purine metabolites, as suggested by the finding that “suppressor” 
T cells are more sensitive than helper T cells, in drug-induced models of ADA- 
deficiency (Ratech et al., 1984).
1.8.3.4 Additional non-immunological abnormalities
Since the ADA gene is expressed ubiquitously, the increased levels of purine 
metabolites cause also multisystemic pathologic changes in non-lymphoid tissues of
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ADA-SCID patients (Ratech et al., 1989). Approximately 50% of the affected children 
exhibit detectable radiologically bony lesions, flared costochondrial junctions and 
“rachitic rosary”. Histological studies demonstrated the lack of organized cartilagine 
columnar and trabecular formation with ininterrupted areas of calcified cartilagine 
(Cederbaum et al., 1976). Anatomic malformations of the urinary tract and 
abnormalities in renal function, consequent to mesangial sclerosis, have been reported 
in some patients (Ratech et al., 1985). Neurological disturbs have been also documented 
and consist in mental retardation, spasticity, head lag, motor dysfunction, nystagmus 
and inability to focus (Rogers et al., 2001; Tanaka et al., 1996) (Albuquerque and 
Gaspar, 2004; Honig et al., 2007). Although the relationship of these disturbances to 
ADA-deficiency remains unclear, their improvement with the enzyme replacement 
therapy (Hirschhom et al., 1980) has suggested that these abnormalities might reflect 
interaction of high concentration of Ado with adenosine Ai receptors in nervous system.
1.9 ADA-SCID: Clinical management
There are currently three different classes of therapeutic options available. They 
include: (1) bone marrow transplantation with histocompatible donors or with 
alternative donors; (2) enzyme replacement therapy; and (3) gene therapy.
1.9.1 Bone Marrow transplantation
Untreated severe ADA deficiency is usually fatal within the first years of life. 
BMT is generally the first choice therapeutic option for ADA-SCID patients for which 
an HLA-identical sibling donor is available (Antoine et al., 2003) (Stephan et al., 1993). 
This therapeutic manoeuvre displays a favorable positive outcome, with the 3-year 
survival post-BMT reaching over 90% (Antoine et al., 2003). This type of BMT is 
usually given without the requirement of prior conditioning, to reduce the risk of 
chemotherapy-associated toxicity, and generally results in a split chimerism, with T
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lymphocytes of donor origin, while other lineages, including B cells, remaining host- 
derived (Antoine et al., 2003). This may lead to variable correction of B-cell deficiency 
and of the metabolic defect (Hirschhom et al., 1981). Indeed, dAdo-based metabolites, 
even dramatically lower than in untreated patients, are still detectable higher than 
normal. Ado in the plasma persists at very high level apparently without any adverse 
effect. Haploidentical BMT with conditioning has resulted in elevated morbidity and 
mortality, with a 3-year survival of 29% (Antoine et al., 2003), in contrast to an overall 
better outcome for all forms of SCID (54%). The main reported causes of death were 
infections (56%), graft versus host disease (25%), and B-cell lymphoproliferative 
syndrome (5%). The occurrence of acute graft versus host disease led to poorer survival 
in related HLA-mismatched transplantation; no effect was apparent for chronic graft 
versus host disease. A significant improvement towards a better prevention of GVHD 
episodes in the non HLA-identical setting came from the first attempts to pursue BMT 
from T-cell depleted parental bone marrow early in life and without conditioning, to 
avoid toxicity of high dose chemoterapy (Buckley et al., 1999). The improved 
conditioning regimens and donor matches have opened new perspective for transplant 
from matched unrelated donors (MUD) or umbilical cord blood donors (UCB). 
However, there is currently limited information on the outcome of these transplants in 
ADA-SCID. Thus, in the absence of an HLA-identical sibling donor, BMT for ADA- 
SCID from an alternative donor remains a high-risk treatment.
1.9.2 Enzyme replacement therapy
ADA enzyme replacement therapy was first evaluated in 1986 as non-curative, 
life-saving treatment for SCID lacking HLA matched bone marrow donors (Hershfield 
et al., 1987). A polyethylene-glycol-modified bovine ADA (PEG-AD A) was developed 
and commercialized based on the concept that reduction of ADA substrates 
concentration in plasma results in lowering of intracellular concentrations of metabolites
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(Hershfield, 1995b). This chemical modification has allowed prolonging the circulating 
life of the enzyme, diminishing immunogenicity, and preventing degradation by 
proteases and binding by antibody. PEG-ADA is administered weekly or bi-weekly by 
intramuscular injection throughout life at an average dosage of 30-60 U/Kg. The drug 
acts in plasma to eliminate circulating dAdo and Ado, but does not cross the cell 
membrane. The kinetics and the extent of immune recovery vary between patients. In 
patients who respond to therapy, PEG-ADA results in immunological improvement 
(Weinberg et al., 1993) and decreases incidence of opportunistic infections (Hershfield, 
1995a). However, the immune reconstitution is usually incomplete since most of the 
patients remain lymphopenic after the first year, in vitro lymphocytes responses to recall 
antigens have been inconsistent, and 50% continue to require IVIg replacement 
(Hershfield, 1998). Retrospective studies evaluating the long-term effectiveness of 
PEG-ADA treatment have indicated that the partial immune recovery may be related to 
decreased diversity of B lymphocyte and to the reduced thymic activity insufficient to 
compensate for the increased commitment to apoptosis of T lymphocytes in the 
periphery (Malacarne et al., 2005) (Chan et al., 2005). Enzymatic activity was found 
mostly in the plasma, with minimal amounts detected in tissues, as thymus and spleen. 
While circulating PEG-ADA may act as a metabolic sink detoxifying systemic levels of 
Ado and dAdo, it may not completely reduce intracellular levels in susceptible 
lymphoid progenitors or mature lymphocytes. In some cases (20%), patients treated 
with PEG-ADA show no or little improvement, with fatal course occurred due to causes 
related to the immune deficiency or with development of neutralizing antibody 
(Hershfield, 1998). In one fifth of the children who developed anti-ADA antibody (50- 
60%), the neutralization of ADA activity has required the increasing in dosage, 
administration of steroids or cessation of therapy (Hershfield, 1995a). Occurrence of 
autoimmune manifestation has also been reported (Hershfield, 1995a). More recently a
case of severe haemolytic anemia was observed in one patient, enrolled in PBL-gene 
therapy protocol in our institute, after reintroduction of PEG-ADA (Aiuti A., personal 
communication). The major drawback for the worldwide diffusion of enzyme 
replacement therapy consists in its high cost estimated € 200.000,00-400.000,00 per 
patient, annually.
1.9.3 Gene therapy
Since the first pilot trials, gene therapy for ADA-SCID was supported by a 
strong rationale. The ADA gene is a housekeeping gene, widely expressed, for which a 
tightly regulated expression does not appear to be required. Low amount of correction 
and/or of engrafted HSC may result in successful therapy because as low as 10% of 
ADA activity can allow normal immune functions in healthy individuals (Hirschhom, 
1999) and wild type or gene corrected cells have a selective survival advantage over 
deficient cells in hematopoietic cell transplantation and preclinical gene therapy models 
(Ferrari et al., 1991) (Aiuti et al., 2003).
1.9.3.1 Pilot gene therapy studies
Pilot trials initiated in the 1990s were based on retroviral-mediated gene 
transduction but differed considerably with regards to the target cells, the retroviral 
construct, and the transduction procedure (reviewed in (Aiuti et al., 2003)). Patients 
eligible for gene therapy satisfied these inclusion criteria: absence of a histocompatible 
BMT sibling donor or poor immunological reconstitution upon replacement treatment. 
However, all patients continued to receive the PEG-ADA administration to avoid the 
risk of further impairing their incomplete immune functions, as the efficacy of gene 
therapy was under investigation.
1.9.3.2 Gene therapy with peripheral blood T lymphocytes
Three different trials reported the use of engineered peripheral blood T- 
lymphocytes (Blaese et al., 1995) (Bordignon et al., 1995) (Onodera et al., 1998). The
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protocols employed repeated infusion of autologous T lymphocytes transduced with 
replication-deficient, recombinant retroviral vectors, derived from the Moloney Murine 
Leukemia virus (MMLV, see section 1.10) backbone, encoding ADA cDNA (Table II). 
The marker gene encoding neomycin resistance (neoR) was usually inserted in the 
vector to allow for identification and selection of transduced cells. The available follow 
up extends to over 13 years in the first treated children, with no adverse events or 
toxicity observed. The majority of the patients displayed substantial improved immune 
functions and transduced cells persisted many years after the infusions were 
discontinued, thus showing the safety and the therapeutic potential of PBL gene 
therapy. However, the real therapeutic impact of gene therapy was difficult to evaluate, 
because the concomitant administration of enzyme replacement therapy to all patients 
likely prevented the selective growth advantage of gene-corrected cells.
Investigators Patients Gene transfer protocol Other treatments
Blease et al.1’2 2 Transduction after stimulation 
with anti-CD3 mAb and  IL-2
PEG-ADA
Bordignon et al.3 2 Transduction after stimulation 
with PHA an d  IL-2
PEG-ADA
Onodera eta l.4 1 S am e as1 PEG-ADA
Aiuti e ta l.6 1 S am e a s  3 PEG-ADA then  
discontinued
Table II. Gene therapy trials for ADA-SCID based on engineered peripheral blood 
lymphocytes.
PEG-ADA, polyethylene glycol-adenosine deaminase; IL-2, interleukin-2.
1,2- (Blaese et al., 1995); (Muul et al., 2003)
3- (Bordignon et al., 1995)
4- (Onodera et al., 1998)
5- (Aiuti et al., 2002b)
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1.9.3.3 Impact of PEG-ADA discontinuation on PBL gene therapy
Despite the solid rationale for discontinuation of enzyme replacement therapy, as 
envisaged above, it was from an ethical point of view difficult to justify cessation of a 
potential beneficial treatment. Our group reported the discontinuation of PEG-ADA in a 
patient treated with PBL-gene therapy, which failed to sustain detectable immune 
responses and showed clinical features of immune imbalance during enzyme 
replacement treatment (Aiuti et al., 2002b). The protocol included a tapering down 
phase in which PEG-ADA dosage was gradually reduced whereas the infusion of 
transduced cells was intensified. In a non-detoxified environment, genetically corrected 
T-lymphocytes progressively replaced the untransduced counterpart leading to an 
increase in PBL ADA activity and, more importantly, to the correction of their 
functional defect (Aiuti et al., 2002b). However, the increase of purine metabolites in 
RBCs was associated with a decrease of B-cell number and immunoglobulin levels 
suggesting that the purine metabolic defect was only partially corrected (Aiuti et al., 
2002b). This experience provided a strong rationale for a better approach allowing the 
correction of the immune defect and a sufficient systemic detoxification.
1.9.3.4 Gene therapy with hematopoietic stem cells
HSCs were considered the optimal target cells to achieve the appropriate 
expression of the normal ADA gene in all haematopoietic cells. Because their long- 
lasting self-renewal and multilineage differentiation capacity, HSCs had the greatest 
potential to correct the immune defect and provide the highest level of systemic 
detoxification.
Eight patients were treated with genetically modified HSCs in the early trials (Table III) 
(Bordignon et al., 1995; Hoogerbrugge et al., 1996; Kohn et al., 1995). Cells were
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collected from the BM or umbilical cord blood (UCB), enriched for HSCs, transduced 
and infused back into the patients without myeloablation.
Investigators Patients Gene transfer protocol Other treatments
Bordignon et al.1 2 Infection of BM m ononuclear cells with 
viral supernatan t, no cytokines added
PEG-ADA
Kohn et al.2-3-4 3 Infection of UBC CD34+ cells with viral 
supernatant, in p resen ce  of cytokines 
(IL-3, SCF, IL-6)
PEG-ADA, discontinued 
briefly in o n e  patient
Hoogerbrugge etal. 6 3 Co-culture of BM CD34+ cells on 
Irradiated producer with IL-3
PEG-ADA, in o n e  of the 
patien ts started  after 4 
m onths
Aiuti eta l.6 
(and unpublished data)
10 Infection of BM CD34+ cells with viral 
supernatant, in p resen ce  of retronectin and 
cytokines (IL-3, SCF, TPO, FLT3 ligand)
No PEG-ADA; low 
intensity conditioning 
with busulfan
Candotti eta l.7 4 Infection of BM CD34+ cells with viral 
supernatan t, in p resen ce  of retronectin 
and  cytokines ( SCF, TPO, FLT3 ligand)
PEG-ADA; no 
conditioning
Gaspar eta l.8 2 Infection of BM CD34+ cells with viral 
supernatant, in p re sen ce  of retronectin and 
cytokines ( IL-3, SCF, TPO, FLT3 ligand)
No PEG-ADA; mild 
intensity conditioning 
with m elphalan
Table III. Gene therapy trials for ADA-SCID based on engineered haematopoietic stem 
cells.
SCF, stem cell factor; TPO, thrombopoietin; IL-3, interleukin-3; IL-6, interleukin-6; PEG-ADA, 
polyethylene glycol-adenosine deaminase.
1- (Bordignon et al., 1995)
2,3,4- (Kohn et al., 1995); (Kohn et al., 1998); (Schmidt et al., 2003)
5- (Hoogerbrugge et al., 1996)
6- (Aiuti et al., 2002a)
7- (Candotti et al., 2003)
8- (Gaspar et al., 2006)
Patients enrolled in the HS Raffaele trial received multiple infusions of BM-enriched
progenitors cells and PBLs, transduced with similar vectors but carrying different
molecular markers (Bordignon et al., 1993). This study reported a progressive
replacement of circulating T cells derived from transduced PBLs with BM-derived T
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cells and, after two years of treatment, the long-term survival of BM-derived transduced 
cells was demonstrated in T-, B-lymphocytes, granulocytes and BM cell subsets. In the 
three patients that received genetically-corrected UCB CD34+ cells, the four years 
follow up still indicated the presence and expression of the ADA gene in the BM and 
PB (Kohn et al., 1995). However, no conditioning was administered to the patients and 
the level of engraftment of transduced cells was insufficient for achieving ADA 
expression at therapeutic levels (Kohn et al., 1998). In addition, the efficacy of gene 
therapy was difficult to evaluate because all patients continued to receive enzyme 
replacement therapy. Overall these results represented a proof of principle of the 
feasibility and safety of infusion of engineered stem/progenitor cells, paving the way to 
new clinical trials based on improved design and protocols.
1.9.3.5 HCS gene therapy combined with non-myeloablative conditioning
A novel clinical study based on improved gene transfer protocol combined with 
a strong selective advantage for the engraftment and the expansion of HSCs and their 
lymphoid progeny was carried out at the HSR-TIGET (Aiuti et al., 2002a) starting from 
September 2000. Transduction protocol of HSCs was optimized using retroviral 
supernatant produced under conditions adapted for human CD34+ cells and a culture 
medium containing a cocktail of cytokines (Illustration VIII) (Dando et al., 2001) 
(Ficara et al., 2004). In order to provide an initial advantage for adequate HSCs 
engraftment, low-intensity conditioning was introduced before the infusion with 
autologous gene-corrected cells (Aiuti et al., 2002a). The rationale for the use of non- 
myeloablative regimen originated from gene marking studies in animal models and the 
recent experience with BMTs for haematological disorders (Huhn et al., 1999) 
(Rosenzweig et al., 1999) (Slavin, 2002). Busulfan was chosen as a single 
chemotherapeutic agent because of its large use in BMT for pediatric patients, including 
patients with SCID (Bolinger et al., 2000). The dosage utilized (2mg/Kg for two
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consecutive days) represented about 25% o f the typ ical dosage used in full 
myeloablative regimens.
Day 0: Infusion
Busulfan 
2 mg/Kg/day 
(Days -3, -2)
H ADA 1 )TNeo
No PEG-ADA
Days -3 to -1:
3 cycles of transduction 
on retronectin + cytokines
¥ ©  Day -4: Purification of \^j BM-derived CD34+ cells
©
Day-4: prestimulation 
(TPO, FLT3-ligand,SCF, IL-3)
Aiuti et al. Science, 2002
Illustration XIV. Gene transfer protocol into autologous BM-CD34+ cells of ADA-SCID 
patients. CD34^ cells were harvested and purified from BM and prestimulated for 24h in the 
presence o f cytokines. Subsequently, cells were transferred to retronectin-coated bags 
previously baded with retroviral particles and further transduced twice, for a total culture period 
of 4 days. Before reinfusion of the gene corrected cells, the patients received busulfan from day 
-3 to -2, at a total dose of 4 mg/kg.
Two patients, who did not have access to PEG-ADA, were enrolled in the initial phase 
o f the trial. This condition enabled to fully exploit the selective advantage for gene- 
corrected cells and to evaluate the clinical efficacy o f gene therapy alone. Using this 
protocol, gene therapy resulted in sustained engraftment o f engineered HSC w hich 
differentiated in multiple lineages, increased lymphocyte counts, improved cellular and 
humoral responses, including antigen-specific responses, and in a substantial reduction 
in the toxic m etabolites (Aiuti et al., 2002a). These results represented the first 
demonstration o f the clinical efficacy o f HSC gene therapy alone for ADA-SCID and
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have been now extended to additional eight patients treated with the same protocol, of 
which six have been followed up for more than one year. All patients are healthy and 
show partial to full immune reconstitution, with improved systemic detoxification (Aiuti 
et al., manuscript in preparation). More recently, another group reported a successful 
HSC gene therapy protocol combined with mild chemotherapy regimen in one patient 
who showed poor response to PEG-ADA (Gaspar et al., 2006). The human ADA cDNA 
expression was driven, in this case, by the SFFV LTR of a gammaretroviral vector, 
which also contained a mutated WPRE. Two years after the procedure, immunological 
and metabolic correction has been maintained, with reconstitution of cellular immunity, 
reinitiation of thymopoiesis and systemic detoxification, in absence of any side effect.
1.9.4 Open issues in gene therapy with HSC
A key issue determining the final outcome of HSC gene therapy remains the 
degree of chimerism. Despite the overall improvement of both the immune and 
metabolic defect of ADA-SCID children enrolled in the clinical trial, one patient, 
displaying limited engraftment of gene-corrected stem/progenitor cells, achieved partial 
immune recovery and systemic detoxification (Aiuti et al., 2002a). Several explanations 
may be accounted for the reduced level of engraftment: 1) the significant lower number 
of transduced CD34+ cells infused, 2) the older age, which can be crucial factor for HSC 
engraftment, as shown for BMT transplantation in SCID (Buckley et al., 1999), 3) the 
reduced degree of BM ablation, since the patient received oral Busulfan. Therefore, 
establishing the correct balance between the amounts of transduced HSC that need to be 
infused to get long-term engraftment and the safety and low toxicity of the current 
conditioning regimen appears critical in the determining the definitive successful 
outcome of gene therapy. Moreover, it is critical to reach an adequate size of the gene 
corrected compartment, to allow sufficient degree of systemic detoxification and 
immune recovery. Thus, understanding which is the minimal level of ADA enzyme
activity sufficient to ensure metabolic and immune reconstitution becomes important 
and it would also be useful for future improvement of GT protocol. In this regard, it has 
been reported that ADA activity in leukocytes of children with partial ADA deficiency, 
which is due to mutations leading to absence of ADA in erythrocytes but residual 
activity in other cell types and usually associated with normal immune function 
(Jenkins, 1973), ranges between 2-10% of normal (Jenkins et al., 1976). It is 
conceivable that these levels are close to the threshold required for normal immune 
function. Besides the safety record of all ADA-SCID gene therapy protocols, the 
adverse events occurred in one of the SCID-X1 GT trials have raised general concerns 
on the potential risk of insertional mutagenesis caused by retroviral vector (RV) 
integration, and the long-term safety of gene therapy is now being a crucial open issue. 
The potential and the actual side effects of RV gene transfer will be discussed in detail 
in sections 1.11 and 1.12.
1.10 Retroviral vectors: Murine leukaemia virus
Among the vectors currently available for gene therapy, retroviral vectors (RV) 
are the most widely used. Most of them, as the one used in our HSC gene therapy trial, 
were derived from the retrovirus MMLV (Moloney murine leukemia virus) (reviewed in 
(Verma and Weitzman, 2005)). The genome of MMLV is constituted by a single strand 
RNA, which, after infection of the host cell, is transcribed into a double strand DNA 
molecule, by the viral enzyme reverse-transcriptase (pol) (Illustration XV). Transport of 
the viral DNA to the nucleus requires nuclear membrane breakdown occurring during 
mitosis (Roe et al., 1993). Therefore, MMLV and MMLV-derived retroviral vectors are 
able to infect only dividing cells. The viral genome, flanked at either ends by two 
identical LTRs, is constituted by three main genes: gag, pol and env, which encodes 
respectively for structural proteins (gag), reverse transcriptase and integrase (pol), and
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proteins of the viral envelope (env). The peculiarity of retrovirus, which make them 
suitable and safe vectors for gene therapy, is that the only elements required for viral 
replication and packaging in cis are represented by the 5’ and 3’ long terminal repeats 
(LTR), which contain promoter, poly-adenylation sequence and the packaging site (ip). 
All the other proteins can be supplied in trans. Therefore, all the genes encoding for 
proteins necessary to produce infectious particles can be removed and replaced with a 
cDNA encoding for the gene of interest. Transcription of this cDNA can be driven 
either by viral LTR or by an internal promoter. Since it is often necessary to express two 
genes within the same retroviral vector (usually one is the gene of interest and the other 
is a selectable marker gene), different strategies have been exploited to this purpose.
One possibility is to use the viral LTR to drive the expression of one gene and an 
internal exogenous promoter to drive the expression of the second gene. However, the 
presence of two promoters, in the context of the same vector, reduces cDNA expression. 
Therefore, alternative strategies have been developed, such as the use of a polycistronic 
message with the addition of an internal ribosome entry site (IRES) (Zitvogel et al., 
1994). To produce RV, packaging cell lines have been developed. GP+Aml2 (Freas- 
Lutz et al., 1994) is a third-generation packaging cell lines, generated by stably 
transfecting NIH 3T3 cell line with two different plasmids, encoding for gag-pol and 
env proteins, respectively. Vector production by the packaging cell line is achieved by 
stable or transient transfection with the vector plasmid, derived from the vector 
backbone and containing the op sequence and the gene(s) of interest. Safety of this 
system is guaranteed by the fact that three independent events of recombination would 
be necessary to produce a replication competent virus.
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Illustration XV. Delivery of nucleic acids by retroviral particles. Following receptor- 
mediated uptake (by fusion or via endosomes, depending on the envelope protein), retroviral 
particles can deliver three forms of genetic information: (1) if reverse transcription does not 
occur, the mRNA may be subject to immediate translation; (2) if  integration is blocked, 
episomal circles can be generated that may persist in non-dividing cells; (3) if all steps of the 
retroviral transduction process are completed, a double-stranded DNA integrates in cellular 
chromosomes. DPBS, deletion/mutation of the PBS, Datt, deletion/mutation of the att sites; 
RNAPII, RNA polymerase II.
G P+A m l2 is an amphotropic packaging cell lines, since it express an envelope, which 
allows the infections o f both murine and hum an cells. Soon after, another m urine 
packaging cell was made, the PG13 cell line, w hich differed from  the GP based 
packaging cells for the use o f a different envelope. The envelope was derived from 
Gibbon Ape Leukaemia Virus (GALV) retrovirus, which can efficiently be pseudotyped 
with the MLV Gag-pol (Miller et al., 1991) and targets a receptor very similar but not 
identical to the amphotropic receptor (Miller and Miller, 1994).
1.11 Side effects evaluation of RV-mediated gene transfer
1.11.1 Risks related to vector production
As new biological intended to be used in the clinic, RV has to comply with a 
complete set of requirements regarding their mode of preparation and characterization. 
The possibility of generating replication-competent retrovirus (RCR) during vector 
preparation or use of gene transfer vectors is a major concern associated with any virus- 
derived system. Recombination events that result in the formation of RCR occur 
between the recombinant vector genome, which carries all sequences needed in cis for 
packaging, reverse transcription and integration, and the sequence providing the viral 
proteins in trans, within the packaging system. This can happen at the DNA level 
between: (i) co-transfected plasmid; (ii) a transfected plasmid and a chromosomal 
sequence bearing homologous sequences; (iii) the proviral vector DNA generated after 
target cell transduction and chromosomal sequence. Much more frequently in RV 
system, recombination occurs at the RNA levels.
1.11.2 Risks related to transgene insertion
Due to the fact that during replication, viral RNA genome was reverse 
transcribed into a DNA copy that becomes integrated into the host cell genome, RV 
may theoretically induce cell transformation by a phenomenon known as insertional 
mutagenesis. Historically, this risk has been generally evaluated as very low, basing on 
the probability of insertion in a given site of the host cell genome. Unfortunately, 
clinical adverse events, linked to vector integration leading to LM 02  proto-oncogene 
transactivation, occurred in otherwise successful HSC-based gene therapy trial of SCID- 
XI (Hacein-Bey-Abina et al., 2003) (see section 1.12). These events have raised serious 
concerns on the use of RV in clinical application and the safety of this treatment has 
become a primary consideration.
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1.11.2.1 Patterns of integration of RV vectors
The readily accessible human genome sequence and the development of robust 
PCR-based technologies prompted to the diffusion of mapping studies of RV integration 
sites (RIS) with regard to their exact chromosomal location, relation to neighboring 
sequences and potential interference with coding and regulatory regions. A comparative 
analysis of cell lines, non-human primate and human hematopoietic progenitors cells 
transduced with HIV-1 or MLV based vectors showed that each vector type produces a 
unique pattern of RIS distribution in the human genome. MLV integrants were found 
preferentially surrounding the transcription start sites (TSS) and regulatory regions 
(CpG islands) of active genes, while HIV preferentially targeted intragenic sites with a 
distribution along the entire length of the active gene (Schroder et al., 2002; Wu et al., 
2003) (Mitchell et al., 2004) (Hematti et al., 2004) (Laufs et al., 2004). Moreover, 
studies with gene trap vectors performed in primary hematopoietic cells confirmed the 
stronger bias of MLV vectors to insert in promoter-proximal windows, as compared 
with similarly designed HIV-derived vectors (De Palma et al., 2005). Therefore, MLV 
vector integrations near 5’ ends of genes may be more likely to disrupt transcriptional 
control and result in deregulated expression of potentially oncogenic gene products, 
while the main risk of LV could be the abrogated production of the normal gene 
(Illustration XVI). A striking finding in this large-scale integration survey was the 
evidence for the formation of integration hotspots (Mitchell et al., 2004; Schroder et al.,
2002) (Calmels et al., 2005) (Kustikova et al., 2003). Recurrent integration in specific 
gene loci has provided evidence that the insertion may confer a non-random growth or 
survival advantage to the affected cell clones (Calmels et al., 2005; Kustikova et al.,
2003). This aspect will be discussed in section 1.11.2.3.
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Illustration XVI. Activation of cellular genes by insertional mutagenesis. (A) A prototypic 
gene, for instance an oncogene, is shown with its promoter, exons, and introns. The primary 
transcript originating from the promoter is represented as a purple line. Integrations of a 
retrovirus or a retroviral vector near the promoter can stimulate the latter via enhancer elements 
located in the virus LTR or internal promoter (blue arrows), resulting in the increased 
production of the physiological primary transcript (dark blue line). Aberrant transcripts can also 
originates from promoters contained in the vector itself (orange line). (B) MLV vectors (green) 
integrating in and around the promoter have a high chance o f stimulating cellular gene 
expression by either enhancer (blue arrows) or promoter (orange arrows) effects. The transcript 
emanating from vector-contained promoters will be full-length or nearly full-length. As they 
integrate farther away along the transcribed region of the gene, HIV vectors (yellow) may have 
a lower chance of stimulating the cellular promoter via enhancer effects, and can only give rise 
to significantly truncated version of the normal cellular transcript.
1.11.2.2 Factors influencing integration site selection
The integration reaction requires specific sequences at the double strand ends of 
the viral cDNA, which bind the viral-encoded integrase and other proteins to form 
preintegration complexes (PICs; (Schroder et al., 2002)). Studies using integration in 
vitro  have begun to clarify factors influencing integration site selection in simplified 
models. DNA-binding proteins bound to target DNA create “hot spot” for integrations. 
The mechanism is still unclear, but DNA distortion around nucleosomes may favor the 
access o f the viral integration com plexes to receptive DNA  (Bushm an, 1994).
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Integration may be promoted by increased chromatin accessibility in transcribed regions 
through favorable interactions between PICs and locally bound transcription factors or 
chromosomal proteins. In support of this idea, it has been established that retroviral 
integrase enzymes fused to sequence-specific DNA-binding domains can direct 
integration preferentially to local regions when tethered at specific DNA sites 
(Bushman, 1994). Thus, the ultimate pattern of vector integration may reflect both the 
integration preferences of the vector system used and the nature of the regulatory 
elements included within the vector. The analysis of chromosomal regions favored for 
integration confirmed a role for locally bound proteins. Statistical test have indicated 
that favourable regions were typically short (100-250 Kb) and for MLV these landed 
within or near CpG islands. CpG islands are thought to be regulatory regions that bind 
distinctive sets of transcription factors. Therefore, a distinctive set of sequence-specific 
DNA-binding proteins bound at or near CpG islands favour MLV integration, while 
proteins bound in active transcription units are favourable for HIV insertion (Mitchell et 
al., 2004). A further possibility is that the intranuclear environment of active genes 
favors integration. However, whether transcription promotes integration directly or by 
indirect mechanisms is currently unclear.
1.11.2.3 Hot spots for retroviral integration
Analysis of MLV integrations pattern in natural or experimentally induced 
leukaemia/lymphomas have shown the existence of insertion sites recurrently associated 
with a malignant phenotype. These “common insertion site” (CIS) include proto­
oncogenes or other genes associated with cell growth and proliferation, the activation or 
deregulation of which has a causal relationship with the establishment and/or 
progression of neoplasia (Wu et al., 2006). Some of these sites, such as the EVI1-MDS1 
locus, have been identified at relatively high frequency also in the non-malignant 
progeny of transduced hematopoietic cells in mice (Kustikova et al., 2005) and non­
human primates (Calmels et al., 2005), indicating that insertion into certain genes may 
cause clonal amplification of transduced progenitors in vivo. More recently, insertions 
into EVI1-MDS1 locus and into the related gene, PRDM16, have been found in the 
dominant clones with myeloid expansion in the two patients of the GT trial of CGD (see 
section 1.12), suggesting that these genes can influence regulation of normal long-term 
hematopoiesis in humans. The lack of progression towards monoclonality or leukemia, 
observed in these studies, would indicate that these events likely depends on the 
occurrence of additional mutations or on cooperating effects of the transgene. Low 
incidence of CIS insertion has been reported for human gene-modified T lymphocytes 
(Recchia et al., 2006).
1.11.2.4 Impact of integration on expression of nearby genes
Detailed information is beginning to accumulate about the impact of specific 
integration events on the expression of nearby genes, a phenomenon known as 
transcriptional perturbation. Dominant clones that contributed to hematopoiesis in 
secondary transplant recipients were consistently found to have increased expression of 
a gene within the region of the integrated RV genome that could be implicated in 
potentially causing proliferation or survival advantage (Kustikova et al., 2003). A large 
scale-mapping of RIS in modified T lymphocytes from leukemic patients after 
allogeneic stem cell transplantation has shown that RV vectors integrated preferentially 
around TSS and in genes expressed during transduction (Recchia et al., 2006). Some 
integrations, landed within 25 Kb upstream from the TSS or more than 100 Kb 
downstream, can deregulate gene expression independently from their transcriptional 
orientation, albeit without consequences on the biology and function of transplanted 
cells (Recchia et al., 2006). Another continuing study has examined the impact of LV 
vectors integrated into primitive hematopoietic cells (Hargrove P. W. , 2004). Despite 
the occurrence of rare cases of transcriptional perturbation in genes some distance (as
far as 300Kb) from the integration site, the majority of integrated vector genomes had 
no discernible impact on expression of nearby genes even when the integration had 
occurred in a gene-rich area.
1.11.2.5 Silencing
Vector integration into, or next to heterochromatin may induce, through specific 
retroviral enhancer elements, inhibition of transcription (position-dependent silencing) 
or may result in varying expression in progeny cells (position-effect variegation) 
(Brenner et al., 2003). Indeed, it is commonly agreed that gene silencing tends to occur 
in undifferentiated cells that go through a long differentiation process. CpG methylation 
is strongly correlated with gene silencing. Regions rich in nonmethylated CpG are 
found in many functional promoter elements. Integration of foreign DNA sequences 
into the genome itself triggers methylation of CpG dinucleotides and DNA methylation 
inhibits transcriptional activity. A link between DNA methylation and chromatin 
structure has recently been identified. By binding to methylated viral sequences, host 
proteins mediate the recruitment of histone deacetylases (HD AC) to the transduced gene 
locus. HDAC deacetylate specific histones and lead to chromatin condensation and 
transcriptional silencing (Wolffe and Matzke, 1999).
1.11.3 Risks related to transgene expression
Using available vectors and HSCs as targets, somatic gene transfer typically 
results in ectopic and nonregulated expression of the transgene, both with respect to the 
cell type affected and the level of expression achieved. Moreover, the repertoire of 
vector integration sites may also modulate different aspects of the transgene expression, 
including duration, level and differentiation dependence. The ectopic and deregulated 
expression of the transgene may cause, in some instances, dose-dependent toxicity 
(Schiedlmeier et al., 2003) or even severe side effects (Zhou et al., 2001). Toxicity 
related to transgene expression may most frequently manifest in a competitive
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disadvantage, leading to extinction of the affected cell (clone). However, transgene 
interference with cellular behavior may eventually results in new disease manifestation. 
Therefore, it can be predicted that any transgene product has a specific therapeutic 
window, defined by the balance between desired function and unwanted effects. The 
exact definition of this window, which would be crucial for the evaluation of gene 
transfer therapeutic potential, may depend on the ability to maintain a regulated 
expression, thus highlighting the importance of developing vectors for spatially and 
temporally controlled expression of the transgenes.
1.11.4 Risks related to conditioning
Following genetic modification of HSCs in vitro, their engraftment and 
contribution to hematopoiesis in vivo are dependent upon the strategies used for 
conditioning or selective amplification. Irradiation or cytotoxic agents, which provide a 
moderate to severe (myeloablative) lymphohematotoxicity, can however be complicated 
by severe long-term toxicity. Nonmyeloablative regimens with sublethal toxicity have 
been investigated (Sandmaier et al., 2000) and show great promise for HSC-mediated 
gene therapy (Aiuti et al., 2002a). However, it remains unclear whether chimerism will 
be maintained in a stable manner, long term, when nonmyeloablative protocols are 
performed in autologous clinical setting. Indeed, key factors such as incomplete 
tolerance and absence of selective advantage for engineered cells may determine the 
final outcome. A selective survival advantage for gene modified HSCs can be promoted 
upon transfer and expression of selectable marker genes (Mavilio et al., 1994) (Li et al., 
2002). For most of these markers, drugs are required to trigger their function (Bonini et 
al., 1997). Therefore, side effects related to their use represent an important aspect in the 
preclinical and clinical evaluation. Indeed, while some of these agents have a well- 
documented toxicity profile in humans (Sorrentino, 2002), others potentially less toxic 
may provide incomplete, lineage restricted or unstable expansion (Matsuda et al., 1999).
Clonal amplification of transgenic cells is another important variable. Although gene- 
marking studies have indicated that the size of grafted stem cells implies a modest 
expansion pressure and a high likelihood for polyclonal reconstitution (Schmidt et al.,
2002), single clones of transduced HSCs may achieve normal multilineage 
hematopoiesis (Pawliuk et al., 1997). However, the minimal number of HSCs that 
stably support primate hematopoiesis remains to be defined.
1.11.5 Risks related to immune surveillance
A further category of side effects is related to innate or acquired immunity 
against vector components or immune surveillance of engineered cells. In principle, a 
transient exposure to antigens may derive from remnants of vector particles or culture 
media components on infused cells (Balague et al., 2000). This risk appears relatively 
low with the conventional retroviral transduction protocols, but the probability of viral 
contamination may increase with the use lentiviral vectors, for which the time of cell 
culturing after the final round of vector exposure may be shortened (Scherr et al., 2002). 
Accordingly, repetitive infusion of engineered cells may be complicated either by 
sensitization to vector- or culture-related antigens, or transgene expression, potentially 
resulting in clearance of transgenic cells (Tuschong et al., 2002) or even severe acute 
adverse reactions. Immune responses against transgene may develop with some latency. 
This concern is of particular relevance when introducing artificial or xenogenic 
sequences (as in the use of some selectable marker genes). Indeed, although BMT may 
promote tolerance to multiple or individual antigens (Heim et al., 2000) (Kang et al., 
2001), this does not necessarily occur following nonmyeloablative conditioning 
regimens. Immune-mediated rejection of transgenic cells expressing the xenogenic 
marker enhanced green fluorescent protein has been documented in a study with non 
human primates (Rosenzweig et al., 2001), suggesting that tolerance induction should 
be a key issue for future gene therapy applications.
1.12 Genotoxic effects of RV gene transfer in GT clinical trials: the paradigm of 
SCID-X1 and Chronic Granulomatous Disease
Recently, the potential genotoxic effect of RV has dramatically come to the 
attention, due to the occurrence of adverse events in one ongoing RV-based clinical trial 
for SCID-X1. The genetic defect originates from the lack of the y subunit of the IL-2 
receptor, also called the common y chain (Kovanen and Leonard, 2004). Gene therapy 
trials were based on the use of MMLV-derived retroviral vectors. Autologous BM- 
derived CD34+ cells were transduced ex vivo and then re-infused into the SCID patients 
in absence of any preparative conditioning (Cavazzana-Calvo et al., 2000) (Gaspar et 
al., 2004). In the French trial, the effectiveness of the treatment was demonstrated in 9 
out of 11 patients enrolled with sustained transgene expression and immunological 
reconstitution (Cavazzana-Calvo et al., 2005). However, three patients developed 
leukaemia, approximately 2.5 years after gene therapy. Genetic analysis of the leukemic 
clones showed that in the two first cases the retroviral-vector had integrated within or 
upstream of the LM 02  locus causing an insertional activation of the proto-oncogene 
transcription mediated by retroviral LTR. The third case also seems to be associated 
with this event, among additional proto-oncogene insertions (Hacein-Bey-Abina et al.,
2003) (Lttp://afssans.sante.fr/ang/indang.htnT). LM 02  is normally expressed in 
haematopoietic progenitors and its locus is involved in chromosomal translocation in 
cases of acute T-cell leukaemia (T-ALL) (Rabbitts et al., 1999). Although vector 
integration close to LM 02 gene was found to reside within FRA1 IE, a common fragile 
site (Bester et al., 2006) (Hacein-Bey-Abina et al., 2003) and chromosomal aberrations 
were detected in the expanded clones of both patients, the mature phenotype of such 
clones cannot be associated with T-ALL (Hacein-Bey-Abina et al., 2003). No 
overexpression of yc gene or constitutive activation of downstream transducing 
molecules was observed in either the normal corrected or the leukemic T cells from
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patients (Hacein-Bey-Abina et al., 2003). Furthermore, gain-of-function mutations of 
the yc receptor were excluded by sequencing the integrated provirus (Hacein-Bey-Abina 
et al., 2003). Beside these findings, evidence has emerged recently supporting the 
hypothesis that RV-driven yc transgene expression may synergistically cooperate to the 
oncogenic transformation, possibly influencing T cell differentiation (Dave et al., 2004) 
and even act as an oncogene itself in murine models of leukemogenesis (Woods et al., 
2006). However, this interpretation have been challenged other studies indicating the 
inability of overexpressed IL2Ryc to affect normal T cell development (Pike-Overzet et 
al., 2006; Pike-Overzet et al., 2007) and increase tumor incidence in different mouse 
models (Thrasher et al., 2006). Thus, the potential interaction, if  any, between LM 02  
overexpression and RV-mediated yc gene expression remains uncertain. No vector 
integration in LM 02  oncogene was detected in the English trial (A. Thrasher, oral 
presentation, 3th Stem Cell and Genotoxicity Retreat, 2007, Orlando). Therefore, 
additional factors may be more related to the gene therapy protocol, such as ex vivo 
culture conditions, vector pseudotype or the kinetic of lymphoid reconstitution. The 
results of the HSC gene therapy trial for CGD, gained by Ott and collegues, throw 
different light on the influence of transcriptional perturbation on gene therapy outcome. 
CGD is a rare inherited immunodeficiency caused by a functional defect in the 
microbial killing activity of phagocytes (Segal, 1996). Almost 70% of CGD patients 
carry defects in the X-linked gene encoding for gp91phox (X-CGD) (Winkelstein et al., 
2000), essential subunits of the phagocytic NADPH oxidase complex. The clinical 
protocol was based on ex vivo retroviral gene transfer of gp91phox cDNA into (G- 
CSF)-mobilized PB CD34+ cells combined with non-myeloablative conditioning (L-Bu) 
(Ott et al., 2006a). Results of the trial have indicated the restored enzyme activity in 
transduced phagocytes, which was paralleled by the resolution of natural occurring 
bacterial and fungal infections in the three patients enrolled (Ott et al., 2006a) (Ott et al.,
2006b). The high level of correction achieved in phagocytes resulted from an 
unexpected in vivo expansion of gene corrected myeloid cells, due to activating 
common integration sites in the zinc finger transcription factor homologs MDS1/EVI1, 
PRDM16 or SETBP1 (Ott et al., 2006a). Among the three clusters of integrations, the 
relative contribution of each clone changed over time with dominant clones retaining 
the major stable contribution. Unfortunatly, a progressive decrease in the number of 
gene corrected cells and in the functional activity of the predominant clone was 
observed more than two years after GT in Ptl, leading to his fatal course due to severe 
bacterial sepsis (Ott et al., 2006b). Althought the molecular causes are still to be 
determined, vector silencing consequent to methylation of the R and U5 LTR regions 
seems to be implicated (M. Grez, oral presentation, 3th Stem Cell and Genotoxicity 
Retreat, 2007, Orlando). Importantly, no evidence of malignant transformation was 
found in peripheral blood or bone marrow aspirates from this patient, as demonstrated 
also by growth factor-dependent proliferation of transduced cells.
Several factors, primarily related to the gene transfer protocol, could be accounted to 
explain the clonal expansion/selection observed in CGD trial. The use of a vector with 
SFFV long terminal repeat sequences, which contains potent enhancer elements for 
gene expression in hematopoietic stem and myeloid progenitors cells, may have favored 
the activation of specific genes and led to the observed clonal over-representation. 
Integrations in MDS/EVI1 and PRD M 16 genes were also described in other gene 
therapy studies (see section 1.11), suggesting that these genes can influence regulation 
of normal long-term hematopoiesis in humans. Although longer follow up is required 
for safety considerations, the experience of CGD trial lead to consider additional 
implications in the balance between clinical benefit and the potential risk associated to 
the type of treatment. Indeed, the therapeutic benefit was achieved in treated CGD 
patients through the insertional side effects of gene therapy approach, which provided
selective growth advantage for affected cells.
1.13 Future perspective for safety improvement
Third generation lentiviral vectors are constructed in a way to address the 
biosafety requirements, which implies the removal of all the proteins involved in AIDS 
pathogenesis, while all the other structural and enzymatic proteins are provided in trans 
in three different plasmids. These vectors were shown to efficiently transduce human 
BM-derived repopulating CD34+ cells after short ex vivo manipulation (Guenechea et 
al., 2000) and to provide high level and stable transgene expression, making them a 
suitable tool for gene therapy trials in haematological diseases (Mortellaro et al., 2006).
The use of cellular instead of strong viral promoters would allow regulated and tissue- 
specific expression of the therapeutic gene, avoiding ectopic expression and reducing 
the potential toxicity of the treatment. As for RV, LV carries the risk of insertional 
mutagenesis. In spite of this, LV are likely to become the vectors of choice for the 
future gene therapy clinical trial, as they accomplish two important safety requirements: 
the usage of transcriptional regulatory elements and low genotoxicity due to the 
possible influence of the vector on the transcription of neighbouring genes (Montini et 
al., 2006). However, to demonstrate that LV would be less prone than their 
oncoretroviral counterparts to cause tumors by insertional mutagenesis, more extensive 
and long-term studies in relevant animal models need to be pursued.
The construction of vectors with the so-called self-inactivating (SIN) LTRs, which rely
on a single internal promoter to drive transcription of the transgene (Miyoshi et al.,
1998), would significantly reduce the risk of aberrant expression of adjacent genes. This
was achieved by creating a deletion in the U3 region of the 3 ’ LTR. During reverse
transcription in the target cells, this deletion is transferred to the 5’ LTR of the proviral
DNA. If the deletion is efficient to abolish the transcriptional activity of the LTR
promoter, the transcription of the full-length vector RNA would be eliminated in
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transduced cells. The possibility of insertional activation of adjacent cellular oncogenes 
would also be reduced. Furthermore, as there would be no complete U3 sequence in the 
producer system, recombination to generate a wild type U3 would not be possible. In 
addition to improved biosafety, the use of SIN vectors has two added advantages: 
elimination of transcriptional interference by LTR promoter, and the possibility to 
create tissue-specific and inducible vectors, which would be difficult in the presence of 
non-specific transcription from the LTR promoter (Zufferey et al., 1998).
Insulators are DNA elements with enhancer-blocking activity that can also be 
engineered into therapeutic vectors to inhibit transactivation of adjacent genes in the 
genomic DNA (West et al., 2002). In oncoretroviral vectors, insulators have been 
shown to attenuate position effects (Rivella et al., 2000), but further investigations in 
appropriate animal models would be required for efficacy evaluation. A different 
approach to tackle the risk of insertional oncogenesis would be to incorporate into 
vector a safety function that could be activated in the case of tumor formation, as 
proposed for the elimination of alloreactive T lymphocytes (Bonini et al., 1997). The 
functional reliability, the transcriptional regulation and the immunogenicity of existing 
suicide systems remains to be established.
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1.14 SPECIFIC AIMS
ADA-deficient SCID is a complex genetic disease with the major involvement 
of lymphoid compartment in the disease pathogenesis. Different mechanisms whereby 
ADA deficiency may affect the development and function of T lymphocytes have been 
suggested, including ADA substrates accumulation and aberrant adenosine receptor 
signaling. However, the precise mechanisms of this toxicity are not yet defined in 
humans, as no in depth studies have been performed in ADA-SCID patients.
ADA-deficiency can be successfully treated with HSC-based gene therapy. 
Results of the clinical trial established at HSR-TIGET have shown the correction of the 
immunological and metabolic defect in the patients enrolled, with full clinical benefits 
in the absence of side effects (Aiuti et al., 2002a). However, despite the excellent safety 
record of ADA-SCID trial, the long-term safety of retroviral-mediated therapeutic gene 
transfer has been recently questioned based on the risk of insertional mutagenesis, 
which has emerged as a serious drawback in the context of GT for SCID-X1 (Hacein- 
Bey-Abina et al., 2003).
The main aims of my PhD project were to study the molecular basis of ADA- 
SCID pathogenesis and to evaluate the efficacy and safety of HSC gene therapy as a 
curative treatment for the disease.
Untransformed polyclonal T-cell lines established from ADA-SCID patients 
before and after gene therapy have provided a unique model to investigate i) the 
molecular events responsible for immunological defects in ADA-deficient SCID; ii) the 
role of ADA substrates in controlling T cell survival, proliferation and functions; iii) the 
efficacy of gene therapy in restoring normal metabolic and immune functions.
In order to evaluate the long-term safety of HSC gene therapy, a systematic 
analysis of retroviral vector insertion sites has been carried out in five ADA-SCID
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patients. Both inverse- and LM-PCR were set up and performed in purified 
hematopoietic cells subsets. The genomic impact of retroviral vector integration pattern 
was analyzed in terms of influence on gene expression profile at the bulk and single-cell 
level. Affymetrix Gene Chip arrays were used to assess expression profile in bulk 
population, whereas quantitative transcript analysis of genes targeted by vector 
integration in T-cell clones was performed by low-density gene expression array 
technique with two specifically designed microfluidic cards.
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CHAPTER 2 -  Materials and Methods
2.1 Patients and clinical trial
Five ADA-SCID patients have been studied in this work. Patients Ptl and Pt2 
have been previously described (Aiuti et al., 2002a) while Pt3, Pt4 and Pt5 were 
diagnosed as early onset ADA-SCID (<6 months of age), after showing recurrent 
pulmonary infections and failure to thrive. All patients were treated with gene therapy 
after failure of haploidentical BMT transplant (Pt2, Pt3, Pt4), or PEG-AD A treatment 
(Pt4, Pt5). The ADA-SCID clinical trial was approved by the H. San Raffaele Ethical 
Committee, the Italian Istituto Superiore di Sanita and received Orphan Drug Status by 
the European Medicines Agency. The patients received 0.9 to 9.4 x 106 BM CD34+ 
cells/kg transduced with an ADA-expressing MLV vector after low-dose conditioning 
with busulphan, as previously described (Aiuti et al., 2002a). Multilineage, stable 
engraftment of gene corrected stem/progenitor cells was achieved in all patients. The 
proportion of vector-containing cells ranged from 70 to 100% in T cells and 0.7 to 16% 
in granulocytes, with the exception of Pt2 who displayed low myeloid engraftment 
(<0.1 %) (Aiuti et al., 2002a). Following gene therapy a progressive increase in 
lymphocyte counts, restoration of polyclonal thymopoiesis and normalization of 
proliferative responses to mitogens and antigens was observed in all patients. Anti­
microbial prophylaxis has been either discontinued or reduced after gene therapy. 
Improved serum Ig levels and production of specific antibodies after IVIG 
discontinuation and antigen vaccination was observed in three patients. Sustained ADA 
activity in lymphocytes and RBC resulted in the correction of purine metabolism and 
amelioration of systemic toxicity. No adverse events related to gene transfer were 
observed in a follow-up with a median of 3.1 years (A.A. et al., manuscript in 
preparation).
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2.2 Cells
Blood samples from ADA-SCID patients and healthy donors were obtained after 
informed consent following standard ethical procedure and with approval of the San 
Raffaele Scientific Institute Internal Review Board for ADA-SCID GT (Gene ADA) 
and healthy donors.
2.2.1 Purification of cell subsets from peripheral blood and BM
Mononuclear cells from PB and BM samples were isolated by density gradient 
centrifugation on Ficoll-Hypaque. The PB granulocyte fraction was enriched by 
consecutive separations on dextran and Ficoll-Hypaque gradient. Thereafter, the 
different subpopulations were isolated by immunomagnetic tecnique using antibody- 
coated microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and FACS cell- 
sorting using fluorescine-labelled antibodies (FACS Vantage, BD Bioscience, CA, 
USA). The following monoclonal antibodies were used for positive selection: anti- 
CD 15 (granulocytes), anti-CD 19 (B cells), anti-CD61 (megakaryocytes), anti- 
glycophorin A (erythroid cells), anti-CD56 (NK cells), anti-CD3 (T cells), anti-CD4 
(CD4+ T cells), anti-CD8 (CD8+ T cells). Two steps of purification were performed to 
increase the purity to >98-99%.
2.2.2 T-cell lines
Untransformed T-cell lines were generated from PBMCs purified by density 
gradient centrifugation on Ficoll-Hypaque (Nycomed Pharma AS, Oslo, Norway) and 
seeded at the concentration of 0.5x106/ml. Cells were stimulated with 1 (ig/m l 
phytohemagglutinin (PHA) (Roche Diagnostics Corp.), 600IU/ml rhIL-2 (Chiron Corp., 
Emeryville, USA) in the presence of an allogeneic feeder mixture of 1x10 6/ml PBMC 
(X-ray irradiated at 60 Gy) and 105/ml JY cells (X-ray irradiated at 100 Gy), an EBV- 
lymphoblastoid cell line expressing high levels of HLA and costimulatory molecules
78
(Bacchetta et al., 1994). The cultures were performed in IMDM (Cambrex Bio Science, 
Verviers, Belgium) supplemented with 10% YSSEL medium (Dyaclone, Besanfon, 
France), 5% Hyclone (Cambrex Bio Science) and lOOU/ml penicillin/streptomycin 
(Bristol-Myers Squibb, Sermoneta, Italy). T cells were expanded by adding fresh 
medium with rhIL-2 and restimulated as described every 14 days. CD4+ T cells subsets 
were purified from established T cell lines by immunomagnetic tecnique using anti- 
CD4 antibody-coated microabeads (Miltenyi Biotech, Bergische Gladbach, Germany) 
according to the manufacturer’s instructions (purity was > 98%). All experiments 
shown were performed in T cell lines between day 12-15. EBV-transformed B cell line 
JY and was maintained in IMDM supplemented with 10 % FBS and 
penicillin/streptomycin.
2.2.3 T-cell clones
PBMCs from Pt2 and Pt3 were isolated by Ficoll-Hypaque gradient separation 
and enriched for T lymphocytes by immunomagnetic-based depletion of monocytes 
(CD 14) and B cells (CD 19). Individual T-cell clones were obtained by plating cells in 
96-well plates at a concentration of 0.3-1-3 cells per well. Cells were stimulated with 
with 1 [xg/ml PHA (Roche Diagnostics Corp.), lOOIU/ml rhIL-2 (Chiron Corp., 
Emeryville, USA) in the presence of an allogeneic feeder mixture of lx l0 5/well PBMC 
(X-ray irradiated at 60 Gy) and 104/well JY cells (X-ray irradiated at 100 Gy). The 
cultures were performed in IMDM (Cambrex Bio Science, Verviers, Belgium) 
supplemented with 10% YSSEL medium (Dyaclone, Besan9on, France), 5% Hyclone 
(Cambrex Bio Science) and lOOU/ml penicillin/streptomycin (Bristol-Myers Squibb, 
Sermoneta, Italy). T-cell clones were expanded by adding fresh medium with 600IU/ml 
rhIL-2 and restimulated as described every 14 days.
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2.3 Reagents
Adenosine, 2’-deoxyadenosine, the selective A2A adenosine receptor agonist 
(CGS21680), the selective A2A adenosine receptor antagonist (SCH58261), the 
nucleoside uptake inhibitor (Dipirydamole), the adenylyl cyclase inhibitor (2’,5’- 
Dideoxyadenosine 3’-triphosphate tetrasodium) were purchased from Sigma Aldrich (St 
Louis, USA). The inhibitor of cAMP-dependent protein kinase A (PKAI) was from 
Alexis Biochemicals (UK).
Formulation of buffers used for Western Blot: CELL LYSIS BUFFER (50 mM 
Tris-HCL pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% ND-40, anti-proteases added fresh 
every time); LAEMMLI BUFFER (62.5 mM Tris-HCL pH 6.8; 2% w/v SDS, 10% 
glycerol, 5% Beta-Mercaptoethanol, Bromophenol Blu); TBS (10X: 24.2 g Tris-Base,
80 g NaCl, pH 7.6 with HC1), BLOCKING BUFFER (TBS IX, 0.1% Tween-20, 5% 
BSA); TRANSFER BUFFER (250 mM Tris-Base, 2mM Glycine, Methanol final 20%).
2.4 Flow cytometry
2.4.1 ADA expression
Expression of ADA protein was assessed in patients and control T-cell lines with 
intracellular staining. Cells were fixed and permebilized with the Cytofix/Cytoperm kit 
(BD Biosciences Pharmingen) and incubated with anti-human ADA monoclonal antibody 
(kindly provided by Dr. M. Hershfield) revealed by a secondary goat anti-mouse Alexa 488 
antibody (Southern Biotechnology, USA).
2.4.2 A2A Adenosine receptor expression
Expression of A2A Adenosine receptor was assessed in patients’ and control T- 
cell lines with intracellular staining. Cells were fixed and permebilized as described 
above, incubated with anti-A 2A Adenosine receptor (Sigma Aldrich) polyclonal 
antibody and revealed by goat anti-rabbit PE (Molecular Probe, Invitrogene, USA).
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2.4.3 Apoptosis
After time course incubation with drugs, cells were stained with Annexin 
V-FITC (BD Biosciences) andpropidium iodide (50 pg/ml, Sigma-Aldrich).
2.4.4 TCR-Vbeta repertoire
Cells (2x105) were stained with a mix of directly conjugated TCR Vb antibodies 
corresponding to 24 different specificities, according to manufactory instructions 
(IOTest Beta Mark kit; Immunotech, Marseille, France).
In all the experiments, the analyses were performed using FACScan flow cytometer 
using CellQuest software (BD Biosciences)
2.5 ADA and SAHH enzymatic activity
Intracellular ADA enzyme activity was analyzed in cell lysates (0.5x106 cells) by 
an adenosine to inosine conversion assay, followed by high-performance-capillary- 
electrophoresis (HPCE) (Carlucci et al., 2003). Intracellular SAHH activity was 
determined in cell lysates (0.5x106 cells) by an adenosine consumption assay, followed 
by HPCE (Carlucci et al., 2003). Results were expressed as nmol/h/mg protein.
2.6 T-cell proliferation
Resting patients’ and control T-cell lines were seeded at 1x10s cells/well in a 
96-well plate round-bottom pre-coated with the indicated dose of anti-CD3 mAb 
(OKT3, Janssen Cilag, Ltd.) for 48 hours in the presence or absence of drugs with or 
without soluble anti-CD28 mAb (10 pg/ml; BD Biosciences), in a final volume of 200 
pi. T-cell proliferation was analyzed after 48 hr of stimulation, by a 16- hours pulse 
with 1 pCi/well 3H-thymidine (Amersham Pharmacia Biotech) followed by harvesting 
using the 96-well plate harvester (Tomtec, Hamden, USA) and counting by liquid 
scintillation. All experiments were performed in duplicate or triplicate wells.
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2.7 Analysis of cytokine production
2.7.1 ELISA
The secretion of cytokines was measured in the supernatants of resting and 
activated patients’ and control T cell lines, which were plated at the initial density of 
lxlO5 cells/well. Supernatants were collected at different time points (18 hr for IL-2 and 
48 hr for the other cytokines) and the presence of cytokines was detected by standard 
capture ELISA, which was performed according to the manufacturer’s instructions (BD 
Biosciences Pharmingen). Concentration of cytokines was calculated by parallel 
measurement of a standard curve, generated using recombinant human cytokines (R&D 
System).
2.7.2 Intracellular cytokine staining
Resting T cells ( lx l0 6/ml) were stimulated either with coated anti-CD3 mAbs 
plus soluble anti-CD28 mAbs or with 10 ng/ml TPA plus 500 ng/ml ionomycin in 
complete medium, at 37°C, in a 5% CO2 atmosphere. Upon initiation of the experiment, 
plates were centrifuged for 2 min at 800 rpm. After 3 hr, 10 (ig/ml Brefeldin A 
(Calbiochem) was added to the wells. After additional 3 hr, T cells were collected and 
fixed in 2% formaldehyde. After fixation, T cells were permeabilized by 10 min 
incubation in blocking buffer (PBS 0.3% BSA, 0.1% NaN3) supplemented with 0.5% 
Saponin (Sigma Aldrich). Permeabilized T cells were incubated in blocking buffer with 
0.5% Saponin in the presence of PE-labelled anti-hIL-4, PE-labelled anti-hIL-2 and 
FITC-labelled anti-hIFN-y(BD Biosciences Pharmingen). After washing, cells were 
analyzed by FACS and data were analyzed by CellQuest software.
2.7.3 Cytokine mRNA expression
CD4+ T cells from ADA patients and healthy donors were stimulated with 
immobilized anti-CD3 mAb (1 ng/ml) plus soluble anti-CD28 mAb (10 ng/ml) for 5 
hours. Total RNA was extracted from lx l0 6 cells using Eurozol reagent (Euroclone
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S.p.A., Milan, Italy) and reverse transcribed by using the High Capacity cDNA Archive 
Kit (Applied Biosystems, CA, USA) according to the manufacturer’s instructions. 
Expression analysis of IL-2, IL-4 and IFN-y genes was carried out with TaqMan system, 
developed as custom “assay on demand” by Applied Byosistems. The data were 
analyzed by the ABIPRISM 7700 with the sequence detector system software. Samples 
were run in duplicate and the relative expression of cytokines was determined by 
calculating the difference between threshold cycles for the stimulated (target) and 
unstimulated (control) samples (ACT method) after normalization to the housekeeping 
gene hypoxanthine guanine phosphoribosyl transferase (HPRT), which was run in the 
same tube. The results for each T cell line were expressed as n-fold difference relative 
to the control sample.
2.8 T-bet and GATA-3 mRNA expression
To measure T-bet and GATA-3 mRNA levels, CD4+ T cell lines from ADA 
patients and healthy donors were stimulated with immobilized anti-CD3 mAbs plus 
10 pg/ml soluble anti-CD28 mAbs for four hours. Total RNA was extracted from 
lxlO6 cells using Eurozol (Euroclone S.p.A., Milan, Italy) and RNA was reverse 
transcribed by using the High Capacity cDNA Archive Kit (Applied Bio Systems, 
Foster City, CA, USA) according to the manufacturer’s instructions. T-bet and 
GATA-3 mRNA species were quantified using the Assay on Demand kit (Applied 
Biosystems) and Taqman Master Mix (Applied Biosystems). Each sample was 
analysed in duplicate and the relative expression of T-bet and GATA-3 was defined 
by calculating the ACt, with respect to the housekeeping gene HPRT, run in the same 
tube.
2.9 Adenosine receptors mRNA expression
Total RNA was isolated from CD4+ T cell lines, of ADA-SCID patients and 
healthy donors, resting or stimulated with immobilized anti-CD3 mAb (1 pg/ml) plus
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soluble anti-CD28 mAb (10 jig/ml) for 6 hours. The RNA was reverse transcribed by 
using the Archive Kit (Applied Biosystems, CA, USA). Expression analysis of A2R 
genes was carried out using Assay-on-Demand real time PCR kits (Applied 
Byosistems). The expression was determined by relative quantification method. 
Essentially, two standard curve of serially diluted pooled cDNA, generated from resting 
CD4+ T cell lines of 3 different NDs sample, were set up to amplify the target gene and 
HPRT, as endogenous control. The A2R expression in the normalized samples was 
expressed as n-fold difference relative to reference sample as calibrator.
2.10 Intracellular cAMP detection
Bulk or CD4+ T cells (2xl05cells/well) were treated with dAdo (5mmol/L) or 
CGS21680 (lmmol/L) with or without the inhibitor of Adenylyl cyclase (lmmol/L), in 
presence of 3-isobutyl-1-methylxanthine (IBMX, lmmol/L). After 15 min incubation 
supernatants were decanted and cells used directly for cAMP determination, according 
to the manufacturer’s protocol for the Direct cAMP Enzyme Immunoassay Kit 
(Amersham Biosciences). The assay was performed in duplicate wells.
2.11 Western Blotting
2.11.1 ADA expression
Cell extracts were prepared from lxlO6 resting T cells. Briefly, T cells were 
washed in PBS and resuspended in lysis buffer supplemented with protease inhibitor 
cocktail (Sigma Aldrich, St-Louis, USA). After 30 min on ice, lysates were cleared by 
centrifugation and an aliquot of supernatants was used for determining protein 
concentration with the BCA protein assay (Pierce, Rockford, USA). Laemmli buffer 
was added to supernatants and, after boiling, equal amounts of proteins were subjected 
to SDS-PAGE. Proteins were transferred to nitrocellulose membrane and ADA was 
detected by the anti-ADA monoclonal Ab (kindly provided by Dr. Hershfield, Duke 
University Medical Center, Durham, NC) followed by secondary HRP-conjugated anti­
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mouse Abs (Dako Cytomation). Control of protein loading was performed by 
hybridizing the same membranes with an anti-G3PDH mAb (Chemicon, Temecula, CA, 
USA). Detection was performed using ECL detection system (Amersham Pharmacia 
Biotech, Little Chalfont, UK).
2.11.2 Analysis of ERK1/2 phosphorylation
CD4+ T cell lines from ADA patients and from healthy donors were starved for 
12 hours in IMDM containing low fetal bovine serum (1%), then stimulated, in the 
same medium supplemented or not with dAdo (0.5 mmol/L), by TCR cross-linking with 
1 ng/ml anti-CD3 mAb plus 10 ng/ml anti-CD28 mAb for the indicated times. Reactions 
were stopped by wash in cold PBS and immediate lysis in whole-cell lysis buffer. After 
30 min on ice, lysates were cleared by centrifugation and an aliquot of supernatants was 
used to determine protein concentration with the Bradford protein assay (Bio-Rad). 
Laemmli buffer was added to supernatants and, after boiling, samples with equal 
amount of proteins were subjected to SDS-PAGE. Proteins were transferred to 
nitrocellulose membrane and phosphorylated ERKs were detected by anti- 
phosphoERKl/2 mAb (Cell Signaling Technologies, Inc., Danvers, MA, USA). To 
detect levels of total ERK1/2, membranes were stripped by a 15-min incubation, at 
room temperature, in Restore Buffer (Pierce Biotechnology, Rockford, USA) and re­
probed with anti-ERKl/2 pAb (Cell Signaling Technologies, Inc.). Incubation with 
primary Abs was followed by incubation with goat anti-mouse or anti-rabbit HRP Ab, 
according to the specificity of the primaru Abs (Dako Cytomation). Detection was 
perfomed by ECL detection system (Amersham Pharmacia Biotech).
2.11.3 Analysis of CREB and IkBa phosphorylation
CD4+ T cells from ADA patients and healthy donors were starved for 12 hours 
in low serum (1%), then stimulated by TCR cross-linking with 1 pg/ml anti-CD3 plus 
10 ^ig/ml anti-CD28 for the indicated times. Reactions were stopped by wash in cold
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PBS and immediate lysis in whole-cell lysis buffer. After 30 min on ice, lysates were 
cleared by centrifugation and an aliquot of supernatants was used to determine protein 
concentration with the Bradford protein assay (Bio-Rad). Laemmli buffer was added to 
supernatants and, after boiling, samples with equal amount of proteins were subjected to 
SDS-PAGE. Upon blotting onto nitrocellulose membrane, levels of phosphorylated 
CREB were detected by anti-phosphoCREB mAb (Cell Signaling Technology, Inc.), 
followed by membrane re-probing with Total-CREB pAb (Cell Signaling Technology, 
Inc.). Phosphorylation levels of IkBa were detected by anti-phosphoIkBa (Cell 
Signaling Technology, Inc.). Control of protein loading was performed by hybridizing 
the same membranes with anti-G3PDH Ab.
2.12 DNA purification and quantitative PCR for vector positive cells
Genomic DNA was extracted from T cells using QIAamp DNA Blood Mini kit 
(Qiagen Inc. Valencia, California). Quantitative PCR analysis for vector positivity was 
performed as previously described (Aiuti et al., 2002b). Briefly, two sets of primers and 
probes specific for NeoR gene and GAPDH were used to detect transduced cells and 
standardize for DNA content, respectively. The frequency of transduced cells was 
calculated using a standard curve and expressed as the proportion of cells containing the 
NeoR reporter gene.
2.13 Analysis of retroviral vector integration site.
In order to avoid potential biases related to the use of restriction enzyme or 
amplification steps, two different techniques were used for analysis of integration sites: 
the inverse (I-) and linker-mediated (LM-) PCR.
2.13.1 Inverse-PCR
I-PCR was performed by a modification of previously described primers and 
PCR conditions (Kim et al., 2000). Briefly, 50 ng of genomic DNA were digested with 
TaqI and the LTR-containing fragments self-ligated and subjected to two rounds of
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am plification using the following LTR-specific primers: Forward: 5 ’- 
CTGTTCCTTGGGAGGGT-3 ’; Reverse: 5 ’ - AGGAACT GCTT ACC AC A-3 ’; nested 
forw ard: 5 ’-G CG TTA CTTA A GCTA GCTTG -3’; nested  reverse: 5 ’-
GATTGACTACCCACGACGGG-3’. Reaction conditions were identical for the first 
and second round of PCR: 94° denaturation for 1 min, 50° annealing for 1 min, 72° 
extension for 1.5 min, for a total of 29 cycles.
2.13.2 LM-PCR
For LM-PCR, 200 ng of genomic DNA were digested with Pstl and Ms el to 
prevent amplification of an internal viral fragment from the 5’LTR, and ligated to an 
MseI double-strand linker. Nested PCR was performed with LTR- and linker-specific 
primers as previously described (Wu et al., 2003).
2.14 PCR products cloning
The resultant PCR products were shotgun-cloned without purification with the 
PCR 2.1 TOPO TA cloning kit (Invitrogen, CA, USA) and transformed into libraries of 
vector-integration junctions. Alternatively, nested PCR products were separated either 
on 2% agarose or on Spreedex gels (Elchrom Scientific, Switzerland), excised and 
directly sequenced (Primm s.r.l., Italy). Mapped integrations were selected for analysis 
only if contained the correct LTR- and primer-specific sequences and yielded a unique 
best hit with >95% of identity to the human genome.
2.15 Integrants-specific Q-PCR
To determine the relative contribution of ZM92-related molecular clones over 
time, real-time Q-PCR were set up to specifically amplify the pro viral-genomic junction 
of integrations within the LM 02  locus (Sl_049, S4_048, S3_042 and S5_144). Two 
molecular clones isolated from Pt3 T cells mapping to “neutral” regions of the genome 
(S3_082 and S3_l 16), were used as control of physiological clonal fluctuations. The Q- 
PCR analysis was performed on 50 ng of genomic DNA, directly isolated from sorted
87
cells, using the specific unique genomic flanking primers in combination with common 
LTR primer and probe (Primm s.r.l.). The primers sequence was as follows: LTR 
Primer: 5 ’ -GTTTGCATCCGAATCGTGGT-3 ’;
LTR probe: 6-FAM-TCTCCTCTGAGTGATTGACTACCCACGACG-TAMRA; 
Sl_049 Primer: 5’-GGAATCAGGCACCTTCTCTCTC-3’;
S4_048 Primer: 5’GGTTAAGATCACAGGCTGTGGTG-3 ’;
S3_042/S5_144 Primer: 5 ’ -TCTCTCCTATCAGCCAATAAAGGG-3 ’;
S3_082 Primer: 5’-CGGCTCGGGTGTCCTG-3’;
S3_l 16 Primer: 5’-AAGTGTCGGTGTTAGTACCC-3 ’.
Each sets of primers allowed to unambiguously track the corresponding clone, as 
assessed by the absence of amplification in samples from different patients. The 
frequency of each individual clone, expressed as the proportion of cells containing the 
specific vector sequence, was calculated on the basis of a standard curve of the relative 
integrants diluted in untransduced PB lymphocytes (from 5x104 to 5x10°).
2.16 RNA purification and retrotranscription
Total RNA was isolated from CD3+, CD4+ or CD8+ T cells as well as CD15+ 
granulocytes purified either from GT-treated patients, untreated ADA-SCID patients or 
age-matched healthy donors. The RNA was reverse transcribed by using the Archive 
Kit (Applied Biosystems, CA, USA).
2.17 RT- PCR analysis for LM02 expression
Expression analysis of L M 02  gene was carried out with TaqMan system, 
developed as custom “assay on demand” by Applied Byosistems. The data were 
analyzed by the ABIPRISM 7700 with the sequence detector system software. LM 02  
expression was determined by relative quantification method. Essentially, two standard 
curve of serially diluted cDNA, obtained from one healthy donor granulocytes sample, 
were set up to amplify the target gene and HPRT, as housekeeping endogenous control.
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The LM 02  expression in the normalized samples was expressed as n-fold difference 
relative to reference sample as calibrator.
2.18 Microarray: Affymetrix HG-U133A Gene Chip Array
RNA was isolated from BM-derived CD34+ cells (n=2) cultured ex vivo 
according to the cytokine conditions used in the clinical protocol, and from primary 
CD3+ T cells (n=5) or CD4+ T cells (n=8). The transcribed biotinylated cRNA, was 
cleaned up using RNeasy spin columns (Affymetrix), fragmented and hybridized to an 
Affymetrix HG-U133A Gene Chip Array. The scanned images were analyzed using the 
Affymetrix MAS 5.0 suite, and the signal intensity of detected transcripts (probesets) 
was determined with the MAS 5.0 absolute analysis algorithm. Following inter-array 
normalization of overall fluorescence intensities, the differences in gene expression 
levels were expressed as numeric values. In the correlation between integrations and 
gene activity, the expression values of each probeset classified as a “present” by the 
software, were assigned to three arbitrary classes corresponding to 0-25th, 25th -75th and
th th75 -100 percentile of expression level of all present genes (probesets) in a
normalized data distribution.
2.19 Taqman Low Density Array
cDNA were reverse transcribed according to the Archive Kit (Applied 
Biosystems) manufacturing instructions. Taqman PCRs were carried out onto custom 
7900 Taq-man low density arrays on an ABI PRISM 7900 HT (Applied Biosystems). 
Taqman strategies for each gene were developed as “Assay on Demand” by Applied 
Biosystems. Gene expression profiling was achieved by using the comparative cycle of 
threshold (CT) method for relative quantification. For each detector, in the normalized 
sample, the AACt expression was calculated by using the average of ACts in all samples 
as calibrator.
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2.20 Functional clustering analysis
Probesets corresponding to genes targeted by retroviral vector insertions were analyzed 
for functional clustering into specific categories according to Gene Ontology criteria. 
The probability of over-representation of each category was determined using the EASE 
bioinformatics package (http://david.niaid.nih.gov/david/ease.htm). The default metric 
used by EASE to rank categories of genes by over-representation provides the EASE 
score.
2.21 Bioinformatics
The bioinformatic analysis was performed by dedicated Perl scripts allowing the 
storage, retrieval, analysis and summary of the data through a database. Human RefSeq 
chromosome sequence FASTA files for the May 2004 human genome freeze (NCBI 
v.35) were downloaded from the NCBI genome project website and converted to be 
used in local Blast search. Coordinates of RefSeq genes and other annotation tables for 
the same genome reference sequence freeze were accessed through the Ensembl Perl 
API from the Ensembl genome project. In the present study, we assumed the definition 
of “gene” as the genomic region between the transcriptional start site and stop 
boundaries of one of the 24.194 RefSeq genes mapped to the human genome, as 
reported by Wu et al.
2.22 Statistics
A two-tailed Mann Whitney U test was used for the analysis of statistically 
significant differences comparing two independent groups of individuals, ADA-SCID 
patients versus healthy controls. Responses within the same individual were compared 
by the (two tailed) Wilcoxon signed rank test for paired data. Comparisons between in 
vitro and ex vivo RIS frequency were tested with a Pearson Chi-Square test. In the gene 
expression studies, given the different sample sizes to account for the difference 
distribution between each sample and an asymptotic approximation was considered via
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the Monte-Carlo method based on 50.000 or 100.000 replications. Statistical 
significance was evaluated by a parametric likelihood test, distributed as a Chi-square. 
Analysis of overrepresentation of probesets classes in the integration data set was 
performed by means of both Fisher’s exact test as well as Easy Score (DAVID-EASE 
software). The results were corrected for multiple testing errors within each data 
set/system combination with Holm and Bonferroni correction methods.
91
CHAPTER 3 - Results
3.1 Generation of untransformed T-cell lines from ADA-SCID patients
Primary ADA-deficient T lymphocytes are difficulty available for experimental 
investigations since patients affected by ADA-SCID are severely lymphopenic. Most of 
information about the role ADA in the biochemical and cellular metabolism of human 
ADA-deficient cells has been derived from studying either ADA-deficient EBV- 
transformed B-cell lines and Herpes Virus-transformed T-cell lines (Otsu et al., 2002) 
(Ariga et al., 2001). However, different parameters, such as ADA activity, might not be 
faithfully reflected in virus-transformed cell lines. Moreover, the immunological defect 
was incompletely investigated. We successfully proceeded to in vitro expansion of 
untransformed T-cell lines from five patients (Table 1), before (ADA'7') or 6 to 48 
months after gene therapy (GT) with autologous genetically-corrected hematopoietic 
stem/progenitor cells (Illustration XVII). The culture protocol used (see methods 
section) allowed to growth T-cell lines quite long-term without any alteration in their 
original metabolic and immune phenotype. Indeed, in agreement with what we have 
observed analyzing Vbeta TCR repertoire in whole blood, while ADA'7' cell lines 
display a more oligoclonal profile, T-cell lines generated after GT have a polyclonal 
pattern (data not shown), which were maintained throughout the culture period.
The percentage of vector-positive cells, as detected by qPCR, ranged between 87-100% 
in GT cell lines (Aiuti et al., 2002a) (Aiuti A. et al., manuscript in preparation).
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Illustration XVII. Experimental model.
Patient nt Change Site aa Change Zygosity
Pt1 CAC-CCC exon 2 His17Pro homozygous
Pt2 C7T3-CCG exon 4 Leu107Pro heterozygous
CGT-C/AT exon 7 Arg211 His heterozygous
Pt3 GGC-GTC exon 4 Gly74Val heterozygous
GGC-GAC exon 10 Arg282Gln heterozygous
Pt4 GGC-G4C exon 10 Arg282Gln homozygous
Pt5 GGG-AGG exon 7 Gly216Arg heterozygous
del AGA exon 10 Glu319fsX3 heterozygous
Table 1. Mutations of ADA-SCID patients.
3.2 Restoration of ADA expression after gene therapy corrects the SAHH defect in 
ADA-deficient T cells.
In order to investigate the effect of mutations in ADA gene on protein stability 
and enzyme activity, ADA protein expression was analyzed by intracytoplasmic 
staining in T cells from patients and age-matched healthy controls (ND) after short-term 
culture in FBS-free medium, to avoid the potential interference of the bovine ADA in 
the analysis. ADA expression is completely absent in ADA'7' bulk T cells whereas it is 
restored in GT cells, displaying an intermediated ADA phenotype with respect to the 
controls (Fig. 1A). In agreement, a stronger ADA enzymatic activity was measured in 
GT cells as compared to ADA'7' cells (Fig. IB, p<0.05), demonstrating that in these 
cells the enzyme was expressed but, more importantly, functional.
The metabolic consequences associated with the ADA-deficiency have been 
implicated in the irreversible intracellular inactivation of the enzyme S- 
adenosylhomocysteine hydrolase (SAHH) in the erythrocytes of untreated ADA- 
deficient children (Hershfield, 2001). This secondary deficiency has been pointed out as 
an additional hallmark of the disease. Interestingly, a markedly reduced SAHH activity 
was found in ADA'7' T cells compared to NDs (Fig. 1C, p<0.01), indicating that an 
intrinsic defect in the purine metabolism persist in ADA'7'cells even when cultured ex- 
vivo in potential toxins-free conditions. Remarkably, SAHH activity was completely 
restored at normal level in GT cells, suggesting that in these cells the transgene 
expression is at therapeutic level, enabling the full correction of the purine metabolic 
defect.
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Figure 1. Restored ADA and SAHH activity in T cells from ADA-SCID patients after gene 
therapy. (A) Bulk T-cell lines established from five ADA-SCID patients, before (black line) 
and after HSC gene therapy (grey line), and from healthy controls were cultured for four days 
without serum prior to intracytoplasmic labeling o f ADA. M.F.I. values are indicated in the 
histogram plots. (B) ADA activity and (C) SAHH activity were measured in T-cell lines (1*106 
cells) as described in the methods section.
95
3.3 Characterization of the defective T-cell functions in ADA' " T cells
3.3.1 ADA'7' T cells show defective proliferation in response to TCR/CD28-mediated 
stimulation
Our T cell cultures contain a mixed population of CD4+ and CD8+ T cells, with a 
preferential expansion of CD4+ T cells in cultures (not shown). These two cell subsets 
can have intrinsic differences in their response to anti-CD3 mAb stimulation, which 
could derive from different threshold required for activation, response to co-stimulation 
or even susceptibility to activation induced cell death (AIDC). In addition, it is possible 
that in a mixed culture the response of one cell subset is influenced by the other one, by 
expression of membrane molecules or by release of soluble factors. Therefore, we 
decided to perform experiments using purified CD4+ and CD8+ T cell lines, in order to 
clarify their relative contribution in the immune defect.
Upon activation with escalating doses of plate-bound anti-CD3 mAb, which is known to 
provide a strong TCR-mediated stimulation, the proliferative responses of purified 
ADA'7' CD4+ T cells were severely impaired, irrespectively of the dose of mAb used 
(p<0.01, Fig. 2A). In contrast, normal proliferative responses were observed in T-cell 
lines derived ex-vivo from patients treated with gene therapy (Fig. 2A). Similar results 
were obtained with CD8+-enriched T-cell lines (purity > 85%) of both patients and 
healthy controls (data not shown). The addition of anti-CD28 mAb (10 pg/ml) enhanced 
the proliferative ability of ADA'7' T cells without achieving the normalization (data not 
shown).
3.3.2 Defective production of cytokines by ADA'7" CD4+ T cells upon TCR/CD28 
triggering
A defective proliferation could result, at least in part, from weak IL-2-driven 
signals delivered to T cells. To determine whether a sub-optimal IL-2 secretion could be
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primarily linked to the defect observed in ADA'7' cells, we measured the release of IL-2 
in the supernatants of anti-CD3 stimulated cells. As shown in Fig. 2B, ADA'7' CD4+ T 
cells released 2-log less IL-2 compared with cells from healthy controls (p<0.01). 
Interestingly, the restored IL-2 secretion in GT CD4+ cells (p<0.05 vs ADA'7') 
paralleled the correction of the proliferative responses (Fig. 2A-B). To investigate 
whether the deficient cytokine secretion in ADA'7' cells was IL-2-specific or also 
affected other cytokines, we further analyzed the cytokine profile. Secretion of IFN-y, 
TNF-a and IL-10 was severely compromised in ADA'7' CD4+ cells (Fig. 2B, p<0.01 vs 
NDs). In contrast, the defect in IL-4 and IL-5 secretion was less pronounced, even if 
still present (Fig. 2B, p<0.05). These data were confirmed when production of IL-2, 
IFN-y and IL-4 was measured at single cell level in CD4+ T cells. Upon TCR/CD28 
triggering, the percentages of IL-2 and/or IFNy-producing cells were strongly reduced 
in ADA'7' CD4+ cells with respect to healthy donors (p<0.01; Fig. 2C and Table 2). In 
particular, the population of cells producing IFN-y was predominantly affected. The 
production of IL-4 by ADA'7' CD4+ T cells was higher compared to other cytokines but 
still below the control range (p<0.05; Fig. 2C and Table 2). However, the cells 
producing both IL-4 and IFN-y were almost completely absent in ADA'7' cells. 
Stimulation with TP A and calcium ionophore, which bypass the TCR, resulted in 
significantly higher production of all cytokines but confirmed the defective production 
of IFN-y (p<0.05; Fig. 2C and Table 2). Collectively, these data demonstrate that in 
ADA-deficient CD4+T cells, defective cytokine secretion is the consequence of their 
blocked production. Moreover, there is also clear indication that, although not 
specifically restricted, the impaired anti-CD3/anti-CD28 response in ADA'7' cells is 
particularly affecting the Thl-type cytokines. In contrast, in gene-corrected CD4+ T 
cells the production of both Thl- and Th2-like cytokines was significantly improved
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compared to deficient cells (p<0.05), reaching the range of controls (Fig. 2C and Table 
2).
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Table 2.
aCD3/aCD28 TPA/lono
IL-2+ 
cells (%)
IL-4+ 
cells (%)
IFN-Y+ 
cells (%)
IL-2+ 
cells (%)
IL-4+
cells (%)
IFN-y+ 
cells (%)
ADA*'- (n=5) 1 .1 8 -1 .8 5 * * 3.6 - 5.6* 0 .1 4 -1 .2 3 * * 66.1 -7 2 .4 44.4 - 89.7 1 4 .6 -3 7 .1 *
GT (n=5) 7.4 - 24.8 1 0 -2 9 .2 2 .8 -2 3 .2 63.5 - 89.4 33.1 -6 7 .4 1 4 .3 -5 9 .2
ND (n=7) 9 .0 7 -1 6 .0 4 4 .7 -1 5 .6 9 .5 -1 5 .5 31.1 -82 .1 2 1 .4 -5 8 .2 1 6 .7 -5 8 .2
* p<.005 vs  ND 
** p<.001 vs  ND
Figure 2. Characterization of the T-cell effector functions defect in CD4+ADA-deficient T 
cells. (A) Purified CD4^ T cell lines from five patients and five healthy controls were stimulated 
with immobilized anti-CD3 mAb at the indicated concentrations and [3H]thymidine 
incorporation was measured after 48 hours. (B) Supernatants were collected after 18 (IL-2) or 
48 hours (all other cytokines) in cells stimulated with 1 pg/ml of anti-CD3 and cytokine 
concentrations were quantified by capture ELISA. Each value represents the mean of cytokine 
concentration measured in triplicate cultures for each patients and healthy controls. Median 
values are also reported. Background levels were subtracted. One determination out of 3 is 
shown. (C) Production of IFN-y vs either IL-2 or IL-4, was analyzed by intracytoplasmic 
staining in CD4 T-cell lines from ADA-SCID patients and healthy donors following 6 hours 
stimulation with immobilized anti-CD3 (1 jig/ml) plus anti-CD28 (10 [ig/ml) mAbs, or with 
TPA plus ionomycin. The experiment shown is representative of 5 independent experiments. 
Two ADA-SCID patients and one healthy donor are reported. Range values corresponding to 
five patients and seven NDs are indicated in the Table 2.
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3.3.3 Defective cytokine production reflects impaired cytokine gene transcription in 
ADA' CD4+ T cells
As a result of TCR engagement, activation-specific genes are induced by binding of 
multiple transcription factors within the promoter regions. Among them, cytokine genes 
are the most acutely transcribed (Hughes-Fulford et ah, 2005), because of their key role in 
sustaining the following phases of cell proliferation and differentiation. To investigate 
whether defective transcription of cytokine genes could account for their impaired 
production in ADA-deficient cells, we analyzed by Real-Time PCR the cytokine mRNA 
levels in CD4+T cells from five ADA-SCID patients and four healthy controls.
Upon TCR/CD28-dependent activation, the overall levels of IL-2, IL-4 and IFN-y 
expression were significantly lower in ADA'7' cells compared to those detected in NDs 
(Fig. 3; p<0.01 for IL-2; p<0.05 for IL-4 and IFN-y) or in post-GT cells (p<0.05). 
Interestingly, ADA'7' CD4+ T cells reproducibly showed higher IL-4 versus IFN- 
y mRNA ratio than control CD4+ T cells, indicating a difference in the balance between 
these two cytokines. Stimulation with TPA and calcium ionophore, which bypass the 
TCR, confirmed the Thl biased cytokine mRNA profile for ADA'7' CD4+ cells (data not 
shown), but in contrast to TCR/CD28 stimulation, the differences with respect to 
control cells did not reach the statistical significance. Overall these results indicate that 
the cytokine defect is present at the transcriptional level after TCR-dependent 
activation.
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Figure 3. Analysis of cytokine mRNA expression in CD4+ T-cell lines. (A) Measurement of 
cytokine gene expression after TCR/CD28-mediated stimulation of CD4+ T-cell lines from five 
patients and four healthy donors. Total RNA was prepared from either resting or stimulated cells (1 
pg/ml anti-CD3 plus 10 pg/ml anti-CD28 mAbs) and gene expression was measured by semi- 
quantitative RT-PCR. Values were normalized for the expression of the housekeeping gene HPRT 
and correspond to duplicate samples. Results are expressed as n-fold difference relative to resting 
condition. One representative experiment out of three in shown. *p<0.05; **p<0.01
3.4 Reduced T-bet mRNA induction in ADA'/'CD4+ T cells stimulated via TCR/CD28
We next analyzed the levels of T-bet and GATA-3 mRNA in ADA'7’ CD4+ T cell 
lines, as these transcription factors are involved in the transcription of IFN-y and IL-4 
genes, respectively (Szabo et al., 2002) (Zheng and Flavell, 1997). Level of T-bet mRNA 
was lower in resting ADA'7' CD4+ T cells compared to healthy controls (p<0.05; Fig. 4, 
upper panel). Upon stimulation with 1 jig/ml anti-CD3 plus 10 pg/ml anti-CD28 mAbs, T- 
bet mRNA expression was significantly higher in control and gene-corrected cells than in 
ADA'7' CD4+ T cells (p< 0.01; Fig. 4, upper panel). Stimulation with TPA plus ionomycin 
confirmed the defective T-bet expression in ADA'7' CD4+ T cells (p<0.05; Fig 4, upper 
panel). In contrast, levels of GATA-3 mRNA were comparable in resting and activated 
CD4+ T cells from ADA-SCID patients and healthy controls (Fig. 4 lower panels).
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These data show that ADA-deficient CD4+ T cells have a reduced ability to 
induce T-bet mRNA upon activation. Moreover, reduced T-bet expression in resting 
may be reflective of a defect in T-cell development.
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Figure 4. Analysis of T-bet and GATA-3 relative mRNA levels in resting and activated 
CD4+ T-cell lines from ADA-SCID patients. Measurement o f T-bet (upper panels) and 
GATA-3 (lower panels) gene expression before and after stimulation of CD4+ T cells from 
five ADA-SCID patients and five healthy controls. Total RNA was prepared from either 
resting or stimulated cells and gene expression was measured by semi-quantitative RT-PCR. 
Values were normalized on expression of the housekeeping gene HPRT and correspond to 
duplicate wells. Results derived from one out o f three independent experiments are shown. 
Statistical significance is represented as follows: * p<0.05; ** p<0.01
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3.5 Biochemical basis for impaired effector function of ADA'7' T cells
3.5.1 Reduced ERK1/2 phosphorylation in ADA"7' CD4+ T cells
Since the impaired effector functions, in ADA-deficient cells, was proved to be 
strictly dependent on TCR engagement, we investigated whether it could result from 
poor activation of ERKs signaling, the main pathway integrating TCR-activating signals 
in mature T cells (Rincon et al., 2001). Stimulation of control CD4+ T cells, with high 
dose of cross-linked anti-CD3 mAh and anti-CD28 mAh, lead to a strong induction of 
ERK1/2 phosphorylation, peaked as early as 2 min, and remaining detectable for later 
time points before waning at 240 min (Fig. 5). In ADA"7" CD4+ T cells ERKs 
phosphorylation was consistently below the threshold of activation detected for the 
healthy controls, suggesting that an intrinsic reduced T-cell activation underlies the 
observed hypo-responsiveness. Interestingly, in GT CD4+ T cells ERKs 
phosphorylation occurred properly at 2 and 15 min after the TCR cross-linking, and was 
maintained, to a lesser extent, throughout the time course (Fig. 5).
These data, showing that activation of ERK1/2 is defective in ADA'7" CD4+ T 
cells, indicate that the signaling leading to the activation of these molecules, 
downstream of TCR/CD28, is also likely impaired in ADA-deficient T cells.
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Figure 5. Analysis of ERK1/2 phosphorylation in CD4+ T-cell lines from ADA-SCID 
patients. The levels of ERK1/2 phosphorylation were analyzed by Western blot in CD4T T-cell 
lines from patients and healthy donors following stimulation with cross-linked lpg/ml anti-CD3 
plus 10 pg/ml anti-CD28 mAbs for the indicated time points. After blotting with anti-phospho- 
ERKs the membranes were stripped and re-probed with anti-total-ERKs and anti-GAPDH for 
control of protein loading. Upper panel: results of Western blot analysis are shown for Ptl and 
Pt5 and for one healthy donor. Lower panel: densitometric analysis on three patients and three 
NDs is reported. Values corresponding to unstimulated cells were subtracted.
3.5.2 Defective CREB phosphorylation in ADA'" CD4+ T cells
In previous experiments, we observed a defective transcription o f cytokine genes 
in ADA-deficient T cells from patients. Since these findings m irrored a sub-optim al 
induction o f the transcriptional machinery, we examined the status of activation a early 
transcription factor, which is mandatory for the transcription o f IL-2 and other cytokine 
genes, CREB (Hughes-Fulford et ah, 2005). Upon TCR engagement, CREB is rapidly 
phosphorylated on S e ri33, resulting in its activation (Johannessen et al., 2004). Patients 
and control CD4+ T cells were stimulated with cross-linked anti-CD3 plus anti-CD28
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mAbs, and CREB phosphorylation was analyzed by western blot. As expected, upon 
TCR triggering, CREB was rapidly (2 min.) phosphorylated/activated in normal T cells, 
returning to basal level within 30-60 min o f stimulation (Fig. 6). In contrast, early 
CREB activation was strongly impaired in ADA'7' cells from all five patients tested (Fig 
6, p<0.01 vs NDs.). Remarkably, this pre-transcriptional event occurred normally in GT 
T cells.
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Figure 6. Analysis of CREB phosphorylation in CD4+ T-cell lines from ADA-SCID  
patients. Immunoblots depicting phosphorylated CREB, total CREB and GAPDH are shown. 
CD4+ T-cell lines were stimulated with cross-linked (lpg/m l) anti-CD3 plus (10 pg/ml) anti- 
CD28 mAbs for the indicated time points. The same membranes were sequentially probed for 
the different Abs. Upper panel: a representative experiment in Pt3 and one healthy donor 
studied in parallel. Lower panel: densitometric analysis and stastistical significance (**p<0.01) 
on five patients and five NDs are shown. Values corresponding to unstimulated cells were 
subtracted.
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3.5.3 Defective IkBa phosphorylation in ADA'7’ CD4+ T cells
We then analyzed the activation of another family of transcription factor, NFkB, 
which is involved in the transcription of IL-2 and other cytokine genes. In resting cells 
NFkB proteins are retained in the cytoplasm through binding to IkB proteins. Upon 
receptor triggering, IkB proteins are rapidly phosphorylated and therefore targeted for 
ubiquitination and proteasome-mediated degradation. IkB degradation allows nuclear 
translocation of NFkB dimers. We analyzed the phosphorylation of IkBa induced by 
stimulation of patients and control CD4+ T cells by TCR cross-linking with anti-CD3 plus 
anti-CD28 mAb. As shown in Fig.7, IkBa was phosphorylated in control CD4+ T cells 
after 30 min of stimulation and still sustained after 2 hours. Conversely, in ADA'7' cells the 
levels of phosphorylated IkBa remained low or undetectable for the time points examined 
(Fig.7, p<0.05 vs ND). Remarkably, pre-transcriptional events involving IkBa occurred 
almost normally in gene-corrected cells, resulting in the correction of the cytokine 
transcriptional defect (Fig.7).
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Figure 7. Analysis of IkBa phosphorylation in CD4+ T-cell lines from ADA-SCID 
patients. Anti-phospho-IkBa of CDT T cells stimulated as described above. Filters were stripped 
and re-probed with an anti-GAPDH mAb. Upper panel: immunoblots from two patients and two 
representative healthy controls are shown. Lower panel: cumulative data of densitometric analysis 
from four patients and four NDs are presented. Results of the statistical analysis are represented as 
follows: * p<0.5; ** p<0.01. Values corresponding to unstimulated cells were subtracted.
3.6 dAdo completely abrogates T-cell activation and function in ADA'7' T cells
In order to further dissect the biochem ical events linking an altered purine
m etabolism to the immune defect, we exposed T cells from patients and controls to
ADA-SCID-like in vivo conditions. The m ost striking metabolic alteration in ADA-
SCID is the m assive accum ulation o f dATP in erythroid cells (Hirschhorn, 1993)
(Hershfield, 1998). Since dATP levels directly reflect the amount o f dAdo excreted in
the body fluids, this ADA metabolite may have more relevant clinical im pact w ith
respect to Ado. For these reasons, we studied T cell activation and effector functions in
the presence o f exogenously added dAdo at concentrations expected to be found in
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ADA-SCID patients (500 jimol/L). We first investigated the activation of ERKs 
signaling. CD4+ T cells from ADA-SCID patients and healthy donors were stimulated 
with cross-linked anti-CD3 plus anti-CD28 mAbs in absence or presence of dAdo, and 
activation of ERK1/2 pathway was examined by western blot. Previous results have 
indicated that ERKs phosphorylation was consistently reduced in ADA'7' CD4+ T cells. 
Treatment with dAdo almost completely abolished ERKs activation in ADA-deficient 
cells, indicating a TCR-antagonizing effect (Fig. 8A).
Exposure to dAdo during TCR/CD28-mediated stimulation did not affect the induction 
of ERKs expression in GT (Pts n=3) and control cells (n=3) (Fig. 8A). However, it 
resulted in delayed kinetics of ERKs activation, as indicated by the shifted peaks of 
phosphorylation (Fig. 8A), thereby providing clear evidence for an existing cross-talk 
between TCR- and dAdo-triggered biochemical pathways. Accordingly, the same 
concentration of dAdo strongly inhibited T cell proliferation driven by optimal TCR 
stimulation (lp,g/ml anti-CD3) of ADA'7' CD4+ cells (p<0.05 vs NDs, Fig. 8B and data 
not shown). In contrast, GT cells were only minimally affected, not differently from 
healthy controls (Fig. 8B and data not shown). Since this concentration of dAdo did not 
affect cell viability (data not shown), these results prove that dAdo can inhibit TCR- 
triggered activation independently from a direct cytotoxic effect.
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Figure 8. dAdo strongly inhibits ERKs activation and effector functions in ADA-deficient 
T cells. (A) ERKs activation was analyzed in CD4" cells with the stimulation protocol described 
above in absence or presence of dAdo (500 prnol/L). The blots corresponding to basal (medium) 
P-ERKs and T-ERKs expression are the same depicted in Fig.5 for P tl, Pt5 and ND1. Samples 
of untreated and dAdo-treated stimulated cells were prepared in parallel, run on different gels 
but probed with the different Abs at the same time. (B) CD4+ cells were induced to proliferate 
with 1 pg/ml coated anti-CD3 mAb in the absence or presence of dAdo (500 pmol/L). The 
specified compounds (SCH58261 or Dipirydamole) were included into the incubation medium 1 
hr before the addition of dAdo. After 48h cell proliferation was assessed by [3H]thymidine 
incorporation. The results from five patients and five controls were expressed as percentage of 
inhibition with respect to the stimulated untreated conditions. Statistical analysis (* p<0.05) was 
performed on c.p.m. values.
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3.7 dAdo-related inhibitory effects are mdiated by the extracellular A2A adenosine 
receptor signaling
To date, similar suppressive properties on T cell function have been consistently 
attributed to Ado, by virtue of its ability to physiologically signal through Gs-protein 
coupled purinergic receptors (Klinger et al., 2002). Among them, the A2A receptor is the 
major adenosine receptor subtype expressed in human lymphocytes (Koshiba et al., 
1999) (Thiel et al., 2003). To establish a potential role of A2A receptor-mediated 
extracellular signaling in the inhibitory effects exerted by dAdo, we investigated T-cell 
proliferation in the presence of the A2A R selective antagonist SCH58261. Under these 
conditions, the suppressive activity of dAdo on proliferation of ADA'7' T cells was 
significantly inhibited (p<0.05, Fig. 8B). Conversely, blocking of nucleoside uptake by 
a strong inhibitor of the nucleoside transport system, Dypiridamole, had no protective 
effect, and slightly enhanced the inhibitory properties of dAdo, in both patients and 
control cells (Fig. 8B). The effect of Dypiridamole may likely rely on an increased 
dAdo extracellular availability, thereby amplifying its TCR-antagonizing activity. 
Remarkably, the selective A2A R agonist, CGS21680 (Jarvis et al., 1989), mimicked the 
suppressive effect of dAdo on cell proliferation, which, in turn, was blocked by the 
receptor antagonist SCH58261 (Fig. 9), confirming that the dAdo-mediated effects are 
initiated by an extracellular adenosine receptor signaling rather that by its intracellular 
metabolism.
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Figure 9. The selective A2a receptor agonist mimics dAdo-induced inhibitory effect. CD4T 
cells were induced to proliferate with 1 pg/ml coated anti-CD3 mAb in the absence or presence 
of the selective A2a R agonist CGS21680 (100 jimol/L). The A2a R selective antagonist 
(SCH58261) was included into the incubation medium 1 hr before the addition of dAdo. After 
48h cell proliferation was assessed by [3H]thymidine incorporation. The results from five 
patients and five controls were expressed as percentage of inhibition with respect to the 
stimulated untreated conditions (*p<0.05).
3.8 dAdo induces higher intracellular cAMP levels in ADA"" CD4+ T cells
The Gs-protein coupled A2a adenosine receptor signal to increase intracellular 
cAMP (Klinger et al., 2002), which is a w ell-know n negative regulator o f  T cell 
function (see section 1.9.2). Accordingly, exposure to selective A2a receptor agonist (1 
mmol/L) induced elevation o f  intracellular cAMP at similar extent in both control and 
patients’ T cells (Fig. 10A). M easurem ent o f  cAMP levels in T cells cultured in 
presence o f dAdo (5 mmol/L) showed a strong increase over the basal concentration in 
both ADA-SCID patients and healthy controls (Fig. 10B). However, the intracellular 
cAMP levels were 2-fold higher in ADA'" cells compared to norm al and GT cells 
(p<0.05 vs ND and GT). To investigate whether the higher induction o f intracellular 
cAMP in A DA'7' cells could be attributed to difference in receptor density, we analyzed
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the expression of A2A adenosine receptor in resting and activated state. Expression of 
A2A R in resting condition is similar in ADA-deficient, GT and healthy control cells, as 
assessed at protein level, by intracellular staining, or at mRNA level by RT-PCR (Fig. 
10C-D). Upon TCR/CD28 stimulation the expression is markedly upregulated in ADA’7' 
cells as in control and GT cells (FiglOD). Collectively, these results indicate that the 
dAdo-triggered abrogation of T cell function in ADA'7' cells is mediated through A2A 
adenosine receptor and is cAMP-dependent, thus strengthening the proposed concept of 
ADA-SCID as a signaling disease.
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Figure 10. cAMP levels and Ado receptors expression in ADA-deficient cells. (A )
Intracellular cAMP levels were determined, as described in the methods, in CD4+ T cells 
incubated with culture medium containing 1 mmol/L CGS21680 or (B) 5 mmol/L dAdo for 15 
minutes. The inhibitor of adenylyl cyclase (AC) (1 mmol/L) was added 30 min before. The data 
represents the mean ± SD from five patients and four NDs in one out of three independent 
experiments. *p<0.05; **p<0.01. (C) Expression of A2A adenosine receptor in gated CD4" T 
cells. Intracytoplasmic staining was performed in resting cells and M.F.I. values were indicated 
in the histogram plots. (D) Levels of A2a R mRNA in CD4" T cells from patients and healthy
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controls. Total RNA was isolated from either resting or stimulated (lpg/ml anti-CD3 plus 10 
pg/ml anti-CD28 mAbs) cells and adenosine receptor gene expression was measured by 
quantitative RT-PCR using the standard curve of a reference sample. Values were measured in 
duplicates, and normalized by the expression of the housekeeping gene HPRT.
3.9 PKA hyperactivation is the downstream effector of dAdo suppressive function
With few exceptions, the effects of cAMP are mediated by cAMP-dependent 
protein kinase A type I (PKAI) (Torgersen et al., 2002). This isoenzyme is thought to 
play a major role in c AMP-mediated effects in T lymphocytes, because it redistributes 
and colocalizes with the T-cell receptor in lipid rafts during T cell activation (Vang et 
al., 2001). In order to explore the potential involvement of PKA hyperactivation in the 
dAdo-mediated suppressive activity, we used a specific membrane-permeable inhibitor 
of cAMP-dependent protein kinases I and II activation, Rp-8-Br-cAMPS (Gjertsen et 
al., 1995). Addition of PKA inhibitor significantly reduced the inhibitory effect exibited 
by dAdo on proliferative responses of ADA'7' cells (Fig. 11 A; p<0.05). No significant 
improvement in anti-CD3-induced proliferation was observed in ADA'7' cells when Rp- 
8-Br-cAMPS alone was added to cell culture (data not shown), suggesting that the 
intrinsic defect is not related to chronically elevated endogenous cAMP levels. 
Exposure to dAdo had a broad suppressive effect even on cytokine production in T 
cells, with the most important alterations in ADA'7' cells (Fig. 1 IB and data not shown). 
Therefore, we examined the effect of Rp-8-Br-cAMPS on cytokine production ability of 
anti-CD3-stimulated CD4+ T cells from five ADA-SCID patients and five controls. In 
presence of PKA antagonist, the suppressive activity of dAdo on cytokine production 
ability of ADA'7' T cells was significantly inhibited (Fig. 11B). These results indicate 
that dAdo inhibits T cell activation in ADA-SCID patients through a cAMP/PKA- 
dependent pathway.
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Figure 11. PKA hyperactivation is responsible for dAdo-mediated suppression of T cell 
function in ADA-deficient cells. CD4+ T cells were stimulated with lpg/m l coated anti-CD3 
mAb in the presence or absence of dAdo (500 pmol/L) with or without the inhibitor o f cAMP- 
dependent protein kinase A, Rp-8-Br-cAMPS (150 pmol/L). Rate o f proliferation was evaluated 
by [3H]thymidine incorporation after 48 hours (A) while supernatants were collected for 
cytokine production quantification by ELISA after 18 (IL-2) or 48 hours (all other cytokines) 
(B). The percentages o f inhibition of proliferation and cytokine production in the presence of  
the drugs relative to control are indicated. The data represents the mean ± SD o f five patients 
and five healthy controls from one o f three independent experiments. Statistical analysis 
(*p<0.05) was performed on real values.
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3.10 Increased susceptibility to apoptosis in ADA'7' cells upon exposure to ADA 
substrates
The metabolic consequences associated with ADA deficiency have been 
demonstrated to trigger apoptosis in cultured mouse thymocytes (Van De Wiele et al., 
2002) and peripheral T cells treated with an ADA inhibitor (Kizaki et al., 1990) 
(Benveniste and Cohen, 1995). To determine whether apoptosis may play a major role 
in the T lymphocytopenia observed in ADA-SCID patients, T cells were exposed to 
increasing concentrations of dAdo or Ado for different time, and apoptosis was assessed 
by Annexin V/PI staining. A different kinetic in terms of time and concentration 
dependence was showed for both ADA substrates, with Ado displaying a stronger 
apoptosis-inducing effect than dAdo. Indeed, longer treatments (15 hours vs 6 hours) 
and relatively higher concentrations (5 mmol/L vs 1 mmol/L) were required by dAdo to 
induce a comparable percentage of cell death in ADA'7' cells (Fig. 12A). Cumulative 
results from five patients confirmed that treatments with ADA substrates induced a 
three- to four-fold higher proportion of apoptotic cells in ADA'7" T cells, as compared to 
healthy control cells. In contrast, GT cells were rescued from apoptosis as control cells, 
in agreement with the expression of functional ADA (Fig. 12B). To better understand 
the metabolic pathway involved, we evaluated the effects dAdo/Ado on cell viability in 
the presence of nucleoside transporter inhibitors. As shown in Figure 12B, 
Dipyridamole was able to completely prevent Ado- but not dAdo-mediated apoptosis in 
ADA-deficient cells. Similar effect was obtained using an additional inhibitor of the 
nucleoside transport, NBTI (data not shown). These data suggest that Ado-induced cell 
death is due to its direct intracellular action consequent to a membrane entry through the 
equilibrative nucleoside transporter. Since neither Dipyridamole nor NBTI (data not
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shown) failed to protect ADA_/‘ cells from dAdo-triggered apoptosis, we explored 
whether it was acting at a cell-surface site through an extracellular signaling involving 
A2A Adenosine receptors. No rescue from apoptosis was observed in ADA-deficient 
cells when exposed to dAdo in presence of non per-se toxic doses of the A2A Adenosine 
receptor selective antagonist SCH58261.
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Figure 12. Dose- and time-dependent apoptosis induced in ADA-deficient T cells by ADA 
substrates. (A) Bulk T cell-lines were incubated with the indicated concentrations o f purine 
metabolites and cultured for 15h (dAdo) or 6h (Ado). In time course experiments, T cells were 
incubated with dAdo (5mmol/L) or Ado (lmmol/L) for the indicated period. The percentages of 
early apoptotic cells (Annexin Vt/PI') are shown for Pt3 and one healthy control as 
representative experiment. (B) Bulk T cell-lines from five ADA SCID patients and six healthy 
controls were cultured for 15h with dAdo (5mmol/L) or 6h with Ado (lmmol/L) in the absence 
or the presence o f the inhibitor o f nucleoside transporter, Dypiridamole (lpmol/L). The 
percentages of Annexin V*'/PT cells as mean + SD are shown. Data are representative o f at least 
5 independent experiments. (**p<0.01).
Altogether, these studies on the molecular mechanisms involved in ADA-deficient T 
cells unresponsiveness to TCR/CD28-mediated stimulation, indicate that ADA-deficient 
environment affect the ability to transduce activating signals through the T-cell receptor, 
and support the role of aberrant extracellular signaling in the disease pathogenesis.
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3.11 Analysis of retroviral vector integrations in hematopoietic cells from ADA- 
SCID patients: In vitro vs Ex vivo integrations
We have performed a systematic analysis to identify and map vector insertion 
sites in ADA-SCID patients treated with CD34+ cell gene therapy. These studies are 
aimed at defining the pattern of retroviral integrations, their potential influence on gene 
expression and the analysis of the clonal composition of transduced HSC and their 
progeny. The genome-wide analysis of RIS was carried out on BM and peripheral blood 
(PB) cell populations derived from five ADA-SCID patients (Ptl-5) before and 1.5 to 
47 months after GT. Vector-genome junctions were cloned from pre-transplant CD34+ 
cells (in vitro) or post-GT hematopoietic cells (ex vivo) by inverse or linker-mediated 
(LM) PCR, sequenced and mapped onto the human genome. Overall, 212 in vitro and 
496 ex vivo integrations could be unambiguously assigned to a unique chromosomal 
position.
3.11.1 Genomic distribution of RV integration sites in ADA-SCID gene therapy
Recent studied have indicated that gammaretroviral vectors integrate in a non- 
random fashion in their host genome, but information on the distribution of retroviral 
insertion sites (RIS) in human long-term reconstituting HSC following therapeutic gene 
transfer is still limited. The distribution of RIS with respect to RefSeq genes is shown in 
Table 3. Integrations within the transcribed portion of genes were more represented in 
the in vitro than in the ex vivo sample (50.9 vs 41.3%, p=0.03). Although both values 
were significantly higher than the frequency of annotated genes in the human genome 
(35.5%, p<0.01), the proportion of intragenic hits ex vivo was not significantly different 
from that obtained from a collection of 398 random sequences from a control DNA 
library (37.9%, p=0.3). Exons were rarely hit, both ex vivo (2.0%) and in vitro (0.5%), 
in agreement with the overall occupancy of coding sequences in the human genome
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(1.8%). We then examined the distribution of vector integrating in intergenic regions, 
and determined the distance to the nearest 5’ and 3’ ends of genes flanking each RIS. 
Integrations <30 kb upstream of a gene were over-represented with respect to those <30 
Kb downstream, particularly in the ex vivo sample, and were more frequent ex vivo than 
in vitro in the 10 kb region upstream from the TSS (Table 3). As reported for human 
cell lines and for hematopoietic cells in primates (Wu et al., 2003) (Hematti et al., 
2004), integrations within a 5-kb window on either side of the nearest TSS were also 
over-represented in both samples (23.6 and 28.8%) (Table 3 and Fig. 13A). A strong 
preference for gene-dense chromosomal regions was observed in the CD34+ cell pre­
transplant sample, with 66.1% of RIS landing in genomic regions containing >10 genes 
per Mb, as compared to the 17% expected from the density of RefSeq genes in the 
human genome (Fig. 13B). This bias was maintained in the HSC progeny post­
transplant (70.6%), with a further enrichment in regions containing >20 genes per Mb 
(Fig. 13B). Accordingly, integrations retrieved from both samples were unevenly 
distributed in human chromosomes, with a tendency to correlate with gene density 
rather than chromosome size (Fig. 13C). Clusters of insertions were observed on 
chromosome llp l3  (8 sites), 18q21.33, 19pl3.3 (7 sites), lq32.1, 10pl5.1, 12pl3.32, 
17ql2, 17q23.2 (6 sites), and lq21.2, 6q25.3, l lp l l .2 , 15q26.1, 17pl3.1 (5 sites).
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In trag en ic
<%)
In te rg en ic
(%)
<30 kb 
upstream
(%)
<10 kb 
upstream  
(%)
<30 kb 
dow nstream
<%)
±5 kb  
from  T S S
(%)
In v itro  (p re - tran sp la n t)  CD34+ c e lls
(212 hits) 50.9* 49.1 19.4 12.3" 4.3* 23.6"
Ex vivo fo llow  u p  (496 hits) 41 .3a 58.7 25.6" 19.6"§ 12.7 28.8"
T otal (708 hits) 44.3 55.7 23.7 17.4 10.2 27.3
E x p ec ted  in  th e  h u m an  g e n o m e 35.5 64.5 n.d. n.d. n.d. n.d.
E x p ec te d  from  ra n d o m  library 37.9 62.1 14.5 4.2 10.5 6.1
Table 3. Retroviral integration site distribution in hematopoietic cells from ADA-SCID 
patients. Distribution of retroviral integration sites unambiguously mapped in CD34+ HSC from 
four ADA-SCID patients before transplantation (in vitro, pre-transplant CD34+ cells, 212 hits), 
from BM- or PB-derived hematopoietic cells from five ADA-SCID patients 1.5 to 47 months 
after gene therapy (496 hits), or total in vitro and ex vivo integrations (708 hits). Integrations 
were distributed as inside (intragenic) or outside (intergenic) RefSeq genes, at a distance o f <30 
kb or <10 kb upstream or <30 kb dowstream from genes, and at a distance o f ±5 kb from 
transcription start sites (TSS). Values expected for the human genome (NCBI35 annotation). 
Values obtained from a collection o f 398 sequences randomly cloned from a library of  
PsH/Msel-restricted, LM-PCR-amplified human DNA.
p<0.00001 vs human genome, p<0.01 vs random, p<0.05 vs ex vivo; Ap<0.01 vs human 
genome; pO.001 vs random; §p<0.05 vs in vitro; p<0.05 vs random. p<0.001 vs ex vivo.
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Figure 13. Genomic distribution of RV integration site in ADA-SCID patients. (A )
Distribution of integration sites within 30 kb window around the transcription start site. Each 
bar corresponds to the frequency of integration sites retrieved by LM-PCR technique in pre-
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transplant CD34+ cells {in vitro, n=212) or post-GT cells {ex vivo, n=251) within a 5-Kb interval 
from the transcription start site o f the nearest gene. (B) Correlation between integration sites and 
gene density within a 1Mb window. The number of RefSeq genes was determined in a region of 
500 kb on either side o f integration site for both "in vitro” and “ex vivo” samples. The data were 
compared to in silico-generated random integration sites (Hematti et al., 2004). (C) Correlation 
between the percentage o f integration events and the percentage o f genes on individual 
chromosomes. The number of genes per chromosome refers to NCBI version 35 of human 
genome. R2 Goodness of fit; p value was determined using the F statistic.
3.12 Retroviral integration hot spots in ADA-SCID gene therapy
We then asked the existence of preferred regions of RV integration. We 
identified “hot spots” by the occurrence of 2 indipendent integrations landed within the 
transcribed portion of a RefSeq gene or 2>2 independent integrations within arbitrarily 
chosen windows of 30 kb (2 hits), 50 kb (3 hits) or 100 kb (>4 hits) (Suzuki et al., 
2002). Cumulatively, 50 genomic loci were recurrently targeted by RV integration, of 
which 21 were in common between the in vitro and ex vivo sample (Table 4A-B). 
Overall, 14.6% (31/212) of in vitro integrations and 15.9% (79/496) of ex vivo 
integrations were classified as “hot spots” (Table 4A-B). The most frequently hit genes 
(s:3 times) encoded a protein kinase (DYRK1A), a putative RNA-binding protein 
(RNPC1), and a cell cycle regulator (CCND2), or were involved in tumor-associated 
chromosomal translocations (BCL2, BLM, LM02) (Table 4B and Fig. 14). The 
MDS1/EVI1 locus, which has been identified at relatively high frequency in previous 
mapping studies of retroviral integration sites (Wu et al., 2006) (Calmels et al., 2005) 
(Ott et al., 2006a), was hit only once, in granulocytes from Pt3 6 months post-GT and 
became undetectable at later time points by sequence-specific PCR (data not shown). 
LM 02  was overall the most frequently hit locus, with one integration cloned from pre­
transplant CD34+ cells (Pt5), two from granulocytes (Pt5) and three from T cells (Ptl, 
Pt3, Pt4) (Fig. 14). Five integrations were located outside the gene, of which three 
within 39 bp in a region at 39.2 Kb from the start site (S3_042: Pt3 18 months post-GT;
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S5_144: Pt5, 6 mo post-GT; S5_P048: Pt5 pre-infusion). The other integrations were 
located 15 Kb upstream (S4_048: Pt4, 26 mo post-GT), 1.3 Kb upstream (Sl_049: P tl, 
27 mo post-GT) and inside the second intron (S5_163: Pt5, +12 mo post-GT) (Fig. 14). 
All integrations were detected occasionally in one sample, and represented only a small 
proportion of the sequences isolated by shotgun cloning.
Integration n° Chr. n° Relative distance (bp) Position RefSeq gene
S3 036 
S3 P029 10 4874 Inside ADD3
S5 042 
S3 P091 3 20281 Inside BBX
S3 086 
S3 P007 19 17343 Inside Q8IUV 1_HUMAN
S5 176 
S3 P049 5 4000 Inside
Q8N8D9 HUMA 
N
S5 010 
S5 P002 22 918 Inside TNRC6B
S3 058 
S3 P054 8 140308 Inside TRPS1
SI 062 
S3 P024 3 34426 Inside NP_002213.1
S5 049 
S5 P020 9 44506 Inside CDW92
S3 135 
S3 053 1 17329 Inside PDE4B
S2 031 
S5 006 9 1353 Inside MLLT3
S3 054 
S5 022 16 12790 Inside BANP
SI 114 
S5 151 22 760 Inside NP_001008496.1
S2 022 
S4 041 22 4130 Inside YV03_human
S5 045 
S5 173 6 66604 Inside Q8TEE4_human
53 063
54 030 8 322230 Inside Q96Q05_human
54 P004
55 P039 10 344 Inside C10orfl07
S3 P043 
S5 P047 9 1811 Inside SHB
S2 P054 
S4 P027 10 87528 Inside ABLIM1
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Table 4A. Hotspots: list of genes hit independently by two integration sites. The relative 
distance refers to the distance between the two insertions inside the target gene. All insertions 
were <30 kb apart, with the exception of ABLIM1, TRPS1, NP_002213.1, Q8TEE4__human, 
CDW92 and Q96Q05_human. Three of these double hits were present in the pre-transplant 
sample, 7 in the post-transplant sample, and 8 in both.
Integration n° Chr. n° Relative distance (bp) Position RefSeq gene
S2 033 
S4 017 10 25789
Upstream
Upstream AKR1CL2
S5 114 
S2 P008 
S5 076 
S2 P015
18 73653
Downstream
Downstream
Downstream
Inside
BCL2
51 092 
S3 108
52 036
15 41359
Upstream
Upstream
Upstream
BLM
S2 045 
S5 026 7 27387
Upstream
Inside CCM2
S5 138 
S5 034 
SI 021
12 29994
Upstream
Upstream
Upstream
CCND2
S5 071 
S3 P018 2 1846
Upstream
Upstream CYP1B1
53 046
54 016 
S3 111
21 14290
Upstream
Upstream
Inside
DYRK1A
S2 004 
S2 019 X 297
Downstream
Downstream EIF2S3
SI 042 
S3 P047 9 7309
Upstream
Upstream GADD45G
S3 P097 
S5 033 6 1178
Upstream
Upstream BTN3A2
S5 056 
S5 086 21 28407
Upstream
Upstream HRMT1L1
S5 P026 
S3 P072 5 99
Upstream
Upstream HTR4
SI 023 
S4 012 1 1879
Upstream
Upstream IRF2BP2
S3 109 
S5 040 13 243
Upstream
Upstream LCP1
S5 163 
SI 049
54 048
55 144 
S3 042 
S5 P048
11 58770
Inside
Upstream
Upstream
Upstream
Upstream
Upstream
L M 02
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S3 009 
S5 014 8 642
Upstream
Upstream MTSS1
SI Oil 
SI 109 6 975
Upstream
Upstream MYCT1
SI 111 
S3 130 14 6548
Downstream
Downstream NFKBIA
S2 007 
S5 145 1 2445
Inside
Upstream NP_859071.1
S2 030 
S2 032 2 1494
Upstream
Upstream PTMA
S5 136 
S5 032 6 4123
Downstream
Downstream Q8TEE4_Human
S3 029 
S3 081 9 4
Downstream
Downstream RANBP6
S5 093
54 P033
55 P051
20 28106
Downstream
Downstream
Downstream
RNPC1
53 047
54 047 3 4502
Downstream
Downstream RYBP
53 P022
54 050 21 52
Upstream
Upstream SAMSN1
S3 083 
S5 P058 7 50
Downstream
Downstream SYPL
S2 021 
S2 P033 17 2560
Upstream
Upstream UBP32_Human
S5 174 
S4 P031 13 10670
Upstream
Upstream WBP4
SI 014 
SI 036 20 15
Upstream
Upstream ZNF217
S5 157 
S5 P028 8 3164
Upstream
Inside ZNF406
S2 P035 
S5 092 1 180
Upstream
Upstream GMEB1
S2 P045 
S5_072 21 685
Downstream
Downstream MRPL39
Table 4B. Hotspots: List of genomic sites frequently hit by retroviral integrations. The data 
report insertions from in vitro or ex vivo samples according to the following categories: 2 RIS 
within 30 Kb, 3 RIS within 50Kb, >4 RIS within 100Kb (Suzuki et al., 2002). In case of three or 
more integrations the relative distance refers to the external boundaries.
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Figure 14. Schematic representation of the most frequent hotspots found in ADA-SCID.
Integrated pro virus is shown as blue (ex vivo integration) or green (in vitro integration) arrows. 
The genes are depicted in red with full boxes and arrows indicating the exons and the 
transcription start sites.
3.13 Long-term monitoring of XM02-carryng clones
To assess the relative contribution of clones carrying L M 02  insertions, we
measured the frequency of four RIS by sequence-specific real-time PCR. Three
integrations were detected in T cells from Ptl (Sl_049), Pt3 (S3_049) and Pt4 (S4_048)
from 6 up to 60 months post-GT, at levels fluctuating between 0.03% and 0.7% of the
total CD3+ populations (Fig. 15). Of notice, integration Sl_049 became undetectable at
latest time of observation (6 years after GT). These integrations were not detectable in
peripheral blood or BM purified granulocytes, BM erythroid cells and BM CD34+ cells
at repeated follow up controls, with the exception of CD34+ cells from Ptl, which were
positive 11 months after GT (0.15%) (data not shown). However, these frequencies are
comparable to those observed for two non-recurrent insertions from Pt3 landed in
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“neutral” region o f the genome (Fig. 15). One integration (S5_144) was undetectable in 
T cells and at the limit o f PCR sensitivity in granulocytes (0.01%) from Pt5 (Fig. 15) 
but was absent in CD34+ cells. B cells were weakly positive at occasional time points in 
Pt3, Pt4 and Pt5 (data not shown). These results indicated that clones carrying L M 02  
insertions undergo in vivo to normal physiological clonal fluctuations.
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Figure 15. Quantification of the contribution of the LM 02  clones to the total T cell 
population. The frequency of four insertions within the L M 0 2  locus was measured by 
sequence-specific Real Time PCR in purified CDS" T cells isolated at different time points after 
gene therapy. In dotted lines are reported the frequencies of non TM 02-related (neutral) 
integrations retrieved from two CD4+ T cell-clones of Pt3, as control of physiologic clonal 
fluctuations. The results are expressed as percentage of total CDS population.
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3.14 LM 02  integrations do not lead to over-expression in vivo
To assess the potential influence o f the nearby vector integration on L M 02  gene 
expression, we m easured mRNA levels in purified cell subpopulations from both 
untreated and treated ADA-SCID patients, and from healthy controls. No up-regulation 
o f L M 0 2  expression was observed in purified bulk T-cell subsets from GT treated 
patients compared to healthy controls (Fig. 16). L M 0 2  expression in granulocytes was 
higher in untreated ADA-SCID patients than in healthy controls, and did not increase in 
samples from GT treated patients.
Granulocytes CD3+T cells CD4+T cells CD8+T cells
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Figure 16. Expression of LM 02  in peripheral blood T cells and granulocytes. Total RNA 
was isolated from freshly purified CD3+, CD4+, CD8+ T cells or CD15+ granulocytes of gene 
therapy-treated patients, ADA-SCID patients under PEG-AD A treatment (not treated with GT), 
and age-matched healthy controls. LM 02  gene expression was measured by quantitative RT- 
PCR using the standard curve of a reference sample. Values were normalized on expression of 
the housekeeping gene HPTR and correspond to duplicate wells.
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3.15 Integrations are found preferentially in/near genes expressed in CD34+ cells
We next analyzed if the bias for the integration pattern near genes and specific 
hot spots reflected a preference for genes expressed in CD34+ cells. To mimic the 
transcriptional activity at the time of gene transfer, we analyzed, by Affymetrix 
GeneChip® microarray analysis, the gene expression profile of cytokine-exposed BM 
CD34+ cells under identical conditions required for the transduction procedure. The 
genes expressed and classified as “present” by the software were divided in 3 arbitrary 
categories comprising 0-25%, 25-75% and 75-100% of expression levels of all genes in 
a normalized distribution. The proportion of expressed genes in the array (42.8%) was 
significantly increased when the analysis was restricted to genes hit by integrations 
inside (60.9%) or within 10 Kb from TSSs (67.4%) in pre-transplant CD34+ cells 
(p<0.005, Fig. 17). Integrations upstream TSSs favored highly expressed genes, 
indicating that transcriptionally active regions are preferentially targeted by retroviral 
vectors in CD34+ cells. Of interest, “hot spot” genes were more frequently expressed 
compared to the whole chip distribution (63.3 vs 42.8%), with a strong over­
representation of highly expressed genes (21.1 vs 10.7%, p<0.005; Fig. 17). These data 
indicate that gene expressed in CD34+ cells at the time of transduction were 
preferentially target by retroviral vector and may at least in part explain the preference 
for insertions retrieved in hot spots, including LM02. The same tendency was observed 
for post-GT samples (ex vivo), although the frequency of “present” or highly expressed 
genes was lower compared to the pre-transplant profile (Fig. 17), suggesting a negative 
selection against integrations into active genes in hematopoietic cells in vivo.
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Figure 17. Correlation between insertion sites and gene expression profile of CD34+ cells 
at the time of transduction. The expression level of all probesets present on an Affymetrix 
HG-U133A microarray was compared to the expression level of probesets o f genes targeted 
(inside or <10 kb upstream) or frequently hit (hot spots) by retroviral vector insertion in pre­
infusion CD34+ cells (in vitro) and post-GT cells (ex vivo) or in both samples, respectively. The 
bars show the percentage distribution of expression levels classified as present and absent by 
MAS 5.0 software. The present probesets are then categorized according to two cut offs 
identified by first (0-25) and third (75-100) quartiles.
3.16 ADA selective advantage favors survival of vector clones integrating in/near 
genes transcriptionally active in T cells
Since T cells in ADA-SCID patients carry a selective advantage if  ADA is 
expressed, we investigated w hether the state o f  expression o f a gene h it by an 
integration could influence the in vivo behavior o f transduced T cells. The gene 
expression profile o f purified T cells was determined and divided in arbitrary expression 
categories as described above (Fig. 18). Hit genes were expressed at a significantly 
higher frequency (53.1 vs 43.3%, p<0.01) and enriched in the high expression category 
(intragenic hits: 14.0 vs 10.8%, p<0.05; hits <10kb from TSS: 22.7 vs 10.8%, p<0.005). 
These data suggest that the selective pressure for vector-derived ADA expression favors
131
the survival o f T cells carrying insertions in the proximity o f transcriptionally active 
regions.
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Figure 18. Correlation between insertion sites and genes expressed in T cells. Comparison 
of expression level of all probesets vs probesets of genes hit (inside or <10 kb upstream) by 
retroviral vector insertion and found in T cells of ADA SCID patients after gene therapy.
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3.17 No evidence of in vivo selection for integrations targeting “dangerous” genes
To understand whether the bias observed in the genomic distribution of RIS was 
associated to in vivo selection of specific integration events, we carried out a functional 
clustering of genes targeted by retroviral integration based on the Gene Ontology (GO) 
classification (Ashbumer et al., 2000). The expected distribution of genes among the 
different GO families was compared with the observed distribution of genes hit by 
integrations (within or ±30 kb from genes) in the in vitro and ex vivo samples. The 
analysis showed a tendency for a modest, statistically not significant over-representation 
of several gene categories (signal transduction, cell cycle, cell growth, enzyme activity, 
immune response) in the pre-transplant CD34+cell sample (Fig. 19). The post-transplant 
dataset displayed a similar profile, with the exception of a slight but significant increase 
in the frequency of genes encoding protein-binding factors (Fig. 19). Overall, proto­
oncogenes were only slightly over-represented (3.1%) compared to their expected 
frequency in the human genome (2.2%). Collectively, these results indicate that the 
occurrence of integrations in the vicinity of genes involved in potentially dangerous 
functions does not necessarily imprint a selective pressure for an in vivo expansion to 
the clones carrying such integrations.
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Figure 19. Gene Ontology (GO) functional clustering of targeted genes. The probesets of 
genes targeted (inside and + 30 kb upstream or downstream) by retroviral insertion were 
classified according with Gene Ontology criteria. Each bar refers to the percentage of all of 
targeted probesets falling within specific gene category. The difference between groups was 
tested by both Fisher Exact test on Ease score, corrected for multiple comparisons with 
Bonferroni-Holm correction. The only difference was revealed for “ex vivo” sample in “protein 
binding” category (p fisher=0.022; p ease score=0.034). Moreover, no major differences were 
observed in vector integration site distribution and hierarchical clustering between lymphoid 
and myeloid cells (data not shown).
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3.18 Normal profile of gene expression in CD4+ T cells from GT treated patients
We then studied the overall transcriptional profile of purified CD4+ T cells from 
three ADA-SCID patients (P tl, Pt2, Pt3), to assess potential alterations in the 
transcriptional activity after gene therapy (10-30 months). The expression of >16.000 
genes was analyzed by Affymetrix HG-U133A Gene Chip® and compared to those of 
age-matched healthy controls. For P tl, we used as control her healthy sibling and 
another sibling who had received an HLA-identical BMT. As shown in Fig. 20A, there 
was little difference between the expression profiles of CD4+ T cells from Ptl and the 
family controls: 139 (0.6%) and 105 (0.5%) probe sets showed a significant increase 
(s.l.r. > 1.5) in expression compared to the BMT patient and control, respectively, 
while 136 (0.6%) and 82 (0.4%) showed a comparable decrease (s.l.r. < 1.5). Similar 
variations were detected in the comparison of the BMT patient and the healthy control. 
In an unsupervised comparison (Fig. 20B) of all CD4+ T-cell samples from controls and 
patients treated with gene therapy, we did not observed a segregation of samples 
according to the treatment. Moreover, the hierarchical clustering of samples performed 
in a supervised analysis showed no significant changes in the expression profile of 
patients and controls (data not shown). Overall these analyses indicate that there is no 
difference in the gene expression program of CD4+ T cells developed after gene therapy 
with respect to BMT or healthy controls.
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Figure 20. Gene expression profile in CD4+ T cells from patients. (A) Microarray gene 
expression analysis of gene therapy (HSC-) Ptl CD4+ T cells compared to healthy sibling (ND- 
P tl) and a BMT-treated sibling (BMT-Ptl) (MAS 5.0 analysis); (B) Unsupervised analysis of 
CD4+ T-cell samples from three gene therapy patients (Pts) and four controls (C).
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3.19 Analysis of vector clonal composition in distinct hematopoietic lineages
To gain a better knowledge of the nature and number of genetically corrected 
HSC and their differentiated progenies in the ADA-SCID patients, we evaluated 
integrations in granulocytes, representative of long-term engrafting HSCs, and T cells, 
which include long-term surviving, mature cells. Among the 496 RIS isolated from ex 
vivo samples from five patients, 124 came from highly purified granulocytes, 399 from 
T cells (per-patient range: 42-121), and 10 from other cell types. Using RIS as a marker 
of cell clonality, T-cell populations remained polyclonal throughout the follow-up, in 
agreement with the polyclonal TCR repertoire observed in the same samples (Fig. 21A 
and data not shown). In contrast, granulocytes showed a more oligoclonal pattern by gel 
electrophoresis analysis (Fig. 21 A), with fewer but stable integrations retrieved by 
random cloning in four patients (range 6-84). This may be in part related to the lower 
proportion of transduced cells engrafted within the myeloid compartment as compared 
to the lymphoid compartment (Aiuti et al., 2002a). No major differences were observed 
in vector integration site distribution and hierarchical clustering between lymphoid and 
myeloid cells, even if the integrations retrieved in granulocytes at early time points after 
GT (+45 days) behaved more similarly to insertions cloned from pre-infusion CD34+ 
cells, in terms of preference for distribution inside genes, compared to later time points 
analysis (> 6 mo; data not shown). While a large numbers of integrations were uniquely 
detected in single time points, few of them were randomly retrieved at different time 
points during the follow up (Figure 2 IB). Remarkably, the analysis performed in 
various hematopoietic lineages during the follow-up of patients revealed the presence of 
shared integrants between myeloid (granulocytes) and lymphoid (T and/or B) cells in 
Pt3 (n=9) and Pt4 (n=4) (Fig. 2 IB) and confirmed in selected cases by specific PCR. 
Collectively, these data demonstrate that the engraftment of transduced HSC with 
multilinage potential has occurred and is maintained in these patients.
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Figure 21. Vector clonal composition in distinct hematopoietic lineages after gene therapy.
(A) Clonal analysis by LM-PCR and inverse-PCR. Analysis of vector integrations in purified 
CD3+ T cells and CD 15+ granulocytes from five ADA SCID patients treated with gene therapy. 
Nested inverse- or LM-PCR products were analysed by electrophoresis on Spreedex agarose 
gels with 100bps ladder, as marker (M). In Pt2, who received a low CD34L cell dose and 
displayed poor myeloid engraftment (<0.1 %) no RIS could be isolated from granulocytes. The 
following representative time points are shown: LM-PCR in T cells: P tl, 20 months (mo); Pt2,
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39 mo; Pt3, 26 mo; Pt4, 22 mo; Pt5, 9 mo. LM-PCR for granulocytes: Ptl,47 mo; Pt3, 33 mo; 
Pt4, 22 mo; Pt5, 12 mo. Inverse-PCR in granulocytes: P tl,5 mo, Pt3, 26 mo; Pt4, 4 mo; Pt5, 3 
mo. (B) Evidence for common integrants identified in different cell subpopulation during long­
term follow up. Each integration from Pt3 (upper panel) or Pt4 (lower panel) is identified by a 
unique number. The circles indicate the presence at a given time after gene therapy (M, months) 
of a specific integration detected by random cloning in the indicated population. Only some 
integrations found at different time points or in different cell populations are represented. The 
presence o f common integrants was demonstrated also by sequence-specific PCR, which 
allowed to unequivocally track integrants (i.e.: S3_027, S3_026) in different lineages (data not 
shown), and confirmed the engraftment of transduced HSC with multilineage potential.
3.20 Generation of T-cell clones from ADA-SCID patients
To study at the clonal level the effects of vector integration on gene expression 
and cell function, we have generated T-cell clones by ex vivo limiting dilution from two 
patients at 18 months after their autologous transplantation with transduced CD34+ cells 
(Pt2, 25 clones; Pt3, 28 clones). A complete characterization of these clones was 
performed in terms of phenotype, TCRVb repertoire, ADA expression/activity and 
functional properties. All clones were CD4+ and displayed a high Vbeta family T-cell 
receptor diversity, as assessed by flow cytometry (data not shown). ADA expression, 
detected by intracellular staining in all T-cell clones, was within the normal range, but 
varied in intensity between different clones, suggesting a position dependent expression 
of the transgene, which we are currently characterizing based on mapped integration 
sites (Fig. 22A and data not shown). Functional analysis showed normal proliferative 
responses after TCR/CD28 stimulation and concomitant production of IL-2, IL-4 and 
IFN-y cytokines for the majority of the clones (Fig.22B and data not shown)
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Figure 22. Characterization of T-cell clones generated from two GT treated ADA-SCID 
patients. (A) ADA protein expression was determined by intracytoplsmic staining as described 
in methods. M.F.I values are indicated, (pink line isotype control; green line ADA). (B) T-cell 
clones from Pt3 were stimulated with immobilized anti-CD3 (1 pg/ml; red bars) in absence or 
presence of anti-CD28 mAb (10 pg/ml; green bars) and 3H-Thymidine incorporation was 
assessed after 48h. (C) In parallel, cytokine secretion was evaluated by ELISA in the 
supernatants collected at 48h.
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3.21 Analysis of RV integration sites in T-cell clones
Among the clones generated from Pt2, four were negative for the neomycin gene 
marker. In all the other clones, vector-genome junctions were cloned by inverse-PCR, 
sequenced and mapped onto the human genome (Fig. 23).
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Figure 23. RIS distribution in T-cell clones from two ADA-SCID patients.
Overall, 39 RIS were unambiguously assigned to a chromosom al position, o f 
which 24 identified from clones o f Pt3 and 15 from Pt2. The large m ajority o f the 
clones contained one vector copy per cell (88%), with few clones carrying two copies 
(12%), as assessed by quantitative PCR.
As for purified hem atopoietic cell populations, RIS distribution analysis showed a 
cluster o f integrations occurring within a 5-kb window upstream or downstream TSSs 
(36.6%) and a strong preference for gene-dense regions (>10 genes/M b) (85% RIS).
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Interestingly, by FACS analysis, we could identify a different Vbeta TCR profile in 
some clones sharing the same insertion site, thus indicating their progenitor cell origin. 
In other clones, in depth analysis o f Vbeta subfamilies is currently ongoing by CDR3 
sequencing. Moreover, we found that some o f these clones shared common insertion 
site w ith freshly isolated CD3+ T cells, CD15+ granulocytes and CD19+ B cells, 
confirming that were derived from transduced HSC with multilineage potential.
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Figure 24. Evidences for stem cell origin of T-cell clones. (A) FACS analysis of Vbeta 
profile in T-cell clones from Pt3. Upper panel: two clones sharing the same RIS have same 
Vbeta profile. Middle panel: two clones sharing the same RIS have distinct Vbeta repertoire. 
Lower panel: clone having two copies of vector inserted, landed in different genomic regions.
(B) One T-cell clone from Pt3 display shared RIS with distinct hematopoietic cell subsets 
purified ex vivo at different time points during the follow up.
3.22 Gene expression analysis of integration-targeted genes
The observed retroviral integration preferences may account for a potential risk o f 
activation and/or deregulation o f host cell genes surrounding the integration sites. To 
directly assess this issue in the context o f ADA-SCID GT trial, the expression o f 125 
genes, mapped within a window of 200 Kb centred on each insertion site, was analyzed 
by real-time RT-PCR on two microfluidics cards designed to measure gene expression 
in quadruplicate in the clones carrying the integration(s) and in (a) all other transduced 
clones (n=49), (b) untransduced clones (n=4), (c) clones from healthy donors (n=4), as
controls. Importantly, custom assays corresponding to different transcripts o f the same
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gene were also included in the analysis, for a total o f 145 probes. For each gene, the 
expression level was m easured as relative mRN A quantity follow ing interarray 
normalization for the level o f  GAPDH, and plotted as ratio (AACt) with respect to the 
average levels, calculated for all but one o f the clones i.e. the clone carrying insertion 
nearby such gene. So far, 105 genes flanking 32 RIS (of which: 9 intragenic and 10 very 
close (<10kb) to TSS), identified from 30 clones, were analysed. The results o f  this 
preliminary analysis showed no alteration in expression level correlated with the nearby 
vector integration, in agreem ent w ith the norm al in vitro  grow th and functional 
behaviour o f T-cell clones (Fig. 25 and data not shown).
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Figure 25. Expression analysis of gene targeted by RIS in T-cell clones. Quantitative PCR 
analysis of the expression of genes hit by a RV integration event in individual T-cell clones. (A) 
Example of an intergenic RIS close to TSS of a gene is shown. RV vector has integrated 5Kb 
upstream the TSS of LKAP gene, in the same transcriptional orientation, and 20Kb upstream 
the TSS of NDE1. Expression analysis of other two genes (C16orf45 and M y H ll)  landed 
within lOOkb window on either side of RIS was also studied. (B) Example of an intragenic RIS. 
RV vector has integrated in the third intron of LOC92017 gene (distance from TSS 34.4Kb) in 
the opposite transcriptional orientation. Expression analysis of other three genes (TNFRSF17; 
FLJ12363 and GSPT1) landed within lOOkb window on either side of RIS was also studied. In 
both cases, after normalization for the level of GAPDH, relative mRNA quantity was plotted as 
AACt ratio with respect to the average level in all the other analysed clones. The expression 
value of the clone interested by the hit is indicated by a pink dot, control clones by blue dots. 
RV orientation is indicated by red arrows.
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CHARPTER 4 -  Discussion
The results obtained during the course of this PhD project represent new 
findings, which provide important insights in the pathogenesis of ADA-SCID and at the 
same time contribute to extend our knowledge on the biology of genetically corrected 
haematopoietic stem/progenitor cells and lymphocytes, which ultimately impact on the 
safety and long-term efficacy of gene therapy. Here, the results obtained will be 
discussed in view of the existing data and in view of their relevance for future clinical 
and experimental applications.
4.1 Characterization of the T cell defect in ADA-SCID patients
In the present study, we uncover the molecular basis underlying the 
immunological defect of T cells from ADA-SCID patients. We established T-cell lines 
from ADA-SCID patients, with a severe clinical phenotype, before their autologous 
transplantation with gene-corrected CD34+ cells. For the first time, TCR-mediated 
activation of ADA-deficient T cells was studied, using a large scale of anti-CD3 mAh 
doses, combined or not with anti-CD28 mAb. Our study showed that ADA-deficient T 
cells have a specific defect in response to TCR triggering induced by immobilized anti- 
CD3 mAb. Importantly, the proliferation defect of ADA-deficient T cells is attributable 
to both CD4+ and CD8+ T cells. Although the addition of anti-CD28 mAb to anti-CD3 
mAb stimulation enhanced the proliferative response of ADA'7' T cells, costimulation 
was not able to restore normal proliferation in these cells (data not shown). Our study 
helped to clarify the role of IL-2 deficiency in the inability of ADA'7' T cells to 
proliferate in response to anti-CD3/CD28 mAb. T-cell proliferation is controlled by 
both TCR/CD28 and IL-2R-mediated signals. Exit from the G1 phase of the cell cycle 
and entering into the S phase requires IL-2 generated signals (Nourse et al., 1994).
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Indeed, triggering of the IL-2 receptor induces key events of Gl-to-S phase transition, 
including up-regulation of cyclin D, down-regulation of p27Kip, and hyper­
phosphorylation of Rb, mediated by PI3K (Brennan et al., 1997). In ADA'7" T cells, 
defective proliferation correlates with reduced IL-2 production. In culture, ADA- 
deficient T-cell lines require high dose of exogenous IL-2 to grow. Therefore, the 
inability to secrete sufficient amounts of IL-2 is likely to be the main reason for the poor 
proliferation of ADA'7' T cells. In our study, analysis of the pattern of cytokine 
production by ADA'7' T cells also revealed a strong impairment in the secretion of both 
Thl (IFN- y and TNF-a) and Th2 cytokines (IL-4, IL-5 and IL-10) after TCR/CD28 
stimulation. For IFN-y and IL-4 we demonstrated that the low levels in the supernatants 
correspond to reduced protein synthesis. However, Thl type cytokines seem to be 
particularly affected, since more IL-4 than IFN-y was produced upon TCR triggering in 
ADA'7' cells. Similar pattern was consistent with the expression of the corresponding 
mRNA species, thus indicating a bias occurring at the transcriptional level. The 
unbalance Th2 versus Thl cytokine production might be related to the higher threshold 
of activation required for Thl cytokine gene transcription with respect to Th2 gene, as it 
has been reported that reduced ERKs activation associates with early IL-4 production 
and Th2 differentiation (Jorritsma et al., 2003). However, defective IFN-y production 
was also present upon strong stimulation with TPA plus ionomycin, suggesting that it 
might likely derive from an intrinsic developmental defect. Analysis of T-bet and 
GATA-3 mRNA levels in resting and activated CD4+ T-cell lines revealed a 
significantly reduced expression of T-bet in ADA'7' compared to control cells. 
Therefore, it is likely that the reduced T-bet expression contributes to the defective IFN- 
y gene transcription in ADA'7' CD4+ T cells, as T-bet is one of the key factors involved 
in IFN-y production by CD4+ T cells (Szabo et al., 2002) (Szabo et al., 2000) and in Thl 
differentiation. T-bet was shown to positively regulate its own expression by a
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mechanism involving IFN-y-induced STAT1 activity (Afkarian et al., 2002). Therefore, 
defective production of T-bet and IFN-y in ADA"7' CD4+ T cells could also result from 
the lack of a positive feedback. On the other hand, ADA'7' CD4+ T cells were able to 
express normal levels of the transcription factor GATA-3 mRNA, which positively 
regulate IL-4 gene transcription and Th2 commitment (Ouyang et al., 2000). In this 
view, our results are in agreement with the clinical phenotype of ADA-SCID patients, 
characterized by recurrent allergic airway inflammations and markedly elevated IgE 
(Hirschhom, 1999). Moreover, our in vitro results are relevant for the understanding of 
the cellular mechanisms associated ADA-SCID immunodeficiency. Reduced IL-2 and 
IFN-y production by activated CD4+ T cells, and overall impairment in Thl 
differentiation is likely to result, in vivo, into poor help to CD8+ T cells during the 
establishment of immune response against viral pathogens. The precise requirements of 
CD4+ T cells for the generation and survival of memory CD8+ T cells has been deeply 
investigated (Rocha and Tanchot, 2004). While the activation and acquisition of effector 
functions by CD8+ T cells during primary immune response do not require CD4+ help at 
the moment of priming, the capacity to undergo clonal expansion upon Ag re-exposure 
is programmed via interaction with CD4+ T cells and APC during primary stimulation 
(Janssen et al., 2003). It has been proposed that help by CD4+ cells confers competitive 
“fitness” to memory CD8+ T cells, thus contributing to the generation of long-term 
surviving memory CD8+ T cells (Johansen et al., 2004). We can speculate that, in ADA- 
SCID patients, the inability to efficiently clear viral infections results from both an 
intrinsic CD8+ T cell defect and from inadequate help by Thl cells.
The above results on cytokine genes transcription strongly suggest that severely
compromised effector functions in ADA-deficient T cells resulted from a defective
ability to transduce activating signals from the membrane TCR/CD28 to the cell
nucleus. We analyzed one of the main signaling events triggered by TCR/CD28
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engagement in ADA-deficient CD4+ T cells. Our observation that phosphorylation of 
MAPK ERK1/2 is generally defective in ADA'7' cells, compared to healthy donors, is in 
accordance with previous data obtained in freshly isolated thymocytes from ADA 
knock-out mice, in which a reduced phosphorylation of the upstream molecule CD3 £ 
chain has been reported (Apasov et al., 2001).
In agreement to the fact that proximal TCR signaling is impaired in ADA'7' T 
cells, a reduction in the activation of CREB was observed early after TCR/CD28 
triggering. This event is linked to AP-1 proteins expression and IL-2 production. 
Indeed, CREB is involved in the induction of c-jun, c-fos, Fra-2, and FosB after TCR 
cross-linking (Kuo and Leiden, 1999). Therefore, our results are consistent with a model 
in which the absence of functional CREB, in ADA'7' T cells, causes defective induction 
of AP-1 and IL-2 and subsequent proliferation impairment. In addition, the production 
of IL-2 is possibly determined by the ratio between pCREB and CREM, a family-related 
transcriptional repressor, which occupies the -180 site of the IL2 promoter (Tenbrock et 
ah, 2003). Since the reduced CREB phosphorylation may limit its nuclear translocation 
and binding to the IL2 promoter, it is possible that an increase CREM ligation to the 
promoter-binding site might be involved in the block of IL-2 production observed in 
ADA'7' cells. It would be important to study the accessibility of IL-2 promoter in ADA- 
deficient cells or the in vivo binding of these transcription factors.
Analysis of Ik B cx phosphorylation in ADA-deficient cells, after TCR/CD28 
triggering, showed that at the time points evaluated the levels of phosphorylation were 
undetectable or markedly reduced compared to controls. IkB cx is normally degraded 
after phosphorylation by the proteosome pathway (Karin and Ben-Neriah, 2000). At the 
later time point evaluated (2h) reduced levels of ftcBa phosphorylation could reflect 
reduced targeting to degradation and hence low level of NFkB translocated in the
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nucleus. It would be therefore interesting to further investigate NFkB activity and 
localization of NFkB subunits in the nucleus of ADA'7' cells.
Collectively, these results suggest that rather than controlling a single pathway 
downstream the TCR, the immune defect in ADA-SCID may involve multiple pathways 
converging towards a defective induction of the transcriptional machinery.
Interestingly, reduced methylation of Vav-1, a regulator of calcium increase, as 
well as impaired ERKs activation and nuclear transcriptional events linked to NFAT 
and NFkB have been recently associated to drug-induced inhibition of SAHH enzyme 
(Blanchet et al., 2005). Block in SAHH activity, classically considered an hallmark of 
ADA-SCID (Hershfield, 2001), has been observed in ADA'7' T cells. These findings 
strongly support the notion that an intracellular toxicity persists in ADA-deficient T 
cells, which developed in vivo in a poisoned environment, even under culture 
conditions. However, in order to directly investigate the role of altered purine 
metabolism in the immune dysfunction, we exposed T cells to ADA-SCID in vivo -like 
condition.
4.2 Role of altered purine metabolism in the defect of ADA-deficient T cells
Although available evidence suggests that the metabolic basis for ADA-deficient 
immunodeficiency is related to the physiological impact of the ADA substrates, there 
remains uncertainty about the relative contribution of Ado- versus dAdo-related 
mechanisms to immune dysfunction. Historically, Ado-induced cAMP formation in 
lymphocytes was one of the first hypothesis offered to explain the lymphopenia 
observed in patients affected by ADA-SCID. However, elevated lymphocyte cAMP was 
not demonstrated in vivo, and in vitro Ado lymphotoxicity could be explained by its 
uptake and intracellular metabolism (Hershfield, 2001).
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Despite the limited knowledge regarding its own physiological function, dAdo-related 
mechanisms have been generally proposed as the primary cause of lymphotoxicity in 
ADA-SCID. Indeed, it is well established the correlation existing between the severity 
of the disease and the concentrations of dAdo and its nucleotides derived (dAXP) in 
erythrocytes and excreted fluids. Moreover, while dAdo accumulation is present from 
birth, the finding of high plasma and urinary Ado in late presenters or patients 
underwent BMT, support the concept that dAdo, but not Ado, is toxic to the immune 
system (Hershfield, 2001) (Hirschhorn, 1999). Therefore, understanding the molecular 
mechanisms, linking elevated dAdo to immune dysfunction, acquires growing 
importance as it may also provide a rationale prediction of the relationship between 
clinical manifestations and molecular defects. With respect to Ado, this metabolite 
displays a lower affinity for adenosine receptor (Fredholm et al., 2001). Whether the 
local overload of dAdo may overcome this reduced activity enabling the initiation of the 
transmembrane signaling has not been explored. Our study describes for the first time a 
dAdo-related mechanism responsible for T cell dysfunction in ADA-SCID, which is 
independent from dAdo intracellular poisoning but consistent with the engagement of 
an aberrant extracellular receptor signaling. We have demonstrated that exogenous 
dAdo, at the concentrations resembling the in vivo accumulation (Aiuti et al., 2002a) 
(Aiuti A. manuscript in preparation), act on the A2A receptor and suppress activation 
and effector functions of ADA-deficient T cells. Our data are consistent with a key role 
of cAMP/PKA in the dAdo-mediated inhibitory effect. The role of cAMP/PKA pathway 
in the physiological control of inflammatory T cell responses has been extensively 
characterized (see chapter 1). However, in the context of defective dAdo-metabolizing 
enzyme, where the intracellular cAMP levels would be reasonably increased, this 
regulation may be overstated, leading to the immune defect. Indeed, interference with 
the proximal biochemical events following T-cell receptor-triggering and inhibition of
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downstream effector functions has been demonstrated by pharmacologic increase of 
intracellular cAMP with the use of A2A receptor agonist (Huang et al., 1997; Skalhegg 
et al., 1992) (Butler et al., 2003) (Lappas et al., 2005). Phosphorylation of ERK1/2 
MAPK was notably abrogated in ADA-deficient T cells stimulated in presence of dAdo, 
suggesting that an ADA-deficient environment in vivo is not likely conducive to normal 
TCR signaling. Moreover, it predicts that other events of TCR signaling may be 
inhibited by dAdo in conditions of ADA-deficiency. In T cells, ERK1/2 MAPK is 
involved in the induction of AP-1 activity by promoting Fos expression (Hunter and 
Karin, 1992). ERK1/2 is linked to IL-2 and IFN-y production (Badou et al., 2001) 
(Koike et al., 2003) and regulates cell proliferation through direct stimulation of DNA 
synthesis (Graves et al., 2000). These activities require translocation of phosphorylated 
ERK1/2 to the nucleus. Therefore, we can reason that, in ADA-SCID patients, 
inhibition of ERK1/2 activation is responsible for the suppressed effector functions.
Preventing MAPK ERK1/2 activation, dAdo may drive TCR-stimulated T cells 
towards an anergic rather than an immunogenic response. Recent studies have 
challenged the biochemical definition of the anergic state, showing that anergic T cells 
are incapable of activating lck, ZAP-70, phosphorylating TCR chain, activating Ras 
and ERK and transactivating AP-1 and NF-AT (Cho et al., 1993) (Madrenas et al., 
1995) (Boussiotis et al., 1996) (Fields et al., 1996) (Mondino et al., 1996) (Kang et al., 
1992). The cAMP/PKA pathway hyperactivation and SAHH inhibition may play a 
causative role in the induction and propagation of this anergic state, as they can affect 
mostly of the above mentioned biochemical events, generally delivering off signals 
(Torgersen et al., 2002) (Blanchet et al., 2005). Therefore, such a mechanisms might be 
responsible for preventing T-cell activation and expansion during Ag-driven immune 
responses and may offer a better comprehension for the clinical autoimmune
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manifestations observed in ADA-SCID patients (Kohn DB, 1996) (Ozsahin et al., 
1997).
Previous results in ADA knockout mouse model have indicated Ado but not 
dAdo as involved in the inhibition of TCR-triggered events leading to T cell survival 
(Apasov et al., 2001), thus suggesting an exclusive dAdo-related intracellular 
mechanism of action. It is conceivable that these opposing results are due to the 
different cell-type, which may exhibit different metabolic pathways and sensitivity. 
Indeed, in thymocytes the pathway of nucleoside phosphorylation is known to be 
particularly active, thus playing a major role in the dAdo-mediated toxicity. However, 
our observation that the inhibitor of nucleoside transport system enhanced the dAdo- 
mediated inhibitory effect on TCR-dependent proliferation of ADA'7' T cells argues in 
favour of two simultaneously cooperating mechanisms in the lymphotoxicity induced 
by dAdo in ADA-deficient T cells: the extracellular signaling through adenosine 
receptors and the intracellular metabolism.
The cause of T lymphopenia, in ADA-SCID, has been primarily attributed to 
induction of apoptosis by elevated levels of ADA metabolites (Kizaki et al., 1990) 
(Benveniste and Cohen, 1995). Indeed, a relatively high fraction of T lymphocytes 
isolated from the peripheral blood of ADA-SCID patients treated with PEG-ADA are 
committed to apoptosis (Malacarne et al., 2005), suggesting that this is a relevant 
mechanism of lymphopenia even in patients undergoing enzyme replacement therapy.
In our study, we found that ADA-deficient T cells exhibit an increase susceptibility to 
apoptosis when exposed to high concentrations of both ADA substrates. Thus, these 
results indicate that a general deregulation of T cell function/homeostasis and a direct T 
cell depletion could be responsible for the complex picture of ADA-SCID clinical 
manifestation, such as immunodeficiency and autoimmunity.
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4.3 Efficacy of HSC gene therapy
The results presented in this PhD thesis complement and extend the clinical 
evidences indicating the efficacy of HSC-based gene therapy in correcting both the 
metabolic and immune defect of ADA-SCID patients.
In untransformed T-cell lines generated from patients after gene therapy ADA 
expression was at therapeutic level, enabling the full correction of the secondary 
additional metabolic defect. Normalization of SAHH activity was pointed out as the 
most sensitive indicator of normalization of metabolite concentrations and, more 
recently, as prerequisite for full T-cell activation and immune responses (Blanchet et al., 
2005). Accordingly, gene-corrected cells displayed restored proliferative responses and 
the normal ability to produce cytokine upon TCR triggering, with no particular skewing 
toward Thl- or Th2-like phenotype. The significant but not exclusive IFN-y production 
in T cells of all patients implies that these lymphocytes are not in anergic state and the 
transduction of intracellular activation signals is not defective. Since IFN-y is release by 
“effector-memory” T cells, it is likely that cells producing this cytokine in vitro had 
responded properly to in vivo antigenic stimulation by becoming terminally 
differentiated effectors.
The biochemical events following TCR triggering occurred properly leading to 
correction of the downstream pre-transcriptional events. Collectively, these results have 
an important impact on the safety of gene therapy approach. T-cell lines generated ex- 
vivo after GT maintained a polyclonal phenotype and a normal, cytokine-dependent, in 
vitro growth and functional behavior, indicating the absence of any gene transfer-related 
toxicity.
While in ADA-deficient cells exposure to dAdo induced a strong inhibition of T 
cell activation, gene-corrected cells were only minimally affected as healthy control
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cells. Moreover, gene-corrected T cells displayed a normal sensitivity to apoptosis 
induced by extracellular and intracellular mechanisms, further confirming the efficacy 
of ADA expression mediated by retroviral gene transfer in restoring normal metabolic 
functions.
Our findings are consistent with a key role of the extracellular isoform of ADA 
in hampering the toxic effects exerted by dAdo in gene-corrected cells. Firstly, the A2A 
selective receptor agonist but not dAdo induced comparable level of intracellular cAMP 
in GT and ADA-deficient cells, leading to inhibition of proliferative responses. 
Secondly, the poorly hydrolizable adenosine analogues, 2-chloro-deoxy-adenosine (2- 
CdA) and 2-chloro-adenosine (2-CA) (data not shown), but not dAdo similarly 
triggered apoptosis in GT and ADA-deficient T cells. However, providing a formal 
demonstration that gene therapy allows the correct translocation of the soluble form of 
functional ADA to the cell membrane would be extremely important.
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4.4 Clonal analysis and in vivo dynamics of hematopoietic stem cells and 
lymphocytes in ADA-SCID patients
In addition to their therapeutic function, stably integrated proviruses represent a 
unique biomarker to study the biology, dynamics and clonality of HSC and their 
progeny after transplantation. Indeed, while T cell population includes also long-term 
surviving mature cells, due to the different half-life, granulocytes are representative of 
long-term engrafting hematopoietic stem/progenitor cells. Clonal analysis in the T-cell 
compartment demonstrated a high number of distinct insertion sites, in agreement with 
the complexity of the T-cell repertoire following immune reconstitution in all patients. 
This heterogeneity was confirmed by the analysis on 49 T-cell clones generated ex vivo 
from Pt2 and Pt3 18 months post-GT, 39 of which had distinct retroviral integrations. T- 
cell clones displayed a high TCR diversity, and carried either one (87%) or two (13%) 
vector copies per cell. Less integrations were retrieved in the myeloid compartment as 
compared to T lymphocytes. These results reflect the 1-2 log difference in HSC vs 
lymphoid engraftment observed in these patients (Aiuti et al., 2002a) (Aiuti et al., 
manuscript in preparation) and the survival advantage of ADA-expressing lymphocytes. 
Importantly, the presence of shared integrants in myeloid and lymphoid cells confirms 
that our gene transfer protocol, combined to low-dose chemotherapy, is adequate to the 
objective of achieving engraftment of genetically corrected, multipotent HSC. 
Contamination of T-cell derived integrations in myeloid cells are unlikely, since cells 
were highly purified by cell sorting and no integrations could be retrieved in multiple 
myeloid cell samples which carried <0.1% transduced cells (Pt2), despite the large 
number of RIS present in peripheral blood lymphocytes. These results differ from those 
obtained in an ADA-SCID GT trial based on retrovirally transduced umbilical cord 
blood CD34+ cells (Schmidt et al., 2003). In this study, one patient showed poor 
engraftment of transduced HSC and as few as one progenitor cell clone contributing to
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long-term T lymphopoiesis (Schmidt et al., 2003). This difference could be explained 
by the fact previous studies did not use pre-transplant conditioning and maintained 
patients on enzyme replacement therapy with PEG-AD A, likely abrogating the selective 
advantage for gene-corrected cells. On the other hand, the existence of transduced 
progenitor cell clones with myeloid and lymphoid potential has been recently obtained 
in the SCID-X1 gene therapy trial (Schmidt et al., 2005), indicating that pre­
conditioning is not an absolute requirement for HSC engraftment. In this context, 
further longitudinal analyses of specific vector integrants in multiple lineages would be 
important to provide a direct estimate of the number of transduced progenitors that 
contribute to long-term lymphopoiesis or myelopoiesis.
4.5 Vector integration sites analysis in ADA-SCID GT trial
Our study provides a comprehensive analysis of the profile of retroviral vector 
integrations in hematopoietic cells before and after transplantation into ADA-SCID 
patients. We found that both in vitro and ex vivo integrations showed a non-random 
distribution of RIS, with a tendency to hit transcriptional units and a strong preference 
for gene-dense regions. In accordance with previous studies in vitro and in animal 
models (Mitchell et al., 2004) (Hematti et al., 2004), targeted genes, and particularly 
those hit near start sites, tended to be expressed, or highly expressed, in CD34+ cells at 
the time of transduction. These data reinforce the concept that also in stem and 
progenitor cells the viral integrating machinery interacts preferentially with factors 
bound in or near genes, as previously observed in transduced haematopoietic cells from 
non-human primates (Hematti et al., 2004). However, our results show that, following 
in vivo repopulation, there is a tendency to select against integrations occurring inside 
transcriptional units, and for those occurring in the vicinity (<30 kb) of transcription 
start sites. This may reflect a growth advantage for clones expressing adequate ADA
levels, in which integration near promoters could increase the chance of a productive 
interaction between the vector and the cell transcriptional machinery. Indeed, ex vivo 
integrations retrieved from T cells were enriched for highly expressed genes, suggesting 
the occurrence of an in vivo selective pressure for vector-ADA expression. 
Alternatively, retroviral insertions might have influenced the expression of genes 
involved in cell expansion or clonal dominance. This explanation appears unlikely, 
since, in contrast to previous observation in animal models (Montini et al., 2006) 
(Kustikova et al., 2003), we observed a comparable frequencies of CIS retrieved in pre- 
and post transplant samples and no in vivo skewing towards integrations in genes 
controlling crucial steps in self-renewal or survival of hematopoietic cells, such as cell 
cycle, proliferation, or signal transduction. Moreover, there were no major differences 
observed in vector integration site distribution and hierarchical clustering between 
lymphoid and myeloid cells (data not shown). Similar findings were observed 
genetically modified T cells in from leukemic patients treated with retrovirally- 
transduced donor lymphocytes, with no evidence of clonal selection after 
transplantation in vivo (Recchia et al., 2006). Thus, the 3-4 fold potential increase in the 
genotoxic risk predicted by the non-random genomic distribution of retroviral 
integrations appears to have a limited impact in the ADA-SCID case, confirming that 
the actual risk of insertional oncogenesis is several order of magnitude lower than the 
simple risk of hitting a potential oncogene (10‘3 to 10'2) (Baum et al., 2006). In 
agreement with other MLV insertion site analysis, we observed the occurrence of 
regional clustering and recurrent integration sites.
Chromosomal clusters of insertions were located not only in gene high density 
regions, but also in relatively low density ones (12pl3.32, 17q23.2, 6q25.3, l lp l l .2 ,  
15q26.1), implying the existence of peculiar substructures within chromosomal regions 
that favor retroviral integration. Comparison of RIS data from different clinical trials
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should allow identifying genomic regions that are preferential targets of retroviral 
vectors, independently from the cell target and the therapeutic gene.
4.6 Comparison with other GT clinical trials
A comparison of our RIS collection with that of a recently reported CGD gene 
therapy trial (Ott et al., 2006a) reveals that 9.7% of the RIS detected in vitro (n=24) or 
in vivo (n=46) are in/near the same genes. However, unlike the CGD trial, in which cell 
clones containing activating insertions in MDS1-EVI1 gene became predominant over 
time, we detected only a single non-persisting integration inside MDS1-EVI1. RIS 
within this genomic locus have also been recently found to be overrepresented (1.9% of 
integrations), albeit not clonally expanded, in a retroviral-based preclinical study in 
primates (Calmels et al., 2005). Of notice, 2 other genes found once in our database 
(ATXN1, RUNX1) were considered as frequently hit genes in the primate study (Hematti 
et al., 2004).
The lack of over-representation and/or expansion of MDS1-EVI1 integrations in 
our study may have several causes, such as i) the use of BM-derived CD34+ cells, which 
have different properties (expression of retroviral receptors, phenotype, cell cycle 
status) compared to the mobilized PB cells used for CGD patients and primates, and/or 
ii) the use of an LTR with substantially less enhancer activity in stem and myeloid cells 
compared to that of the spleen focus-forming virus (SFFV; (Ott et al., 2006a)) used in 
the CGD trial. Interestingly, 34 RIS (4.8%) from our samples are in common with a 
collection of 322 RIS retrieved from PB T lymphocytes transduced with an MLV- 
derived vector in vitro and ex vivo (Recchia et al., 2006). Overall, these results reveal 
the existence of a common fingerprint of vector insertions in human cells, which should 
be further defined in larger collections of RIS and in multiple clinical trials.
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A most striking finding of our study is the over-representation of L M 0 2  
insertions. ZM02-related integrations were detected in pre-transplant CD34+ cells 
(1/212), as well as in granulocytes (2/124) and T cells (3/399) after transplantation.
Remarkably, integrations in the proximity of LM 02  were found also in cord 
blood-derived CD34+ cells (2/450, not shown) as well as in PB cells (2/765) from CGD 
patients (Ott et al., 2006). Taken together, these data indicate that LM 02  is a “hot spot” 
for retroviral integration in human CD34+ cells. Since LM 02  is highly expressed in 
CD34+ cells and lies in a gene-dense region, this bias may just reflect the general 
preferences of gammaretroviral vector. However, specific properties of the LM 02  locus, 
such as binding of transcription factors or other chromatin characteristics, may further 
increase its targeting by the retroviral vector integration machinery. Indeed, the LM 02  
locus ( llp l3 )  is a fragile chromosomal site (FRA11E) (Bester et al., 2006), and is a 
major site of aberrant trans-V(D)J recombination between immune loci in thymocytes 
(Marculescu et al., 2002), a typical marker of genomic instability.
The lack of in vivo expansion of clones carrying LM 02  integrations and the 
absence of LM 02  overexpression, at least at the level of bulk cell population, indicate 
again that insertions landing into potentially dangerous genomic sites are not sufficient 
per se to induce proliferative advantage in T cells in vivo, confirming that multiple 
cooperating events, deregulating various cellular pathways, are required to promote 
oncogenic transformation in humans (McCormack and Rabbitts, 2004). It is tempting to 
speculate that the difference between the ADA-SCID and the SCID-X1 studies may be 
related to the SCID-X1 genetic background (Shou et al., 2006) or the role of the 
therapeutic transgene. Indeed, where ADA is a housekeeping enzyme of the purine 
metabolic pathway and its expression has not been associated with tumor formation, 
therefore providing an excellent “neutral” system for fully assessing the role of
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insertional mutagenesis in HSC, ye is a potentially oncogenic growth factor receptor 
(Dave et al., 2004) (Woods et al., 2006).
This is in agreement with the fact that, with the exception of the SCID-X1 study, 
no other adverse event related to gene transfer have been in GT clinical trials or in long­
term observation studies in large animal models (Kohn et al., 2003) (Kiem et al., 2004). 
On the other hand, we cannot provide conclusive evidence that the integrations detected 
in our ADA-SCID patients influenced L M 02  expression at single cell level. The 
probability for a retroviral vector insertion to induce overexpression of a proximal gene 
was estimated to be 20% in the context of T cells (Recchia et al., 2006). However, we 
were unable to isolate T-cell clones containing LM 02  integrations to directly test this 
hypothesis in our patients.
4.7 Ongoing studies evaluating the potential risk of transcriptional perturbation
A crucial parameter in the calculation of the potential risks of gene transfer is the 
frequency by which an integrated provirus leads to activation, or deregulation, of gene 
expression. T-cell clones generated ex vivo from single-cell represent a unique tool to 
directly establish a relationship between integration sites and gene expression pattern of 
lymphocytes. We have generated 49 T-cell clones from two patients, identified insertion 
sites and evaluated the expression of nearby genes. In a preliminary analysis of 105 
genes flanking 29 RIS, either intragenic or intergenic close to TSS of a gene, we found 
no alteration in expression level correlated with the nearby vector integration, in 
agreement with the normal, cytokine-dependent, in vitro growth and functional behavior 
of T-cell clones. Although incomplete, our results seem to be slightly different to those 
obtained by Recchia et al., which estimated the frequency of transcriptional perturbation 
to be 20% (Recchia et al., 2006), and indicate that insertional gene deregulation, if  any, 
likely manifest in a competitive disadvantage, leading to extinction of the affected cell.
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Accordingly, no evidence of clonal dominance or preferential survival was observed in 
relatively long follow-up of ADA-SCID patients. The transcriptional stability of gene- 
corrected cells was assessed also in polyclonal T cell population. Expression analysis of 
>16.000 genes by Affymetrix GeneChip® showed no significant difference with respect 
to healthy controls, suggesting that our gene therapy protocol does not cause major 
alteration in the gene expression program of T lymphocytes developed after transplant. 
Completion of these studies will provide critical information on the potential 
transcriptional interference occurring at the vector integration site in a relevant cell 
source from a successful gene therapy trial for ADA-SCID.
In summary, our data show that transplantation of ADA-transduced HSC does 
not result in in vivo skewing or selection of expanding or malignant clones, despite the 
occurrence of insertions near potentially oncogenic genomic sites. In addition, 
transduced progeny display a normal gene expression profile, phenotype and immune 
functions. These results, combined to the relatively long-term follow-up of patients, 
indicate that retroviral-mediated gene transfer for ADA-SCID has a favorable safety 
profile while the safety of other trials may be influenced by the nature and regulation of 
the therapeutic gene as well as by disease- and/or protocol-specific factors. Thus, for 
selected genetic diseases requiring transfer of genes potentially involved in the 
oncogenic cascade, further development of potentially safer tools, such as self- 
inactivating lentiviral or retroviral vectors combined to the use of physiologically 
controlled promoters, will be required to reduce the potential risk associated with 
gammaretroviral vectors.
162
REFERENCES
Abrahamsen, H., Baillie, G., Ngai, J., Vang, T., Nika, K., Ruppelt, A., Mustelin, T., 
Zaccolo, M., Houslay, M., and Tasken, K. (2004). TCR- and CD28-mediated 
recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J Immunol 
173,4847-4858.
Acuto, O., and Michel, F. (2003). CD28-mediated co-stimulation: a quantitative support 
for TCR signalling. Nat Rev Immunol 3, 939-951.
Afkarian, M., Sedy, J. R., Yang, J., Jacobson, N. G., Cereb, N., Yang, S. Y., Murphy, T. 
L., and Murphy, K. M. (2002). T-bet is a STAT1-induced regulator of IL-12R 
expression in naive CD4+ T cells. Nat Immunol 3, 549-557.
Aiuti, A., Ficara, F., Cattaneo, F., Bordignon, C., and Roncarolo, M. G. (2003). Gene 
therapy for adenosine deaminase deficiency. Curr Opin Allergy Clin Immunol 3, 461- 
466.
Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., 
Andolfi, G., Tabucchi, A., Carlucci, Fv et a l (2002a). Correction of ADA-SCID by 
stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 
2410-2413.
Aiuti, A., Vai, S., Mortellaro, A., Casorati, G., Ficara, F., Andolfi, G., Ferrari, G., 
Tabucchi, A., Carlucci, F., Ochs, H. D., et al. (2002b). Immune reconstitution in ADA- 
SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med 8,
163
423-425.
Alava, M. A., DeBell, K. E., Conti, A., Hoffman, T., and Bonvini, E. (1992). Increased 
intracellular cyclic AMP inhibits inositol phospholipid hydrolysis induced by 
perturbation of the T cell receptor/CD3 complex but not by G-protein stimulation. 
Association with protein kinase A-mediated phosphorylation of phospholipase C- 
gamma 1. Biochem J 284 ( Pt 1), 189-199.
Albuquerque, W., and Gaspar, H. B. (2004). Bilateral sensorineural deafness in 
adenosine deaminase-deficient severe combined immunodeficiency. J Pediatr 144, 278- 
280.
Antoine, C., Muller, S., Cant, A., Cavazzana-Calvo, M., Veys, P., Vossen, J., Fasth, A., 
Heilmann, C., Wulffraat, N., Seger, R., et a l (2003). Long-term survival and 
transplantation of haemopoietic stem cells for immunodeficiencies: report of the 
European experience 1968-99. Lancet 361, 553-560.
Apasov, S., Chen, J. F., Smith, P., and Sitkovsky, M. (2000). A(2A) receptor dependent 
and A(2A) receptor independent effects of extracellular adenosine on murine 
thymocytes in conditions of adenosine deaminase deficiency. Blood 95, 3859-3867.
Apasov, S. G., Blackburn, M. R., Kellems, R. E., Smith, P. T., and Sitkovsky, M. V. 
(2001). Adenosine deaminase deficiency increases thymic apoptosis and causes 
defective T cell receptor signaling. J Clin Invest 108, 131-141.
Aran, J. M., Colomer, D., Matutes, E., Vives-Corrons, J. L., and Franco, R. (1991).
164
Presence of adenosine deaminase on the surface of mononuclear blood cells: 
immunochemical localization using light and electron microscopy. J Histochem 
Cytochem5P, 1001-1008.
Ariga, T., Oda, N., Yamaguchi, K., Kawamura, N., Kikuta, H., Taniuchi, S., Kobayashi, 
Y., Terada, K., Ikeda, H., Hershfield, M. S., et al. (2001). T-cell lines from 2 patients 
with adenosine deaminase (ADA) deficiency showed the restoration of ADA activity 
resulted from the reversion of an inherited mutation. Blood 97, 2896-2899.
Aronow, B., Lattier, D., Silbiger, R., Dusing, M., Hutton, J., Jones, G., Stock, J., 
McNeish, J., Potter, S., Witte, D., and et al. (1989). Evidence for a complex regulatory 
array in the first intron of the human adenosine deaminase gene. Genes Dev 3, 1384- 
1400.
Arredondo-Vega, F. X., Santisteban, I., Daniels, S., Toutain, S., and Hershfield, M. S. 
(1998). Adenosine deaminase deficiency: genotype-phenotype correlations based on 
expressed activity of 29 mutant alleles. Am J Hum Genet 6 3 ,1049-1059.
Ashbumer, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, 
A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000). Gene ontology: tool for the 
unification of biology. The Gene Ontology Consortium. Nat Genet 25, 25-29.
Bacchetta, R., Bigler, M., Touraine, J. L., Parkman, R., Tovo, P. A., Abrams, J., de 
Waal Malefyt, R., de Vries, J. E., and Roncarolo, M. G. (1994). High levels of 
interleukin 10 production in vivo are associated with tolerance in SCID patients 
transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 179, 493-502.
165
Badou, A., Savignac, M., Moreau, M., Leclerc, C., Foucras, G., Cassar, G., Paulet, P., 
Lagrange, D., Druet, P., Guery, J. C., and Pelletier, L. (2001). Weak TCR stimulation 
induces a calcium signal that triggers IL-4 synthesis, stronger TCR stimulation induces 
MAP kinases that control IFN-gamma production. Eur J Immunol 31,2487-2496.
Bagnara, A. S., and Hershfield, M. S. (1982). Mechanism of deoxyadenosine-induced 
catabolism of adenine ribonucleotides in adenosine deaminase-inhibited human T 
lymphoblastoid cells. Proc Natl Acad Sci U S A 79, 2673-2677.
Balague, C., Zhou, J., Dai, Y., Alemany, R., Josephs, S. F., Andreason, G., Hariharan, 
M., Sethi, E., Prokopenko, E., Jan, H. Y., et al. (2000). Sustained high-level expression 
of full-length human factor VIII and restoration of clotting activity in hemophilic mice 
using a minimal adenovirus vector. Blood 95, 820-828.
Barton, K., Muthusamy, N., Chanyangam, M., Fischer, C., Clendenin, C., and Leiden, J. 
M. (1996). Defective thymocyte proliferation and IL-2 production in transgenic mice 
expressing a dominant-negative form of CREB. Nature 379, 81-85.
Barton, R , Martiniuk, F., Hirschhom, R , and Goldschneider, I. (1979). The distribution 
of adenosine deaminase among lymphocyte populations in the rat. J Immunol 122, 216- 
220.
Baum, C., Kustikova, O., Modlich, U., Li, Z., and Fehse, B. (2006). Mutagenesis and 
oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther 17, 
253-263.
166
Benveniste, P., and Cohen, A. (1995). p53 expression is required for thymocyte 
apoptosis induced by adenosine deaminase deficiency. Proc Natl Acad Sci U S A 92, 
8373-8377.
Berkvens, T. M., Schoute, F., van Ormondt, H., Khan, P. M., and van der Eb, A. J. 
(1987). Adenosine deaminase mRNA expression is regulated posttranscriptionally 
during differentiation of HL-60 cells. Nucleic Acids Res 15, 6575-6587.
Bester, A. C., Schwartz, M., Schmidt, M., Garrigue, A., Hacein-Bey-Abina, S., 
Cavazzana-Calvo, M., Ben-Porat, N., Von Kalle, C., Fischer, A., and Kerem, B. (2006). 
Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. 
Gene Ther.
Bi, K., Tanaka, Y., Coudronniere, N., Sugie, K., Hong, S., van Stipdonk, M. J., and 
Altman, A. (2001). Antigen-induced translocation of PKC-theta to membrane rafts is 
required for T cell activation. Nat Immunol 2, 556-563.
Blackburn, M. R., Datta, S. K., and Kellems, R. E. (1998). Adenosine deaminase- 
deficient mice generated using a two-stage genetic engineering strategy exhibit a 
combined immunodeficiency. J Biol Chem 273, 5093-5100.
Blaese, R. M., Culver, K. W., Miller, A. D., Carter, C. S., Fleisher, T., Clerici, M., 
Shearer, G., Chang, L., Chiang, Y., Tolstoshev, P., et al. (1995). T lymphocyte-directed 
gene therapy for ADA- SCID: initial trial results after 4 years. Science 270, 475-480.
Blanchet, F., Cardona, A., Letimier, F. A., Hershfield, M. S., and Acuto, O. (2005).
167
CD28 costimulatory signal induces protein arginine methylation in T cells. J Exp Med
202,371-377.
Bolinger, A. M., Zangwill, A. B., Slattery, J. T., Glidden, D., DeSantes, K., Heyn, L., 
Risler, L. J., Bostrom, B., and Cowan, M. J. (2000). An evaluation of engraftment, 
toxicity and busulfan concentration in children receiving bone marrow transplantation 
for leukemia or genetic disease. Bone Marrow Transplant 25, 925-930.
Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, 
M., Rossini, S., Mavilio, F., Traversari, C., and Bordignon, C. (1997). HSV-TK gene 
transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 
275, 1719-1724.
Bordignon, C., Mavilio, F., Ferrari, G., Servida, P., Ugazio, A. G., Notarangelo, L. D., 
Gilboa, E., Rossini, S., O'Reilly, R. J., Smith, C. A., and et al. (1993). Transfer of the 
ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment 
of patients affected by ADA-deficient SCID. Hum Gene Ther 4, 513-520.
Bordignon, C., Notarangelo, L. D., Nobili, N., Ferrari, G., Casorati, G., Panina, P., 
Mazzolari, E., Maggioni, D., Rossi, C., Servida, P., et al. (1995). Gene therapy in 
peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. 
Science 275, 470-475.
Boussiotis, V. A., Barber, D. L., Lee, B. J., Gribben, J. G., Freeman, G. J., and Nadler, 
L. M. (1996). Differential association of protein tyrosine kinases with the T cell 
receptor is linked to the induction of anergy and its prevention by B7 family-mediated
168
costimulation. J Exp Med 184, 365-376.
Brennan, P., Babbage, J. W., Burgering, B. M., Groner, B., Reif, K., and Cantrell, D. A. 
(1997). Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle 
regulator E2F. Immunity 7, 679-689. <
Brenner, S., Whiting-Theobald, N. L., Linton, G. F., Holmes, K. L., Anderson-Cohen,
M., Kelly, P. F., Vanin, E. F., Pilon, A. M., Bodine, D. M., Horwitz, M. E., and Malech,
H. L. (2003). Concentrated RD114-pseudotyped MFGS-gp91phox vector achieves high 
levels of functional correction of the chronic granulomatous disease oxidase defect in 
NOD/SCID/beta -microglobulin-/- repopulating mobilized human peripheral blood 
CD34+ cells. Blood 102, 2789-2797.
Brindle, P., Linke, S., and Montminy, M. (1993). Protein-kinase-A-dependent activator 
in transcription factor CREB reveals new role for CREM repressors. Nature 364, 821- 
824.
Bristol, L. A., Sakaguchi, K., Appella, E., Doyle, D., and Takacs, L. (1992). Thymocyte 
costimulating antigen is CD26 (dipeptidyl-peptidase IV). Costimulation of granulocyte, 
macrophage, and T lineage cell proliferation via CD26. J Immunol 149, 367-372.
Buckley, R. H., Schiff, R. I., Schiff, S. E., Markert, M. L., Williams, L. W., Harville, T.
O., Roberts, J. L., and Puck, J. M. (1997). Human severe combined immunodeficiency: 
genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 130, 
378-387.
169
Buckley, R. H., Schiff, S. E., Schiff, R. I., Markert, L., Williams, L. W., Roberts, J. L., 
Myers, L. A., and Ward, F. E. (1999). Hematopoietic stem-cell transplantation for the 
treatment of severe combined immunodeficiency. N Engl J Med 340, 508-516.
Bushman, F. D. (1994). Tethering human immunodeficiency virus 1 integrase to a DNA 
site directs integration to nearby sequences. Proc Natl Acad Sci U S A 91, 9233-9237.
Butler, J. J., Mader, J. S., Watson, C. L., Zhang, H., Blay, J., and Hoskin, D. W. (2003). 
Adenosine inhibits activation-induced T cell expression of CD2 and CD28 co­
stimulatory molecules: role of interleukin-2 and cyclic AMP signaling pathways. J Cell 
Biochem 89, 975-991.
Calmels, B., Ferguson, C., Laukkanen, M. O., Adler, R., Faulhaber, M., Kim, H. J., 
Sellers, S., Hematti, P., Schmidt, M., von Kalle, C., et al (2005). Recurrent retroviral 
vector integration at the M dsl/Evil locus in nonhuman primate hematopoietic cells. 
Blood 106,2530-2533.
Candotti, F., Notarangelo, L., Visconti, R., and O'Shea, J. (2002). Molecular aspects of 
primary immunodeficiencies: lessons from cytokine and other signaling pathways. J 
Clin Invest 109 ,1261-1269.
Candotti, F., Podsakoff, G., Schurman, S., Muul, L. M., Engel, B. C., Carbonaro, D. A., 
Jagadeesh, G. J., Hematti, P., Tuschong, L. M., Carter, C. S., et a l (2003). Corrective 
gene transfer into bone marrow CD34+ cells for adenosine deaminase (ADA)- 
deficiency: results in four patients after one year of follow-up. Molecular Therapy, 
S448-S449.
170
Cantrell, D. A. (2001). Phosphoinositide 3-kinase signalling pathways. J Cell Sci 114,
1439-1445.
Cantrell, D. A. (2003a). GTPases and T cell activation. Immunol Rev 192,122-130.
Cantrell, D. A. (2003b). Regulation and function of serine kinase networks in 
lymphocytes. Curr Opin Immunol 15, 294-298.
Carlucci, F., Tabucchi, A., Aiuti, A., Rosi, F., Floccari, F., Pagani, R., and Marinello, E.
(2003). Capillary electrophoresis in diagnosis and monitoring of adenosine deaminase 
deficiency. Clin Chem 4 9 ,1830-1838.
Carson, D. A., and Seegmiller, J. E. (1976). Effect of adenosine deaminase inhibition 
upon human lymphocyte blastogenesis. J Clin Invest 57 ,274-282.
Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., Gross, F., Yvon, E., 
Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J. L., et al. (2000). Gene therapy 
of human severe combined immunodeficiency (SCID)-Xl disease. Science 288, 669- 
672.
Cavazzana-Calvo, M., Lagresle, C., Hacein-Bey-Abina, S., and Fischer, A. (2005). 
Gene therapy for severe combined immunodeficiency. Annu Rev Med 56, 585-602.
Cederbaum, S. D., Kaitila, I., Rimoin, D. L., and Stiehm, E. R. (1976). The chondro- 
osseous dysplasia of adenosine deaminase deficiency with severe combined 
immunodeficiency. J Pediatr 89, 737-742.
171
Chan, B., Wara, D., Bastian, J., Hershfield, M. S., Bohnsack, J., Azen, C. G., Parkman, 
R., Weinberg, K., and Kohn, D. B. (2005). Long-term efficacy of enzyme replacement 
therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency 
(SCID). Clin Immunol 117,133-143.
Chechik, B. E., Schrader, W. P., and Minowada, J. (1981). An immunomorphologic 
study of adenosine deaminase distribution in human thymus tissue, normal 
lymphocytes, and hematopoietic cell lines. J Immunol 126,1003-1007.
Chen, C. Y., Gherzi, R., Andersen, J. S., Gaietta, G., Jurchott, K., Royer, H. D., Mann, 
M., and Karin, M. (2000). Nucleolin and YB-1 are required for JNK-mediated 
interleukin-2 mRNA stabilization during T-cell activation. Genes Dev 14, 1236-1248.
Chen, Z., Harless, M. L., Wright, D. A., and Kellems, R. E. (1990). Identification and 
characterization of transcriptional arrest sites in exon 1 of the human adenosine 
deaminase gene. Mol Cell Biol 10, 4555-4564.
Chinsky, J. M., Ramamurthy, V., Fanslow, W. C., Ingolia, D. E., Blackburn, M. R., 
Shaffer, K. T., Higley, H. R., Trentin, J. J., Rudolph, F. B., Knudsen, T. B., and et al. 
(1990). Developmental expression of adenosine deaminase in the upper alimentary tract 
of mice. Differentiation 4 2 ,172-183.
Cho, E. A., Riley, M. P., Sillman, A. L., and Quill, H. (1993). Altered protein tyrosine 
phosphorylation in anergic Thl cells. J Immunol 151, 20-28.
Chow, C. W., and Davis, R. J. (2000). Integration of calcium and cyclic AMP signaling
172
pathways by 14-3-3. Mol Cell Biol 20, 702-712.
Churchill, P. C., and Bidani, A. K. (1982). Hypothesis: adenosine mediates 
hemodynamic changes in renal failure. Med Hypotheses 8, 275-285.
Ciruela, F., Saura, C., Canela, E. I., Mallol, J., Lluis, C., and Franco, R. (1996). 
Adenosine deaminase affects ligand-induced signalling by interacting with cell surface 
adenosine receptors. FEBS Lett 380, 219-223.
Daddona, P. E., Shewach, D. S., Kelley, W. N., Argos, P., Markham, A. F., and Orkin, 
S. H. (1984). Human adenosine deaminase. cDNA and complete primary amino acid 
sequence. J Biol Chem 259 ,12101-12106.
Dando, J. S., Aiuti, A., Deola, S., Ficara, F., and Bordignon, C. (2001). Optimisation of 
retroviral supernatant production conditions for the genetic modification of human 
CD34+ cells. J Gene Med 3, 219-227.
Dang, N. H., Torimoto, Y., Shimamura, K., Tanaka, T., Daley, J. F., Schlossman, S. F., 
and Morimoto, C. (1991). 1F7 (CD26): a marker of thymic maturation involved in the 
differential regulation of the CD3 and CD2 pathways of human thymocyte activation. J 
Immunol 147, 2825-2832.
Dave, U. P., Jenkins, N. A., and Copeland, N. G. (2004). Gene therapy insertional 
mutagenesis insights. Science 303, 333.
Davis, R. J. (2000). Signal transduction by the JNK group of MAP kinases. Cell 103,
173
239-252.
De Meester, I., Vanham, G., Kestens, L., Vanhoof, G., Bosnians, E., Gigase, P., and 
Scharpe, S. (1994). Binding of adenosine deaminase to the lymphocyte surface via 
CD26. Eur J Immunol 24, 566-570.
De Meester, I. A., Kestens, L. L., Vanham, G. L., Vanhoof, G. C., Vingerhoets, J. H., 
Gigase, P. L., and Scharpe, S. L. (1995). Costimulation of CD4+ and CD8+ T cells 
through CD26: the ADA-binding epitope is not essential for complete signaling. J 
Leukoc Biol 58, 325-330.
De Palma, M., Montini, E., Santoni de Sio, F. R., Benedicenti, F., Gentile, A., Medico,
E., and Naldini, L. (2005). Promoter trapping reveals significant differences in 
integration site selection between MLV and HIV vectors in primary hematopoietic cells. 
Blood 105, 2307-2315.
de Saint Basile, G., Geissmann, F., Flori, E., Uring-Lambert, B., Soudais, C., 
Cavazzana-Calvo, M., Durandy, A., Jabado, N., Fischer, A., and Le Deist, F. (2004). 
Severe combined immunodeficiency caused by deficiency in either the delta or the 
epsilon subunit of CD3. J Clin Invest 114, 1512-1517.
de Villartay, J. P., Poinsignon, C., de Chasseval, R., Buck, D., Le Guyader, G., and 
Villey, I. (2003). Human and animal models of V(D)J recombination deficiency. Curr 
Opin Immunol 15, 592-598.
Dinjens, W. N., ten Kate, J., van der Linden, E. P., Wijnen, J. T., Khan, P. M., and
174
Bosnian, F. T. (1989). Distribution of adenosine deaminase complexing protein (ADCP) 
in human tissues. J Histochem Cytochem 3 7 ,1869-1875.
Dong, C., Davis, R. J., and Flavell, R. A. (2002). MAP kinases in the immune response. 
Annu Rev Immunol 20, 55-72.
Dong, R. P., and Morimoto, C. (1996). Role of CD26 for CD4 memory T cell function 
and activation. Hum Cell 9 , 153-162.
Ebinu, J. O., Stang, S. L., Teixeira, C., Bottorff, D. A., Hooton, J., Blumberg, P. M., 
Barry, M., Bleakley, R. C., Ostergaard, H. L., and Stone, J. C. (2000). RasGRP links T- 
cell receptor signaling to Ras. Blood 95, 3199-3203.
Erdmann, A. A., Gao, Z. G., Jung, U., Foley, J., Borenstein, T., Jacobson, K. A., and 
Fowler, D. H. (2005). Activation of Thl and Tel cell adenosine A2A receptors directly 
inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood 105, 4707- 
4714.
Ferrari, G., Rossini, S., Giavazzi, R., Maggioni, D., Nobili, N., Soldati, M., Ungers, G., 
Mavilio, F., Gilboa, E., and Bordignon, C. (1991). An in vivo model of somatic cell 
gene therapy for human severe combined immunodeficiency. Science 251, 1363-1366.
Ficara, F., Superchi, D. B., Hernandez, R. J., Mocchetti, C., Carballido-Perrig, N., 
Andolfi, G., Deola, S., Colombo, A., Bordignon, C., Carballido, J. M., et al. (2004). IL- 
3 or IL-7 increases ex vivo gene transfer efficiency in ADA-SCID BM CD34+ cells 
while maintaining in vivo lymphoid potential. Mol Ther 1 0 ,1096-1108.
175
Fields, P. E., Gajewski, T. F., and Fitch, F. W. (1996). Blocked Ras activation in 
anergic CD4+ T cells. Science 271,1276-1278.
Finkelstein, L. D., and Schwartzberg, P. L. (2004). Tec kinases: shaping T-cell 
activation through actin. Trends Cell Biol 14, 443-451.
Fischer, A., Cavazzana-Calvo, M., De Saint Basile, G., DeVillartay, J. P., Di Santo, J. 
P., Hivroz, C., Rieux-Laucat, F., and Le Deist, F. (1997). Naturally occurring primary 
deficiencies of the immune system. Annu Rev Immunol 15, 93-124.
Fox, D. A., Hussey, R. E., Fitzgerald, K. A., Acuto, O., Poole, C., Palley, L., Daley, J.
F., Schlossman, S. F., and Reinherz, E. L. (1984). Tal, a novel 105 KD human T cell 
activation antigen defined by a monoclonal antibody. J Immunol 133 ,1250-1256.
Franco, R., Valenzuela, A., Lluis, C., and Blanco, J. (1998). Enzymatic and 
extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol Rev 161, 
27-42.
Freas-Lutz, D. L., Correll, P. H., Dougherty, S. F., Xu, L., Pluznik, D. H., and Karlsson, 
S. (1994). Expression of human glucocerebrosidase in murine macrophages: 
identification of efficient retroviral vectors. Exp Hematol 22, 857-865.
Fredholm, B. B., and Dunwiddie, T. V. (1988). How does adenosine inhibit transmitter 
release? Trends Pharmacol Sci 9, 130-134.
Fredholm, B. B., Irenius, E., Kull, B., and Schulte, G. (2001). Comparison of the
176
potency of adenosine as an agonist at human adenosine receptors expressed in Chinese 
hamster ovary cells. Biochem Pharmacol 61, 443-448.
Gaspar, H. B., Bjorkegren, E., Parsley, K., Gilmour, K. C., King, D., Sinclair, J., Zhang,
F., Giannakopoulos, A., Adams, S., Fairbanks, L. Dv et al. (2006). Successful 
reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation 
of PEG-ADA and use of mild preconditioning. Mol Ther 14, 505-513.
Gaspar, H. B., Parsley, K. L., Howe, S., King, D., Gilmour, K. C., Sinclair, J., Brouns,
G., Schmidt, M., Von Kalle, C., Barington, T., et al. (2004). Gene therapy of X-linked 
severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. 
Lancet 364, 2181-2187.
Gessi, S., Varani, K., Merighi, S., Cattabriga, E., Avitabile, A., Gavioli, R., Fortini, C., 
Leung, E., Mac Lennan, S., and Borea, P. A. (2004). Expression of A3 adenosine 
receptors in human lymphocytes: up-regulation in T cell activation. Mol Pharmacol 65, 
711-719.
Giblett, E. R., Anderson, J. E., Cohen, F., Pollara, B., and Meuwissen, H. J. (1972). 
Adenosine-deaminase deficiency in two patients with severely impaired cellular 
immunity. Lancet 2, 1067-1069.
Gjertsen, B. T., Mellgren, G., Otten, A., Maronde, E., Genieser, H. G., Jastorff, B., 
Vintermyr, O. K., McKnight, G. S., and Doskeland, S. O. (1995). Novel (Rp)-cAMPS 
analogs as tools for inhibition of cAMP-kinase in cell culture. Basal cAMP-kinase 
activity modulates interleukin-1 beta action. J Biol Chem 270, 20599-20607.
177
Gonzalez, G. A., and Montminy, M. R. (1989). Cyclic AMP stimulates somatostatin 
gene transcription by phosphorylation of CREB at serine 133. Cell 59, 675-680.
Graves, L. M., Guy, H. I., Kozlowski, P., Huang, M., Lazarowski, E., Pope, R. M., 
Collins, M. A., Dahlstrand, E. N., Earp, H. S., 3rd, and Evans, D. R. (2000). Regulation 
of carbamoyl phosphate synthetase by MAP kinase. Nature 403, 328-332.
Green, H., and Chan, T. (1973). Pyrimidine starvation induced by adenosine in 
fibroblasts and lymphoid cells: role of adenosine deaminase. Science 182, 836-837.
Guenechea, G., Gan, O. I., Inamitsu, T., Dorrell, C., Pereira, D. S., Kelly, M., Naldini, 
L., and Dick, J. E. (2000). Transduction of human CD34+ CD38- bone marrow and 
cord blood-derived SCID-repopulating cells with third-generation lentiviral vectors. 
Mol Ther 1, 566-573.
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulfffaat, N., 
Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al (2003). LM02- 
associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. 
Science 302, 415-419.
Hargrove P. W. , H. H., Cheng C., Neale G., Nienhuis A. W., and Persons D. A.
(2004). Assessment of Changes in Gene Expression Caused by Insertions of a Globin 
Lentiviral Vector Containing Globin Regulatory Elements or a Lentiviral Vector 
Containing Retroviral LTR Elements. Blood 104,145.
Hegen, M., Kameoka, J., Dong, R. P., Schlossman, S. F., and Morimoto, C. (1997).
178
Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of 
mitogen-activated protein kinase. Immunology 90 ,257-264.
Heim, D. A., Hanazono, Y., Giri, N., Wu, T., Childs, R., Sellers, S. E., Muul, L., 
Agricola, B. A., Metzger, M. E., Donahue, R. E., et a l (2000). Introduction of a 
xenogeneic gene via hematopoietic stem cells leads to specific tolerance in a rhesus 
monkey model. Mol Ther 1, 533-544.
Hematti, P., Hong, B. K., Ferguson, C., Adler, R., Hanawa, H., Sellers, S., Holt, I. E., 
Eckfeldt, C. E., Sharma, Y., Schmidt, M., et a l (2004). Distinct genomic integration of 
MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol 2, 
e423.
Herrera, C., Casado, V., Ciruela, F., Schofield, P., Mallol, J., Lluis, C., and Franco, R.
(2001). Adenosine A2B receptors behave as an alternative anchoring protein for cell 
surface adenosine deaminase in lymphocytes and cultured cells. Mol Pharmacol 59, 
127-134.
Hershfield, M. S. (1979). Apparent suicide inactivation of human lymphoblast S- 
adenosylhomocysteine hydrolase by 2'-deoxyadenosine and adenine arabinoside. A 
basis for direct toxic effects of analogs of adenosine. J Biol Chem 254, 22-25.
Hershfield, M. S. (1995a). PEG-ADA replacement therapy for adenosine deaminase 
deficiency: an update after 8.5 years. Clin Immunol Immunopathol 76, S228-232.
Hershfield, M. S. (1995b). PEG-AD A: an alternative to haploidentical bone marrow
179
transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. 
Hum Mutat 5, 107-112.
Hershfield, M. S. (1998). Adenosine deaminase deficiency: clinical expression, 
molecular basis, and therapy. Semin Hematol 35, 291-298.
Hershfield, M. S., Buckley, R. H., Greenberg, M. L., Melton, A. L., Schiff, R., Hatem, 
C., Kurtzberg, J., Markert, M. L., Kobayashi, R. H., Kobayashi, A. L., and et al. (1987). 
Treatment of adenosine deaminase deficiency with polyethylene glycol-modified 
adenosine deaminase. N Engl J Med 316, 589-596.
Hershfield, M. S., Snyder, F. F., and Seegmiller, J. E. (1977). Adenine and adenosine 
are toxic to human lymphoblast mutants defective in purine salvage enzymes. Science 
197, 1284-1287.
Hershfield, M. S. a. M., B.S. (2001). Immunodeficiency diseases caused by adenosine 
deaminase deficiency and purine nucleoside phosphorylase deficiency, In The 
Metabolic and Molecular Bases of Inherited Disease, C. R. Scriver, Beaudet, A.L., Sly, 
W.S., and Valle, D., ed. (McGraw-Hill, NewYork), pp. 2585-2625.
Hirschhom, R. (1993). Overview of biochemical abnormalities and molecular genetics 
of adenosine deaminase deficiency. Pediatr Res 55, S35-41.
Hirschhom, R. (1995). Adenosine deaminase deficiency: molecular basis and recent 
developments. Clin Immunol Immunopathol 75, S219-227.
180
Hirschhom, R. (1999). Immunodeficiency disease due to deficiency of adenosine 
deaminase, Vol Prymary Immunodeficiency diseases: Ochs H., Smith C., Puck j.).
Hirschhom, R., Paageorgiou, P. S., Kesarwala, H. H., and Taft, L. T. (1980). 
Amerioration of neurologic abnormalities after "enzyme replacement" in adenosine 
deaminase deficiency. N Engl J Med 303, 377-380.
Hirschhom, R., Ratech, H., Rubinstein, A., Papageorgiou, P., Kesarwala, H., Gelfand, 
E., and Roegner-Maniscalco, V. (1982). Increased excretion of modified adenine 
nucleosides by children with adenosine deaminase deficiency. Pediatr Res 16, 362-369.
Hirschhom, R., Roegner-Maniscalco, V., Kuritsky, L., and Rosen, F. S. (1981). Bone 
marrow transplantation only partially restores purine metabolites to normal in adenosine 
deaminase-deficient patients. J Clin Invest 68, 1387-1393.
Hirschhom, R., Tzall, S., and Ellenbogen, A. (1990). Hot spot mutations in adenosine 
deaminase deficiency. Proc Natl Acad Sci U S A 87, 6171-6175.
Hogan, P. G., Chen, L., Nardone, J., and Rao, A. (2003). Transcriptional regulation by 
calcium, calcineurin, and NFAT. Genes Dev 17,2205-2232.
Honig, M., Albert, M. H., Schulz, A., Sparber-Sauer, M., Schutz, C., Belohradsky, B., 
Gungor, T., Rojewski, M. T., Bode, H., Pannicke, Uv et a l (2007). Patients with 
adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation 
are at high risk of CNS complications. Blood 109, 3595-3602.
181
Hoogerbrugge, P. M., van Beusechem, V. W., Fischer, A., Debree, M., le Deist, F., 
Perignon, J. L., Morgan, G., Gaspar, B., Fairbanks, L. D., Skeoch, C. Hv et al. (1996). 
Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene 
Ther 3 ,179-183.
Huang, S., Apasov, S., Koshiba, M., and Sitkovsky, M. (1997). Role of A2a 
extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of 
T-cell activation and expansion. Blood 90, 1600-1610.
Hughes-Fulford, M., Sugano, E., Schopper, T., Li, C. F., Boonyaratanakomkit, J. B., 
and Cogoli, A. (2005). Early immune response and regulation of IL-2 receptor subunits. 
Cell Signal 77,1111-1124.
Huhn, R. D., Tisdale, J. F., Agricola, B., Metzger, M. E., Donahue, R. E., and Dunbar,
C. E. (1999). Retroviral marking and transplantation of rhesus hematopoietic cells by 
nonmyeloablative conditioning. Hum Gene Ther 1 0 ,1783-1790.
Hunter, T., and Karin, M. (1992). The regulation of transcription by phosphorylation. 
Cell 70, 375-387.
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., and 
Schoenberger, S. P. (2003). CD4+ T cells are required for secondary expansion and 
memory in CD8+ T lymphocytes. Nature 421, 852-856.
Jarvis, M. F., Schulz, R., Hutchison, A. J., Do, U. H., Sills, M. A., and Williams, M. 
(1989). [3HJCGS 21680, a selective A2 adenosine receptor agonist directly labels A2
182
receptors in rat brain. J Pharmacol Exp Ther 251, 888-893.
Jenkins, T. (1973). Red-blood-cell adenosine deaminase deficiency in a "healthy" Rung 
individual. Lancet 2, 736.
Jenkins, T., Rabson, A. R., Nurse, G. T., and Lane, A. B. (1976). Deficiency of 
adenosine deaminase not associated with severe combined immunodeficiency. J Pediatr 
89, 732-736.
Johannessen, M., Delghandi, M. P., and Moens, U. (2004). What turns CREB on? Cell 
Signal 16, 1211-1227.
Johansen, P., Stamou, P., Tascon, R. E., Lowrie, D. B., and Stockinger, B. (2004). CD4 
T cells guarantee optimal competitive fitness of CD8 memory T cells. Eur J Immunol 
34, 91-97.
Jones, S., and Thornton, J. M. (1996). Principles of protein-protein interactions. Proc 
Natl Acad Sci U S A 9 3 ,13-20.
Jorritsma, P. J., Brogdon, J. L., and Bottomly, K. (2003). Role of TCR-induced 
extracellular signal-regulated kinase activation in the regulation of early IL-4 expression 
in naive CD4+ T cells. J Immunol 170, 2427-2434.
Kalman, L., Lindegren, M. L., Kobrynski, L., Vogt, R., Hannon, H., Howard, J. T., and 
Buckley, R. (2004). Mutations in genes required for T-cell development: IL7R, CD45, 
IL2RG, JAK3, RAG1, RAG2, ARTEMIS, and ADA and severe combined
183
immunodeficiency: HuGE review. Genet Med 6 ,16-26.
Kameoka, J., Tanaka, T., Nojima, Y., Schlossman, S. F., and Morimoto, C. (1993). 
Direct association of adenosine deaminase with a T cell activation antigen, CD26. 
Science 261,466-469.
Kang, E., Giri, N., Wu, T., Sellers, S., Kirby, M., Hanazono, Y., Tisdale, J., and 
Dunbar, C. E. (2001). In vivo persistence of retrovirally transduced murine long-term 
repopulating cells is not limited by expression of foreign gene products in the fully or 
minimally myeloablated setting. Hum Gene Ther 12, 1663-1672.
Kang, S. M., Beverly, B., Tran, A. C., Brorson, K., Schwartz, R. H., and Lenardo, M. J. 
(1992). Transactivation by AP-1 is a molecular target of T cell clonal anergy. Science 
257, 1134-1138.
Karin, M., and Ben-Neriah, Y. (2000). Phosphorylation meets ubiquitination: the 
control of NF-[kappa]B activity. Annu Rev Immunol 18, 621-663.
Karin, M., Liu, Z., and Zandi, E. (1997). AP-1 function and regulation. Curr Opin Cell 
Biol 9, 240-246.
Kiem, H. P., Sellers, S., Thomasson, B., Morris, J. C., Tisdale, J. F., Horn, P. A., 
Hematti, P., Adler, R., Kuramoto, K., Calmels, B., et al. (2004). Long-term clinical and 
molecular follow-up of large animals receiving retrovirally transduced stem and 
progenitor cells: no progression to clonal hematopoiesis or leukemia. Mol Ther 9, 389- 
395.
184
Kim, H. J., Tisdale, J. F., Wu, T., Takatoku, M., Sellers, S. E., Zickler, P., Metzger, M. 
E., Agricola, B. A., Malley, J. D., Kato, I., et al. (2000). Many multipotential gene- 
marked progenitor or stem cell clones contribute to hematopoiesis in nonhuman 
primates. Blood 96,1-8.
Kiss, I., Oskolas, H., Toth, R., Bouillet, P., Toth, K., Fulop, A., Scholtz, B., Ledent, C., 
Fesus, L., and Szondy, Z. (2006). Adenosine A2A receptor-mediated cell death of 
mouse thymocytes involves adenylate cyclase and Bim and is negatively regulated by 
Nur77. Eur J Immunol 36, 1559-1571.
Kizaki, H., Suzuki, K., Tadakuma, T., and Ishimura, Y. (1990). Adenosine receptor- 
mediated accumulation of cyclic AMP-induced T-lymphocyte death through 
intemucleosomal DNA cleavage. J Biol Chem 265, 5280-5284.
Klinger, M., Freissmuth, M., and Nanoff, C. (2002). Adenosine receptors: G protein- 
mediated signalling and the role of accessory proteins. Cell Signal 14, 99-108.
Kohn, D. B., Hershfield, M. S., Carbonaro, D., Shigeoka, A., Brooks, J., 
Smogorzewska, E. M., Barsky, L. W., Chan, R., Burotto, F., Annett, G., et al. (1998). T 
lymphocytes with a normal ADA gene accumulate after transplantation of transduced 
autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat 
Med 4, 775-780.
Kohn, D. B., Sadelain, M., Dunbar, C., Bodine, D., Kiem, H. P., Candotti, F., Tisdale, 
J., Riviere, I., Blau, C. A., Richard, R. E., et a l (2003). American Society of Gene 
Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to
185
hematopoietic stem cells. Mol Ther 8, 180-187.
Kohn, D. B., Weinberg, K. I., Nolta, J. A., Heiss, L. N., Lenarsky, C., Crooks, G. M., 
Hanley, M. E., Annett, G., Brooks, J. S., el-Khoureiy, A., and et al. (1995). Engraftment 
of gene-modified umbilical cord blood cells in neonates with adenosine deaminase 
deficiency. Nat Med 7, 1017-1023.
Kohn DB, W. K. (1996). Adenosine Deaminase Deficiency, In The Genes of Primary 
Immunodeficiency - Windows on the Immune System and Prospect for the Gene 
Therapy (Bethesda, MD: National Institutes of Health).
Koike, T., Yamagishi, H., Hatanaka, Y., Fukushima, A., Chang, J. W., Xia, Y., Fields, 
M., Chandler, P., and Iwashima, M. (2003). A novel ERK-dependent signaling process 
that regulates interleukin-2 expression in a late phase of T cell activation. J Biol Chem 
278, 15685-15692.
Koshiba, M., Kojima, H., Huang, S., Apasov, S., and Sitkovsky, M. V. (1997). Memory 
of extracellular adenosine A2A purinergic receptor-mediated signaling in murine T 
cells. J Biol Chem 272, 25881-25889.
Koshiba, M., Rosin, D. L., Hayashi, N., Linden, J., and Sitkovsky, M. V. (1999). 
Patterns of A2A extracellular adenosine receptor expression in different functional 
subsets of human peripheral T cells. Flow cytometry studies with anti-A2A receptor 
monoclonal antibodies. Mol Pharmacol 55, 614-624.
Kovanen, P. E., and Leonard, W. J. (2004). Cytokines and immunodeficiency diseases:
186
critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, 
and their signaling pathways. Immunol Rev 202, 67-83.
Kung, C., Pingel, J. T., Heikinheimo, M., Klemola, T., Varkila, K., Yoo, L. I., Vuopala, 
K., Poyhonen, M., Uhari, M., Rogers, M., et al. (2000). Mutations in the tyrosine 
phosphatase CD45 gene in a child with severe combined immunodeficiency disease. 
Nat Med 6, 343-345.
Kuo, C. T., and Leiden, J. M. (1999). Transcriptional regulation of T lymphocyte 
development and function. Annu Rev Immunol 17, 149-187.
Kurlandsky, L. E., Bennink, M. R., Webb, P. M., Ulrich, P. J., and Baer, L. J. (1994). 
The absorption and effect of dietary supplementation with omega-3 fatty acids on serum 
leukotriene B4 in patients with cystic fibrosis. Pediatr Pulmonol 18, 211-217.
Kustikova, O., Fehse, B., Modlich, U., Yang, M., Dullmann, J., Kamino, K., von 
Neuhoff, N., Schlegelberger, B., Li, Z., and Baum, C. (2005). Clonal dominance of 
hematopoietic stem cells triggered by retroviral gene marking. Science 308, 1171-1174.
Kustikova, O. S., Wahlers, A., Kuhlcke, K., Stahle, B., Zander, A. R., Baum, C., and 
Fehse, B. (2003). Dose finding with retroviral vectors: correlation of retroviral vector 
copy numbers in single cells with gene transfer efficiency in a cell population. Blood 
102, 3934-3937.
Lang, P., Gesbert, F., Delespine-Carmagnat, M., Stancou, R., Pouchelet, M., and 
Bertoglio, J. (1996). Protein kinase A phosphorylation of RhoA mediates the
187
morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. Embo J 
75,510-519.
Lappas, C. M., Rieger, J. M., and Linden, J. (2005). A2A adenosine receptor induction 
inhibits IFN-gamma production in murine CD4+ T cells. J Immunol 7 74, 1073-1080.
Laudanna, C., Campbell, J. J., and Butcher, E. C. (1997). Elevation of intracellular 
cAMP inhibits RhoA activation and integrin-dependent leukocyte adhesion induced by 
chemoattractants. J Biol Chem 272, 24141-24144.
Laufs, S., Nagy, K. Z., Giordano, F. A., Hotz-Wagenblatt, A., Zeller, W. J., and 
Fruehauf, S. (2004). Insertion of retroviral vectors in NOD/SCID repopulating human 
peripheral blood progenitor cells occurs preferentially in the vicinity of transcription 
start regions and in introns. Mol Ther 10, 874-881.
Levy, Y., Hershfield, M. S., Femandez-Mejia, C., Polmar, S. H., Scudiery, D., Berger, 
M., and Sorensen, R. U. (1988). Adenosine deaminase deficiency with late onset of 
recurrent infections: response to treatment with polyethylene glycol-modified adenosine 
deaminase. J Pediatr 113, 312-317.
Lewis, R. S. (2001). Calcium signaling mechanisms in T lymphocytes. Annu Rev 
Immunol 19, 497-521.
Li, Z., Fehse, B., Schiedlmeier, B., Dullmann, J., Frank, O., Zander, A. R., Ostertag, 
W., and Baum, C. (2002). Persisting multilineage transgene expression in the clonal 
progeny of a hematopoietic stem cell. Leukemia 1 6 ,1655-1663.
188
Lin, X., O'Mahony, A., Mu, Y., Geleziunas, R., and Greene, W. C. (2000). Protein 
kinase C-theta participates in NF-kappaB activation induced by CD3-CD28 
costimulation through selective activation of IkappaB kinase beta. Mol Cell Biol 20, 
2933-2940.
Linden, J. (2001). Molecular approach to adenosine receptors: receptor-mediated 
mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 41, 775-787.
Linsley, P. S., and Ledbetter, J. A. (1993). The role of the CD28 receptor during T cell 
responses to antigen. Annu Rev Immunol 11, 191-212.
Macian, F., Lopez-Rodriguez, C., and Rao, A. (2001). Partners in transcription: NFAT 
and AP-1. Oncogene 20, 2476-2489.
Madrenas, J., Wange, R. L., Wang, J. L., Isakov, N., Samelson, L. E., and Germain, R. 
N. (1995). Zeta phosphorylation without ZAP-70 activation induced by TCR 
antagonists or partial agonists. Science 267, 515-518.
Malacarne, F., Benicchi, T., Notarangelo, L. D., Mori, L., Parolini, S., Caimi, L., 
Hershfield, M., and Imberti, L. (2005). Reduced thymic output, increased spontaneous 
apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated 
patients. Eur J Immunol 35, 3376-3386.
Mann, G. J., and Fox, R. M. (1986). Deoxyadenosine triphosphate as a mediator of 
deoxyguanosine toxicity in cultured T lymphoblasts. J Clin Invest 78, 1261-1269.
189
Marculescu, R., Le, T., Simon, P., Jaeger, U., and Nadel, B. (2002). V(D)J-mediated 
translocations in lymphoid neoplasms: a functional assessment of genomic instability by 
cryptic sites. J Exp Med 195, 85-98.
Martin, M., Huguet, J., Centelles, J. J., and Franco, R. (1995). Expression of ecto- 
adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. 
Possible role of adenosine deaminase as costimulatory molecule. J Immunol 155, 4630- 
4643.
Matsuda, K. M., Kume, A., Ueda, Y., Urabe, M., Hasegawa, M., and Ozawa, K. (1999). 
Development of a modified selective amplifier gene for hematopoietic stem cell gene 
therapy. Gene Ther 6 ,1038-1044.
Mavilio, F., Ferrari, G., Rossini, S., Nobili, N., Bonini, C., Casorati, G., Traversari, C., 
and Bordignon, C. (1994). Peripheral blood lymphocytes as target cells of retroviral 
vector-mediated gene transfer. Blood 8 3 ,1988-1997.
McConkey, D. J., Nicotera, P., and Orrenius, S. (1994). Signalling and chromatin 
fragmentation in thymocyte apoptosis. Immunol Rev 142, 343-363.
McCormack, M. P., and Rabbitts, T. H. (2004). Activation of the T-cell oncogene 
LM02 after gene therapy for X-linked severe combined immunodeficiency. N Engl J 
Med 350, 913-922.
Mellor, H., and Parker, P. J. (1998). The extended protein kinase C superfamily. 
Biochem J 332 (P t 2), 281-292.
190
Merrill, J. T., Shen, C., Schreibman, D., Coffey, D., Zakharenko, O., Fisher, R., Lahita, 
R. G., Salmon, J., and Cronstein, B. N. (1997). Adenosine A l receptor promotion of 
multinucleated giant cell formation by human monocytes: a mechanism for 
methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum 4 0 ,1308-1315.
Meuwissen, H. J., Pickering, R. J., and Pollara, B. (1975). Adenosine deaminase 
deficiency in combined immunologic deficiency disease. Birth Defects Orig Artie Ser 
11, 117-119.
Miller, A. D., Garcia, J. V., von Suhr, N., Lynch, C. M., Wilson, C., and Eiden, M. V. 
(1991). Construction and properties of retrovirus packaging cells based on gibbon ape 
leukemia virus. J Virol 65, 2220-2224.
Miller, D. G., and Miller, A. D. (1994). A family of retroviruses that utilize related 
phosphate transporters for cell entry. J Virol 68, 8270-8276.
Mills, G. C., Schmalstieg, F. C., Newkirk, K. E., and Goldblum, R. M. (1979). Cytosine 
and orotic acid in urine of immunodeficient children. Clin Chem 25, 419-424.
Mills, G. C., Schmalstieg, F. C., Trimmer, K. B., Goldman, A. S., and Goldblum, R. M. 
(1976). Purine metabolism in adenosine deaminase deficiency. Proc Natl Acad Sci U S 
A 73, 2867-2871.
Minguet, S., Huber, M., Rosenkranz, L., Schamel, W. W., Reth, M., and Brummer, T.
(2005). Adenosine and cAMP are potent inhibitors of the NF-kappa B pathway 
downstream of immunoreceptors. Eur J Immunol 35, 31-41.
191
Mirabet, M., Herrera, C., Cordero, O. J., Mallol, J., Lluis, C., and Franco, R. (1999). 
Expression of A2B adenosine receptors in human lymphocytes: their role in T cell 
activation. J Cell Sci 112 (P t 4), 491-502.
Mitchell, R. S., Beitzel, B. F., Schroder, A. R., Shinn, P., Chen, H., Berry, C. C., Ecker, 
J. R., and Bushman, F. D. (2004). Retroviral DNA integration: ASLV, HIV, and MLV 
show distinct target site preferences. PLoS Biol 2, E234.
Mittrucker, H. W., Steeg, C., Malissen, B., and Fleischer, B. (1995). The cytoplasmic 
tail of the T cell receptor zeta chain is required for signaling via CD26. Eur J Immunol 
25, 295-297.
Miyoshi, H., Blomer, U., Takahashi, M., Gage, F. H., and Verma, I. M. (1998). 
Development of a self-inactivating lentivirus vector. J Virol 72, 8150-8157.
Mondino, A., Whaley, C. D., DeSilva, D. R., Li, W., Jenkins, M. K., and Mueller, D. L.
(1996). Defective transcription of the IL-2 gene is associated with impaired expression 
of c-Fos, FosB, and JunB in anergic T helper 1 cells. J Immunol 157, 2048-2057.
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C., Sergi 
Sergi, L., Benedicenti, F., Ambrosi, A., Di Serio, C., et al. (2006). Hematopoietic stem 
cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral 
vector integration. Nat Biotechnol 24, 687-696.
Morgan, G., Levinsky, R. J., Hugh-Jones, K., Fairbanks, L. D., Morris, G. S., and 
Simmonds, H. A. (1987). Heterogeneity of biochemical, clinical and immunological
192
parameters in severe combined immunodeficiency due to adenosine deaminase 
deficiency. Clin Exp Immunol 70, 491-499.
Morimoto, C., and Schlossman, S. F. (1998). The structure and function of CD26 in the 
T-cell immune response. Immunol Rev 161, 55-70.
Mortellaro, A., Hernandez, R. J., Guerrini, M. M., Carlucci, F., Tabucchi, A., Ponzoni, 
M., Sanvito, F., Doglioni, C., Di Serio, C., Biasco, L., et al. (2006). Ex vivo gene 
therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and 
corrects their immune and metabolic defects. Blood 108, 2979-2988.
Muul, L. M., Tuschong, L. M., Soenen, S. L., Jagadeesh, G. J., Ramsey, W. J., Long, Z., 
Carter, C. S., Garabedian, E. K., Alleyne, M., Brown, M., et al. (2003). Persistence and 
expression of the adenosine deaminase gene for 12 years and immune reaction to gene 
transfer components: long-term results of the first clinical gene therapy trial. Blood 101, 
2563-2569.
Myung, P. S., Boerthe, N. J., and Koretzky, G. A. (2000). Adapter proteins in 
lymphocyte antigen-receptor signaling. Curr Opin Immunol 12, 256-266.
Neumeister, E. N., Zhu, Y., Richard, S., Terhorst, C., Chan, A. C., and Shaw, A. S. 
(1995). Binding of ZAP-70 to phosphoiylated T-cell receptor zeta and eta enhances its 
autophosphorylation and generates specific binding sites for SH2 domain-containing 
proteins. Mol Cell Biol 15, 3171-3178.
Notarangelo, L. D., Giliani, S., Mazza, C., Mella, P., Savoldi, G., Rodriguez-Perez, C.,
193
Mazzolari, E., Fiorini, M., Duse, M., Plebani, A., et al. (2000). Of genes and 
phenotypes: the immunological and molecular spectrum of combined immune 
deficiency. Defects of the gamma(c)-JAK3 signaling pathway as a model. Immunol Rev 
178, 39-48.
Notarangelo, L. D., Stoppoloni, G., Toraldo, R., Mazzolari, E., Coletta, A., Airo, P., 
Bordignon, C., and Ugazio, A. G. (1992). Insulin-dependent diabetes mellitus and 
severe atopic dermatitis in a child with adenosine deaminase deficiency. Eur J Pediatr 
151, 811-814.
Nourse, J., Firpo, E., Flanagan, W. M., Coats, S., Polyak, K., Lee, M. H., Massague, J., 
Crabtree, G. R., and Roberts, J. M. (1994). Interleukin-2-mediated elimination of the 
p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372, 570- 
573.
Onodera, M., Ariga, T., Kawamura, N., Kobayashi, I., Ohtsu, M., Yamada, M., Tame, 
A., Furuta, H., Okano, M., Matsumoto, S., et al. (1998). Successful peripheral T- 
lymphocyte-directed gene transfer for a patient with severe combined immune 
deficiency caused by adenosine deaminase deficiency. Blood 91, 30-36.
Oravecz, T., Pall, M., Roderiquez, G., Gorrell, M. D., Ditto, M., Nguyen, N. Y., 
Boykins, R., Unsworth, E., and Norcross, M. A. (1997). Regulation of the receptor 
specificity and function of the chemokine RANTES (regulated on activation, normal T 
cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J 
Exp Med 186 ,1865-1872.
194
Otsu, M., Hershfield, M. S., Tuschong, L. M., Muul, L. M., Onodera, M., Ariga, T., 
Sakiyama, Y., and Candotti, F. (2002). Flow cytometry analysis of adenosine deaminase 
(ADA) expression: a simple and reliable tool for the assessment of ADA-deficient 
patients before and after gene therapy. Hum Gene Ther 13, 425-432.
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., 
Kuhlcke, K., Schilz, A., Kunkel, Hv et al. (2006a). Correction of X-linked chronic 
granulomatous disease by gene therapy, augmented by insertional activation of MDS1- 
EVI1, PRDM16 or SETBP1. Nat Med 12,401-409.
Ott, M. G., Schmidt, M., Stein, S., Schwarzwaelder, K., Siler, U., Koehl, U., Kuehlcke, 
K., Schilz, A., von Kalle, C., Hoelzer, Dv et al. (2006b). Long-term clinical follow-up 
and safety/toxicity analysis in three X-CGD patients treated by gene therapy and non- 
myeloablative conditioning. Blood 108, 63a.
Ouyang, W., Lohning, M., Gao, Z., Assenmacher, M., Ranganath, S., Radbruch, A., and 
Murphy, K. M. (2000). Stat6-independent GATA-3 auto activation directs IL-4- 
independent Th2 development and commitment. Immunity 12,27-37.
Ozsahin, H., Arredondo-Vega, F. X., Santisteban, I., Fuhrer, H., Tuchschmid, P., 
Jochum, W., Aguzzi, A., Lederman, H. M., Fleischman, A., Winkelstein, J. A., et al.
(1997). Adenosine deaminase deficiency in adults. Blood 89, 2849-2855.
Pacheco, R., Martinez-Navio, J. M., Lejeune, M., Climent, N., Oliva, H., Gatell, J. M., 
Gallart, T., Mallol, J., Lluis, C., and Franco, R. (2005). CD26, adenosine deaminase, 
and adenosine receptors mediate costimulatory signals in the immunological synapse.
195
Proc Natl Acad Sci U S A 102, 9583-9588.
Palacios, E. H., and Weiss, A. (2004). Function of the Src-family kinases, Lck and Fyn, 
in T-cell development and activation. Oncogene 23, 7990-8000.
Parkman, R., Gelfand, E. W., Rosen, F. S., Sanderson, A., and Hirschhom, R. (1975). 
Severe combined immunodeficiency and adenosine deaminase deficiency. N Engl J 
Med 292,714-719.
Patra, A. K., Na, S. Y., and Bommhardt, U. (2004). Active protein kinase B regulates 
TCR responsiveness by modulating cytoplasmic-nuclear localization of NFAT and NF- 
kappa B proteins. J Immunol 772, 4812-4820.
Pawliuk, R., Eaves, C. J., and Humphries, R. K. (1997). Sustained high-level 
reconstitution of the hematopoietic system by preselected hematopoietic cells 
expressing a transduced cell-surface antigen. Hum Gene Ther 8, 1595-1604.
Perignon, J. L., Durandy, A., Peter, M. O., Freycon, F., Dumez, Y., and Griscelli, C. 
(1987). Early prenatal diagnosis of inherited severe immunodeficiencies linked to 
enzyme deficiencies. J Pediatr 777, 595-598.
Pike-Overzet, K., de Ridder, D., Weerkamp, F., Baert, M. R., Verstegen, M. M., 
Brugman, M. H., Howe, S. J., Reinders, M. J., Thrasher, A. J., Wagemaker, G., et al.
(2006). Gene therapy: is IL2RG oncogenic in T-cell development? Nature 443, E5; 
discussion E6-7.
196
Pike-Overzet, K., de Ridder, D., Weerkamp, F., Baert, M. R., Verstegen, M. M., 
Brugman, M. H., Howe, S. J., Reinders, M. J., Thrasher, A. J., Wagemaker, G., et al.
(2007). Ectopic retroviral expression of LM02, but not IL2Rgamma, blocks human T- 
cell development from CD34+ cells: implications for leukemogenesis in gene therapy. 
Leukemia.
Plana, M., Vinas, 0., De la Calle-Martin, O., Lozano, F., Ingles-Esteve, J., Romero, M., 
Alberola-Ila, J., Yague, J., Vilella, R., and Vives, J. (1991). Induction of interleukin 2 
(IL 2) and interferon-gamma and enhancement of IL 2 receptor expression by a CD26 
monoclonal antibody. Eur J Immunol 27,1085-1088.
Purring-Koch, C., and McLendon, G. (2000). Cytochrome c binding to Apaf-1: the 
effects of dATP and ionic strength. Proc Natl Acad Sci U S A 97, 11928-11931.
Rabbitts, T. H., Bucher, K., Chung, G., Grutz, G., Warren, A., and Yamada, Y. (1999). 
The effect of chromosomal translocations in acute leukemias: the LM 02 paradigm in 
transcription and development. Cancer Res 5 9 ,1794s-1798s.
Ratech, H., Greco, M. A., Gallo, G., Rimoin, D. L., Kamino, H., and Hirschhom, R. 
(1985). Pathologic findings in adenosine deaminase-deficient severe combined 
immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations. Am J 
Pathol 120,157-169.
Ratech, H., Hirschhom, R., and Greco, M. A. (1989). Pathologic findings in adenosine 
deaminase deficient-severe combined immunodeficiency. II. Thymus, spleen, lymph 
node, and gastrointestinal tract lymphoid tissue alterations. Am J Pathol 135, 1145-
197
1156.
Ratech, H., Kim, J., Asofsky, R., Thorbecke, G. J., and Hirschhom, R. (1984). Effects 
of deoxycoformycin in mice. II. Differences between the drug sensitivities and purine 
metabolizing enzymes of transplantable lymphomas of varying immunologic 
phenotypes. J Immunol 132, 3077-3084.
Ratter, F., Germer, M., Fischbach, T., Schulze-Osthoff, K., Peter, M. E., Droge, W., 
Krammer, P. H., and Lehmann, V. (1996). S-adenosylhomocysteine as a physiological 
modulator of Apo-1-mediated apoptosis. Int Immunol 8 , 1139-1147.
Recchia, A., Bonini, C., Magnani, Z., Urbinati, F., Sartori, D., Muraro, S., Tagliafico,
E., Bondanza, A., Stanghellini, M. T., Bernardi, M., et al. (2006). Retroviral vector 
integration deregulates gene expression but has no consequence on the biology and 
function of transplanted T cells. Proc Natl Acad Sci U S A 103, 1457-1462.
Rincon, M., Flavell, R. A., and Davis, R. J. (2001). Signal transduction by MAP kinases 
in T lymphocytes. Oncogene 20, 2490-2497.
Rivella, S., Callegari, J. A., May, C., Tan, C. W., and Sadelain, M. (2000). The cHS4 
insulator increases the probability of retroviral expression at random chromosomal 
integration sites. J Virol 74,4679-4687.
Rocha, B., and Tanchot, C. (2004). Towards a cellular definition of CD8+ T-cell 
memory: the role of CD4+ T-cell help in CD8+ T-cell responses. Curr Opin Immunol 
16, 259-263.
198
Roe, T., Reynolds, T. C., Yu, G., and Brown, P. O. (1993). Integration of murine 
leukemia virus DNA depends on mitosis. Embo J 12, 2099-2108.
Rogers, M. H., Lwin, R., Fairbanks, L., Gerritsen, B., and Gaspar, H. B. (2001). 
Cognitive and behavioral abnormalities in adenosine deaminase deficient severe 
combined immunodeficiency. J Pediatr 139, 44-50.
Rosenzweig, M., Connole, M., Glickman, R., Yue, S. P., Noren, B., DeMaria, M., and 
Johnson, R. P. (2001). Induction of cytotoxic T lymphocyte and antibody responses to 
enhanced green fluorescent protein following transplantation of transduced CD34(+) 
hematopoietic cells. Blood 97, 1951-1959.
Rosenzweig, M., MacVittie, T. J., Harper, D., Hempel, D., Glickman, R. L., Johnson, R. 
P., Farese, A. M., Whiting-Theobald, N., Linton, G. F., Yamasaki, G., et al. (1999). 
Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman 
primates after nonablative conditioning. Blood 94, 2271-2286.
Ruers, T. J., Buurman, W. A., and van der Linden, C. J. (1987). 2'Deoxycoformycin and 
deoxyadenosine affect IL 2 production and IL 2 receptor expression of human T cells. J 
Immunol 138,116-122.
Salvatore, C. A., Tilley, S. L., Latour, A. M., Fletcher, D. S., Roller, B. H., and 
Jacobson, M. A. (2000). Disruption of the A(3) adenosine receptor gene in mice and its 
effect on stimulated inflammatory cells. J Biol Chem 275, 4429-4434.
Sandmaier, B. M., McSweeney, P., Yu, C., and Storb, R. (2000). Nonmyeloablative
199
transplants: preclinical and clinical results. Semin Oncol 27, 78-81.
Saxena, M., Williams, S., Tasken, K., and Mustelin, T. (1999). Crosstalk between 
cAMP-dependent kinase and MAP kinase through a protein tyrosine phosphatase. Nat 
Cell Biol 7, 305-311.
Scharenberg, J. G., Rijkers, G. T., Staal, G. E., and Zegers, B. J. (1989). The mechanism 
of deoxyguanosine mediated toxicity in proliferating human peripheral blood T 
lymphocytes. Adv Exp Med Biol 253B, 281-284.
Scherr, M., Battmer, K., Blomer, U., Schiedlmeier, B., Ganser, A., Grez, M., and Eder, 
M. (2002). Lentiviral gene transfer into peripheral blood-derived CD34+ NOD/SCID- 
repopulating cells. Blood 99, 709-712.
Schiedlmeier, B., Klump, H., Will, E., Arman-Kalcek, G., Li, Z., Wang, Z., Rimek, A., 
Friel, J., Baum, C., and Ostertag, W. (2003). High-level ectopic HOXB4 expression 
confers a profound in vivo competitive growth advantage on human cord blood CD34+ 
cells, but impairs lymphomyeloid differentiation. Blood 101, 1759-1768.
Schmidt, M., Carbonaro, D. A., Speckmann, C., Wissler, M., Bohnsack, J., Elder, M., 
Aronow, B. J., Nolta, J. A., Kohn, D. B., and von Kalle, C. (2003). Clonality analysis 
after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA- 
deficient SCID neonates. Nat Med 9, 463-468.
Schmidt, M., Hacein-Bey-Abina, S., Wissler, M., Carlier, F., Lim, A., Prinz, C., Glimm,
H., Andre-Schmutz, I., Hue, C., Garrigue, A., et al. (2005). Clonal evidence for the
200
transduction of CD34+ cells with lymphomyeloid differentiation potential and self­
renewal capacity in the SCID-X1 gene therapy trial. Blood 105, 2699-2706.
Schmidt, M., Zickler, P., Hoffmann, G., Haas, S., Wissler, M., Muessig, A., Tisdale, J.
F., Kuramoto, K., Andrews, R. G., Wu, T., et al. (2002). Polyclonal long-term 
repopulating stem cell clones in a primate model. Blood 100, 2131-2743.
Schroder, A. R., Shinn, P., Chen, H., Berry, C., Ecker, J. R., and Bushman, F. (2002). 
HIV-1 integration in the human genome favors active genes and local hotspots. Cell 
110, 521-529.
Schwartz, R. H. (2003). T cell anergy. Annu Rev Immunol 21, 305-334.
Schwartzberg, P. L., Finkelstein, L. D., and Readinger, J. A. (2005). TEC-family 
kinases: regulators of T-helper-cell differentiation. Nat Rev Immunol 5, 284-295.
Segal, A. W. (1996). The NADPH oxidase and chronic granulomatous disease. Mol 
Med Today 2,129-135.
Shou, Y., Ma, Z., Lu, T., and Sorrentino, B. P. (2006). Unique risk factors for 
insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci 
U S A  103, 11730-11735.
Shovlin, C. L., Hughes, J. M., Simmonds, H. A., Fairbanks, L., Deacock, S., Lechler, 
R., Roberts, I., and Webster, A. D. (1993). Adult presentation of adenosine deaminase 
deficiency. Lancet 341 ,1471.
201
Simmonds, H. A., Levinsky, R. J., Perrett, D., and Webster, D. R. (1982). Reciprocal 
relationship between erythrocyte ATP and deoxy-ATP levels in inherited ADA 
deficiency. Biochem Pharmacol 31, 947-951.
Simmonds, H. A., Sahota, A., Potter, C. F., Perrett, D., Hugh-Jones, K., and Watson, J.
G. (1978). Purine metabolism in adenosine deaminase deficiency. Ciba Found Symp, 
255-262.
Sitkovsky, M. V. (2003). Use of the A(2A) adenosine receptor as a physiological 
immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol 65, 493- 
501.
Sitkovsky, M. V., Lukashev, D., Apasov, S., Kojima, H., Koshiba, M., Caldwell, C., 
Ohta, A., and Thiel, M. (2004). Physiological control of immune response and 
inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. 
Annu Rev Immunol 22, 657-682.
Skalhegg, B. S., Landmark, B. F., Doskeland, S. O., Hansson, V., Lea, T., and Jahnsen, 
T. (1992). Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects 
of 3',5'-cyclic adenosine monophosphate on cell replication in human T lymphocytes. J 
Biol Chem 267, 15707-15714.
Slavin, S. (2002). Non-myeloablative stem cell transplantation for induction of host- 
versus-graft tolerance for adoptive immunotherapy of malignant and nonmalignant 
diseases and towards transplantation of organ allografts. Transplant Proc 34, 3371-3373.
202
Sloan-Lancaster, J., Shaw, A. S., Rothbard, J. B., and Allen, P. M. (1994). Partial T cell 
signaling: altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell 
anergy. Cell 79, 913-922.
Sorrentino, B. P. (2002). Gene therapy to protect haematopoietic cells from cytotoxic 
cancer drugs. Nat Rev Cancer 2, 431-441.
Stephan, J. L., Vlekova, V., Le Deist, F., Blanche, S., Donadieu, J., De Saint-Basile, G., 
Durandy, A., Griscelli, C., and Fischer, A. (1993). Severe combined immunodeficiency: 
a retrospective single-center study of clinical presentation and outcome in 117 patients. 
J Pediatr 123, 564-572.
Suzuki, T., Shen, H., Akagi, K., Morse, H. C., Malley, J. D., Naiman, D. Q., Jenkins, N. 
A., and Copeland, N. G. (2002). New genes involved in cancer identified by retroviral 
tagging. Nat Genet 3 2 ,166-174.
Szabo, S. J., Kim, S. T., Costa, G. L., Zhang, X., Fathman, C. G., and Glimcher, L. H. 
(2000). A novel transcription factor, T-bet, directs Thl lineage commitment. Cell 100, 
655-669.
Szabo, S. J., Sullivan, B. M., Stemmann, C., Satoskar, A. R., Sleckman, B. P., and 
Glimcher, L. H. (2002). Distinct effects of T-bet in TH1 lineage commitment and IFN- 
gamma production in CD4 and CD8 T cells. Science 295, 338-342.
Szondy, Z. (1994). Adenosine stimulates DNA fragmentation in human thymocytes by 
Ca(2+)-mediated mechanisms. Biochem J 304 ( Pt 3), 877-885.
203
Tanaka, C., Hara, T., Suzaki, I., Maegaki, Y., and Takeshita, K. (1996). Sensorineural 
deafness in siblings with adenosine deaminase deficiency. Brain Dev 18, 304-306.
Tanaka, T., Kameoka, J., Yaron, A., Schlossman, S. F., and Morimoto, C. (1993). The 
costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic 
activity. Proc Natl Acad Sci U S A 90, 4586-4590.
Tenbrock, K., Juang, Y. T., Tolnay, M., and Tsokos, G. C. (2003). The cyclic adenosine 
5'-monophosphate response element modulator suppresses IL-2 production in 
stimulated T cells by a chromatin-dependent mechanism. J Immunol 170,2971-2976.
Thiel, M., Caldwell, C. C., and Sitkovsky, M. V. (2003). The critical role of adenosine 
A2A receptors in downregulation of inflammation and immunity in the pathogenesis of 
infectious diseases. Microbes Infect 5, 515-526.
Thompson, L. F., Van de Wiele, C. J., Laurent, A. B., Hooker, S. W., Vaughn, J. G., 
Jiang, H., Khare, K., Kellems, R. E., Blackburn, M. R., Hershfield, M. S., and Resta, R. 
(2000). Metabolites from apoptotic thymocytes inhibit thymopoiesis in adenosine 
deaminase-deficient fetal thymic organ cultures. J Clin Invest 106, 1149-1157.
Thrasher, A. J., Gaspar, H. B., Baum, C., Modlich, U., Schambach, A., Candotti, F., 
Otsu, M., Sorrentino, B., Scobie, L., Cameron, Ev et al. (2006). Gene therapy: X-SCID 
transgene leukaemogenicity. Nature 443, E5-6; discussion E6-7.
Tischfield, J. A., Creagan, R. P., Nichols, E. A., and Ruddle, F. H. (1974). Assignment 
of a gene for adenosine deaminase to human chromosome 20. Hum Hered 24, 1-11.
204
Torgersen, K. M., Vang, T., Abrahamsen, H., Yaqub, S., and Tasken, K. (2002). 
Molecular mechanisms for protein kinase A-mediated modulation of immune function. 
Cell Signal 1 4 ,1-9.
Torimoto, Y., Dang, N. H., Vivier, E., Tanaka, T., Schlossman, S. F., and Morimoto, C. 
(1991). Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of 
human T lymphocytes. J Immunol 147, 2514-2517.
Tucker, A. L., and Linden, J. (1993). Cloned receptors and cardiovascular responses to 
adenosine. Cardiovasc Res 27, 62-67.
Tuschong, L., Soenen, S. L., Blaese, R. M., Candotti, F., and Muul, L. M. (2002). 
Immune response to fetal calf serum by two adenosine deaminase-deficient patients 
after T cell gene therapy. Hum Gene Ther 1 3 ,1605-1610.
Van De Wiele, C. J., Vaughn, J. G., Blackburn, M. R., Ledent, C. A., Jacobson, M., 
Jiang, H., and Thompson, L. F. (2002). Adenosine kinase inhibition promotes survival 
of fetal adenosine deaminase-deficient thymocytes by blocking dATP accumulation. J 
Clin Invest 110, 395-402.
van Leeuwen, J. E., and Samelson, L. E. (1999). T cell antigen-receptor signal 
transduction. Curr Opin Immunol 11, 242-248.
Vang, T., Torgersen, K. M., Sundvold, V., Saxena, M., Levy, F. O., Skalhegg, B. S., 
Hansson, V., Mustelin, T., and Tasken, K. (2001). Activation of the COOH-terminal Src 
kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell
205
receptor. J Exp Med 193, 497-507.
Vendetti, S., Riccomi, A., Sacchi, A., Gatta, L., Pioli, C., and De Magistris, M. T.
(2002). Cyclic adenosine 5'-monophosphate and calcium induce CD 152 (CTLA-4) up- 
regulation in resting CD4+ T lymphocytes. J Immunol 169, 6231-6235.
Verma, I. M., and Weitzman, M. D. (2005). Gene therapy: twenty-first century 
medicine. Annu Rev Biochem 74, 711-738.
Waddell, D., and Ullman, B. (1983). Characterization of a cultured human T-cell line 
with genetically altered ribonucleotide reductase activity. Model for immunodeficiency. 
J Biol Chem 258, 4226-4231.
Ward, S. G., Westwick, J., Hall, N. D., and Sansom, D. M. (1993). Ligation of CD28 
receptor by B7 induces formation of D-3 phosphoinositides in T lymphocytes 
independently of T cell receptor/CD3 activation. Eur J Immunol 23, 2572-2577.
Weil, R., and Israel, A. (2004). T-cell-receptor- and B-cell-receptor-mediated activation 
of NF-kappaB in lymphocytes. Curr Opin Immunol 16, 374-381.
Weinberg, K., Hershfield, M. S., Bastian, J., Kohn, D., Sender, L., Parkman, R., and 
Lenarsky, C. (1993). T lymphocyte ontogeny in adenosine deaminase-deficient severe 
combined immune deficiency after treatment with polyethylene glycol-modified 
adenosine deaminase. J Clin Invest 92, 596-602.
Werlen, G., Jacinto, E., Xia, Y., and Karin, M. (1998). Calcineurin preferentially
206
synergizes with PKC-theta to activate JNK and IL-2 promoter in T lymphocytes. Embo 
J 17, 3101-3111.
West, A. G., Gaszner, M., and Felsenfeld, G. (2002). Insulators: many functions, many 
mechanisms. Genes Dev 16, 271-288.
Wiginton, D. A., Kaplan, D. J., States, J. C., Akeson, A. L., Perme, C. M., Bilyk, I. J., 
Vaughn, A. J., Lattier, D. L., and Hutton, J. J. (1986). Complete sequence and structure 
of the gene for human adenosine deaminase. Biochemistry 25, 8234-8244.
Wilson, D. K., Rudolph, F. B., and Quiocho, F. A. (1991). Atomic structure of 
adenosine deaminase complexed with a transition-state analog: understanding catalysis 
and immunodeficiency mutations. Science 252 ,1278-1284.
Winkelstein, J. A., Marino, M. C., Johnston, R. B., Jr., Boyle, J., Curnutte, J., Gallin, J.
I., Malech, H. L., Holland, S. M., Ochs, H., Quie, P., et al. (2000). Chronic 
granulomatous disease. Report on a national registry of 368 patients. Medicine 
(Baltimore) 79 ,155-169.
Witte, D. P., Wiginton, D. A., Hutton, J. J., and Aronow, B. J. (1991). Coordinate 
developmental regulation of purine catabolic enzyme expression in gastrointestinal and 
postimplantation reproductive tracts. J Cell Biol 115 ,179-190.
Wolffe, A. P., and Matzke, M. A. (1999). Epigenetics: regulation through repression. 
Science 286, 481-486.
207
Woods, N. B., Bottero, V., Schmidt, M., von Kalle, C., and Verma, I. M. (2006). Gene 
therapy: therapeutic gene causing lymphoma. Nature 440,1123.
Wu, J., Dent, P., Jelinek, T., Wolfman, A., Weber, M. J., and Sturgill, T. W. (1993). 
Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'- 
monophosphate. Science 262,1065-1069.
Wu, X., Li, Y., Crise, B., and Burgess, S. M. (2003). Transcription start regions in the 
human genome are favored targets for MLV integration. Science 300 ,1749-1751.
Wu, X., Luke, B. T., and Burgess, S. M. (2006). Redefining the common insertion site. 
Virology 344, 292-295.
Yang, J. C., and Cortopassi, G. A. (1998). dATP causes specific release of cytochrome 
C from mitochondria. Biochem Biophys Res Commun 250, 454-457.
Zamoyska, R., Basson, A., Filby, A., Legname, G., Lovatt, M., and Seddon, B. (2003). 
The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival 
and activation. Immunol Rev 191,107-118.
Zhang, H., Conrad, D. M., Butler, J. J., Zhao, C., Blay, J., and Hoskin, D. W. (2004). 
Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation 
of STAT5 in T lymphocytes: role of cyclic adenosine 3',5'-monophosphate and 
phosphatases. J Immunol 173, 932-944.
Zhang, W., Trible, R. P., and Samelson, L. E. (1998). LAT palmitoylation: its essential
208
role in membrane microdomain targeting and tyrosine phosphorylation during T cell 
activation. Immunity 9, 239-246.
Zheng, W., and Flavell, R. A. (1997). The transcription factor GATA-3 is necessary and 
sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89, 587-596.
Zhong, H., SuYang, H., Erdjument-Bromage, H., Tempst, P., and Ghosh, S. (1997). The 
transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc 
subunit through a cyclic AMP-independent mechanism. Cell 89, 413-424.
Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A. M., Sampath, J., Morris, J. J., 
Lagutina, I., Grosveld, G. C., Osawa, M., Nakauchi, H., and Sorrentino, B. P. (2001). 
The ABC transporter Bcrpl/ABCG2 is expressed in a wide variety of stem cells and is a 
molecular determinant of the side-population phenotype. Nat Med 7,1028-1034.
Zitvogel, L., Tahara, H., Cai, Q., Storkus, W. J., Muller, G., Wolf, S. F., Gately, M., 
Robbins, P. D., and Lotze, M. T. (1994). Construction and characterization of retroviral 
vectors expressing biologically active human interleukin-12. Hum Gene Ther 5, 1493- 
1506.
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., and Trono,
D. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. 
J Virol 72, 9873-9880.
209
